[
  {
    "id": 10,
    "user_query": "Name synonym of Acrokeratosis paraneoplastica.",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Documents 0 and 1, the synonym for Acrokeratosis paraneoplastica is Bazex syndrome.",
    "llama-2-7b-chat-hf_fact_raw": "1. Acrokeratosis paraneoplastica is also known as Bazex syndrome.",
    "llama-2-7b-chat-hf_fact": [
      "Acrokeratosis paraneoplastica is also known as Bazex syndrome."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true"
    ]
  },
  {
    "id": 47,
    "user_query": "Is Weaver syndrome similar to Sotos?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, Weaver syndrome and Sotos syndrome do share some similarities, but they are not the same condition. Both syndromes are autosomal dominant overgrowth and intellectual disability (OGID) syndromes, caused by pathogenic variants in DNA methyltransferase genes. However, Weaver syndrome is caused by variants in the DNMT3A gene, while Sotos syndrome is caused by variants in the NSD1 gene.\nWhile both syndromes can cause bone overgrowth and changes to the shape and appearance of the face, Weaver syndrome typically affects the long bones of the body, such as the legs and arms, more than Sotos syndrome. Additionally, Weaver syndrome can cause other muscle and skeletal abnormalities, such as joint contractures and spinal deformities, which are less common in Sotos syndrome.\nIt's important to note that each person with Weaver syndrome or Sotos syndrome may experience different symptoms and severity of the condition, as the genetic variations can result in a wide range of clinical features. Therefore, while there are some similarities between the two syndromes, they are distinct conditions with different underlying genetic causes.",
    "llama-2-7b-chat-hf_fact_raw": "1. Weaver syndrome and Sotos syndrome are both autosomal dominant overgrowth and intellectual disability (OGID) syndromes.\n2. Weaver syndrome is caused by variants in the DNMT3A gene.\n3. Sotos syndrome is caused by variants in the NSD1 gene.\n4. Weaver syndrome typically affects the long bones of the body more than Sotos syndrome.\n5. Weaver syndrome can cause muscle and skeletal abnormalities such as joint contractures and spinal deformities, which are less common in Sotos syndrome.",
    "llama-2-7b-chat-hf_fact": [
      "Weaver syndrome and Sotos syndrome are both autosomal dominant overgrowth and intellectual disability (OGID) syndromes.",
      "Weaver syndrome is caused by variants in the DNMT3A gene.",
      "Sotos syndrome is caused by variants in the NSD1 gene.",
      "Weaver syndrome typically affects the long bones of the body more than Sotos syndrome.",
      "Weaver syndrome can cause muscle and skeletal abnormalities such as joint contractures and spinal deformities, which are less common in Sotos syndrome."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Weaver syndrome is caused by variants in the EZH2 gene, not the DNMT3A gene.\n3. TRUE\n4. UNKNOWN\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "unknown",
      "true"
    ]
  },
  {
    "id": 81,
    "user_query": "List the releases of JASPAR database",
    "llama-2-7b-chat-hf_response": "Based on the information provided, the releases of the JASPAR database are:\n1. JASPAR 2022: the 9th release of the open-access database of transcription factor binding profiles (PMID: 34937779)\n2. JASPAR 2016: the 6th release of the open-access database of transcription factor binding profiles (PMID: 27197177)\n3. JASPAR 2016: the 5th release of the open-access database of transcription factor binding profiles (PMID: 27197177)\n4. JASPAR 2015: the 4th release of the open-access database of transcription factor binding profiles (PMID: 26137176)\n5. JASPAR 2014: the 3rd release of the open-access database of transcription factor binding profiles (PMID: 25163775)\n6. JASPAR 2013: the 2nd release of the open-access database of transcription factor binding profiles (PMID: 23931774)\n7. JASPAR 2012: the 1st release of the open-access database of transcription factor binding profiles (PMID: 23353773)\nNote that the releases are listed in reverse chronological order, with the most recent release (JASPAR 2022) appearing first.",
    "llama-2-7b-chat-hf_fact_raw": "1. JASPAR 2022 is the 9th release of the open-access database of transcription factor binding profiles.\n2. JASPAR 2016 is cited as both the 6th and 5th release of the open-access database of transcription factor binding profiles.\n3. JASPAR 2015 is the 4th release of the open-access database of transcription factor binding profiles.\n4. JASPAR 2014 is the 3rd release of the open-access database of transcription factor binding profiles.\n5. JASPAR 2013 is the 2nd release of the open-access database of transcription factor binding profiles.",
    "llama-2-7b-chat-hf_fact": [
      "JASPAR 2022 is the 9th release of the open-access database of transcription factor binding profiles.",
      "JASPAR 2016 is cited as both the 6th and 5th release of the open-access database of transcription factor binding profiles.",
      "JASPAR 2015 is the 4th release of the open-access database of transcription factor binding profiles.",
      "JASPAR 2014 is the 3rd release of the open-access database of transcription factor binding profiles.",
      "JASPAR 2013 is the 2nd release of the open-access database of transcription factor binding profiles."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: JASPAR 2016 is cited as the 6th release of the open-access database of transcription factor binding profiles.\n3. TRUE\n4. TRUE\n5. FALSE [correction]: JASPAR 2010 is the 2nd release of the open-access database of transcription factor binding profiles.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 99,
    "user_query": "What is the function of the viral KP4 protein?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Documents 0 and 1, the function of the viral KP4 protein is to:\n1. Kill sensitive Ustilago strains: The KP4 protein is secreted by the maize smut fungus Ustilago maydis and is toxic to sensitive Ustilago strains.\n2. Inhibit Fusarium growth: The KP4 protein inhibits the growth of Fusarium, which is a type of fungus that is often found in association with plant roots.\n3. Inhibit plant root growth: The KP4 protein inhibits calcium uptake in plant roots, which can lead to inhibited root growth.\n4. Play a critical role in fungal-plant-bacterial associations: The KP4 protein has been shown to play a critical role in fungal-plant-bacterial associations, suggesting that it may be involved in regulating interactions between different organisms in these associations.\nOverall, the KP4 protein appears to be involved in a variety of functions related to the interactions between fungi, plants, and bacteria.",
    "llama-2-7b-chat-hf_fact_raw": "1. The KP4 protein is secreted by the maize smut fungus Ustilago maydis.\n2. The KP4 protein is toxic to sensitive Ustilago strains.\n3. The KP4 protein inhibits the growth of Fusarium, a type of fungus associated with plant roots.\n4. The KP4 protein inhibits calcium uptake in plant roots.\n5. The KP4 protein plays a critical role in fungal-plant-bacterial associations.",
    "llama-2-7b-chat-hf_fact": [
      "The KP4 protein is secreted by the maize smut fungus Ustilago maydis.",
      "The KP4 protein is toxic to sensitive Ustilago strains.",
      "The KP4 protein inhibits the growth of Fusarium, a type of fungus associated with plant roots.",
      "The KP4 protein inhibits calcium uptake in plant roots.",
      "The KP4 protein plays a critical role in fungal-plant-bacterial associations."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: The KP4 protein inhibits the growth of certain plants, not Fusarium, which is a genus of fungi.\n4. UNKNOWN\n5. UNKNOWN\n\nNote: While the KP4 protein is known to have antifungal properties and affects plant cells, the specific roles in fungal-plant-bacterial associations can be complex and are not clearly stated in the provided statements. Therefore, without additional context, it is difficult to determine the truthfulness of statements 4 and 5.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 124,
    "user_query": "Is DITPA a thyroid hormone analog utilized in experimental and clinical studies",
    "llama-2-7b-chat-hf_response": "Based on the information provided, it appears that DITPA is indeed a thyroid hormone analog that has been utilized in both experimental and clinical studies.\nDocument 0 mentions that DITPA has beneficial hemodynamic effects in animal studies and a pilot trial in patients with congestive heart failure. This suggests that DITPA may have a positive inotropic effect, which means that it can increase the force of contraction of the heart muscle.\nDocument 1 further supports this conclusion by stating that DITPA is a synthetic thyroid hormone analog with positive inotropic effects similar to thyroid hormone but with minimal systemic effects. This suggests that DITPA can produce the desired cardiovascular effects without the unwanted side effects associated with traditional thyroid hormone therapies.\nTherefore, based on the information provided, it can be concluded that DITPA is a thyroid hormone analog that has been studied in both experimental and clinical settings for its potential to improve cardiovascular function.",
    "llama-2-7b-chat-hf_fact_raw": "1. DITPA is a thyroid hormone analog.\n2. DITPA has been utilized in both experimental and clinical studies.\n3. DITPA has shown beneficial hemodynamic effects in animal studies.\n4. A pilot trial has been conducted with DITPA in patients with congestive heart failure.\n5. DITPA is designed to have positive inotropic effects with minimal systemic effects compared to traditional thyroid hormone therapies.",
    "llama-2-7b-chat-hf_fact": [
      "DITPA is a thyroid hormone analog.",
      "DITPA has been utilized in both experimental and clinical studies.",
      "DITPA has shown beneficial hemodynamic effects in animal studies.",
      "A pilot trial has been conducted with DITPA in patients with congestive heart failure.",
      "DITPA is designed to have positive inotropic effects with minimal systemic effects compared to traditional thyroid hormone therapies."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE\n\nBased on the context provided, all statements about DITPA (3,5-diiodothyropropionic acid) seem to be consistent with what is known about thyroid hormone analogs and their experimental and clinical uses. However, without specific sources or detailed information, it is not possible to verify the accuracy of the statements with absolute certainty, especially the last one which is quite specific. The statements are treated as true based on general knowledge about thyroid hormone analogs and their research applications.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 144,
    "user_query": "What is the COUGER tool?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Document 0, the COUGER tool is a software tool that supports system definition and specification. According to the document, COUGER describes early tools used in the field of ed analysis and design, including decision table processors and techniques that supported system definition and specification.",
    "llama-2-7b-chat-hf_fact_raw": "1. The COUGER tool is a software tool.\n2. The COUGER tool supports system definition and specification.\n3. COUGER describes early tools used in the field of ed analysis and design.\n4. COUGER includes decision table processors.\n5. COUGER includes techniques that support system definition and specification.",
    "llama-2-7b-chat-hf_fact": [
      "The COUGER tool is a software tool.",
      "The COUGER tool supports system definition and specification.",
      "COUGER describes early tools used in the field of ed analysis and design.",
      "COUGER includes decision table processors.",
      "COUGER includes techniques that support system definition and specification."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. FALSE [correction]: The COUGAR tool describes early tools used in the field of systems analysis and design.\n4. UNKNOWN\n5. UNKNOWN\n\nNote: The correct spelling is COUGAR, not COUGER. However, due to the lack of specific context and information about the COUGAR tool, the veracity of statements 1, 2, 4, and 5 cannot be determined.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "false",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 145,
    "user_query": "Are there drugs for Tick-borne Encephalitis?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, there are currently no drugs available to treat Tick-borne Encephalitis (TBE) virus infection directly. However, a vaccine is available to prevent infection, which is recommended for certain individuals, as mentioned in Document 0.\nFor symptomatic relief, rest, fluids, and over-the-counter pain medications may help alleviate some symptoms, such as headaches and fever. However, it is important to note that there is no specific treatment for TBE, and clinical management is primarily supportive, focusing on relieving symptoms and managing complications.\nIn severe cases of TBE, patients may require pain control for headaches, antiemetic therapy, and rehydration for associated nausea and vomiting, as mentioned in Document 1. It is essential to seek medical attention immediately if you suspect you have TBE, as early diagnosis and treatment can significantly improve outcomes.",
    "llama-2-7b-chat-hf_fact_raw": "1. There are currently no drugs available to directly treat Tick-borne Encephalitis (TBE) virus infection.\n2. A vaccine is available to prevent Tick-borne Encephalitis infection.\n3. Rest, fluids, and over-the-counter pain medications may help alleviate some symptoms of TBE, such as headaches and fever.\n4. Clinical management of TBE is primarily supportive, focusing on relieving symptoms and managing complications.\n5. In severe cases of TBE, patients may require pain control for headaches, antiemetic therapy, and rehydration for associated nausea and vomiting.",
    "llama-2-7b-chat-hf_fact": [
      "There are currently no drugs available to directly treat Tick-borne Encephalitis (TBE) virus infection.",
      "A vaccine is available to prevent Tick-borne Encephalitis infection.",
      "Rest, fluids, and over-the-counter pain medications may help alleviate some symptoms of TBE, such as headaches and fever.",
      "Clinical management of TBE is primarily supportive, focusing on relieving symptoms and managing complications.",
      "In severe cases of TBE, patients may require pain control for headaches, antiemetic therapy, and rehydration for associated nausea and vomiting."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 151,
    "user_query": "Which genome browser database for DNA shape annotations is available?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, the genome browser database for DNA shape annotations that is available is GBshape. According to Document 0, GBshape provides DNA shape annotations of entire genomes, including minor groove width (MGW), propeller twist (ProT), Roll, helix twist (HelT), and hydroxyl radical cleavage (ORChID2) for 94 organisms. Additionally, the database is designed to easily accommodate additional genomes, as stated in Document 1. Therefore, GBshape is the most relevant and up-to-date genome browser database for DNA shape annotations that the user can utilize.",
    "llama-2-7b-chat-hf_fact_raw": "1. GBshape is a genome browser database for DNA shape annotations.\n2. GBshape provides DNA shape annotations for entire genomes.\n3. The DNA shape annotations in GBshape include minor groove width (MGW), propeller twist (ProT), Roll, helix twist (HelT), and hydroxyl radical cleavage (ORChID2).\n4. GBshape contains DNA shape annotations for 94 organisms.\n5. GBshape is designed to accommodate additional genomes.",
    "llama-2-7b-chat-hf_fact": [
      "GBshape is a genome browser database for DNA shape annotations.",
      "GBshape provides DNA shape annotations for entire genomes.",
      "The DNA shape annotations in GBshape include minor groove width (MGW), propeller twist (ProT), Roll, helix twist (HelT), and hydroxyl radical cleavage (ORChID2).",
      "GBshape contains DNA shape annotations for 94 organisms.",
      "GBshape is designed to accommodate additional genomes."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: GBshape contains DNA shape annotations for 81 organisms as of my last update.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 174,
    "user_query": "Which syndromes are associated with mutations in the EZH2 gene?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Documents 0 and 1, the syndromes associated with mutations in the EZH2 gene are:\n1. Weaver Syndrome: The p.Glu745Lys mutation (detected in 2 patients) was previously associated with acute lymphoblastic leukemia and lymphoma in Weaver Syndrome patients.\n2. Inactivation of genes within topologically associating domains: Oncogenic gain-of-function EZH2 mutations alter gene–promoter interactions and lead to silencing of 1,034 genes within topologically associating domains, resulting in inactivation of gene expression.\nIt is important to note that these associations are based on the information provided in the documents and may not be comprehensive or up-to-date. Additional research or consultation with a medical professional may be necessary to provide a more accurate answer to the user's question.",
    "llama-2-7b-chat-hf_fact_raw": "1. Mutations in the EZH2 gene are associated with Weaver Syndrome.\n2. The p.Glu745Lys mutation in the EZH2 gene was previously associated with acute lymphoblastic leukemia and lymphoma in Weaver Syndrome patients.\n3. Oncogenic gain-of-function EZH2 mutations can lead to the silencing of 1,034 genes within topologically associating domains.\n4. The inactivation of gene expression can result from alterations in gene–promoter interactions caused by EZH2 mutations.",
    "llama-2-7b-chat-hf_fact": [
      "Mutations in the EZH2 gene are associated with Weaver Syndrome.",
      "The p.Glu745Lys mutation in the EZH2 gene was previously associated with acute lymphoblastic leukemia and lymphoma in Weaver Syndrome patients.",
      "Oncogenic gain-of-function EZH2 mutations can lead to the silencing of 1,034 genes within topologically associating domains.",
      "The inactivation of gene expression can result from alterations in gene–promoter interactions caused by EZH2 mutations."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: The p.Glu745Lys mutation in the EZH2 gene was previously associated with myeloid malignancies, not specifically with acute lymphoblastic leukemia and lymphoma in Weaver Syndrome patients.\n3. UNKNOWN\n4. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "unknown",
      "true"
    ]
  },
  {
    "id": 193,
    "user_query": "List human proteins that are subject to a dimer-to-tetramer transition.",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Documents 0 and 1, the following human proteins are known to undergo a dimer-to-tetramer transition:\n1. Inositol-Requiring enzyme 1α (IRE1): As mentioned in Document 0, the accumulation of misfolded proteins can activate IRE1, which undergoes a dimer-to-tetramer transition.\n2. Protein kinase R (PKR)-like ER kinase (PERK): Similarly, the accumulation of misfolded proteins can activate PERK, which also undergoes a dimer-to-tetramer transition.\n3. Hemoglobin: As mentioned in Document 1, the dimer-tetramer transition of hemoglobin may represent an intermediate step in the evolution of the more stable tetrameric form found in higher vertebrates.\nIt is important to note that this list may not be exhaustive, as there may be other human proteins that undergo a dimer-to-tetramer transition that have not been identified or reported in the literature.",
    "llama-2-7b-chat-hf_fact_raw": "1. Inositol-Requiring enzyme 1α (IRE1) undergoes a dimer-to-tetramer transition when activated by the accumulation of misfolded proteins.\n2. Protein kinase R (PKR)-like ER kinase (PERK) undergoes a dimer-to-tetramer transition when activated by the accumulation of misfolded proteins.\n3. Hemoglobin undergoes a dimer-to-tetramer transition, which may be an intermediate step in its evolutionary development in higher vertebrates.",
    "llama-2-7b-chat-hf_fact": [
      "Inositol-Requiring enzyme 1α (IRE1) undergoes a dimer-to-tetramer transition when activated by the accumulation of misfolded proteins.",
      "Protein kinase R (PKR)-like ER kinase (PERK) undergoes a dimer-to-tetramer transition when activated by the accumulation of misfolded proteins.",
      "Hemoglobin undergoes a dimer-to-tetramer transition, which may be an intermediate step in its evolutionary development in higher vertebrates."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Protein kinase R (PKR)-like ER kinase (PERK) undergoes a monomer-to-dimer transition when activated by the accumulation of misfolded proteins.\n3. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "unknown"
    ]
  },
  {
    "id": 210,
    "user_query": "Which protein has been found to interact with phospholamban (PLN) and is also an anti-apoptotic protein?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Documents 0 and 1, the protein that has been found to interact with phospholamban (PLN) and is also an anti-apoptotic protein is HAX-1.\nAccording to Document 1, HAX-1 is a mitochondrial protein that interacts with PLN, and it has been shown to have anti-apoptotic functions. The abstract states that \"Phospholamban Interacts with HAX-1, a Mitochondrial Protein with Anti-apoptotic Function.\" This suggests that HAX-1 is involved in the regulation of PLN's function and may play a role in protecting cells from apoptosis.\nTherefore, based on the information provided, the answer to the user's question is HAX-1.",
    "llama-2-7b-chat-hf_fact_raw": "1. HAX-1 is a protein that interacts with phospholamban (PLN).\n2. HAX-1 has been shown to have anti-apoptotic functions.",
    "llama-2-7b-chat-hf_fact": [
      "HAX-1 is a protein that interacts with phospholamban (PLN).",
      "HAX-1 has been shown to have anti-apoptotic functions."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true"
    ]
  },
  {
    "id": 218,
    "user_query": "Has vitamin D has been shown to reduce incidence of falls in older people in clinical trials?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Documents 0 and 1, there is evidence to suggest that vitamin D may reduce the incidence of falls in older people in clinical trials.\nDocument 0 provides a 15-year literature overview of the mechanisms of falls in older adults and the potential role of vitamin D in preventing falls. The document highlights the evidence for a vitamin D action on postural adaptations, including muscles and the central nervous system, which may explain the decreased fall and bone fracture rates. While the document acknowledges the differences and controversies in the literature, it suggests that vitamin D may play a role in reducing the incidence of falls in older people.\nDocument 1 provides a summary of the main message on falls, which is that falls are a common and serious health problem with devastating consequences. The document identifies several risk factors for falls, including muscle weakness, sensory impairment, and gait disturbances, and highlights the importance of evidence-based interventions to prevent falls. While the document does not specifically mention vitamin D, it suggests that falls can be prevented through a combination of single and multicomponent interventions.\nTaken together, these documents provide evidence to suggest that vitamin D may be effective in reducing the incidence of falls in older people in clinical trials. However, it is important to note that the literature on this topic is not without controversy, and further research is needed to fully understand the potential benefits and limitations of vitamin D supplementation for fall prevention.",
    "llama-2-7b-chat-hf_fact_raw": "1. Vitamin D may reduce the incidence of falls in older people according to clinical trials.\n2. Document 0 discusses the mechanisms of falls in older adults and the potential role of vitamin D in preventing these falls.\n3. Document 0 suggests that vitamin D has an action on postural adaptations, including muscles and the central nervous system.\n4. Document 1 identifies muscle weakness, sensory impairment, and gait disturbances as risk factors for falls.\n5. Document 1 highlights the importance of evidence-based interventions to prevent falls in older people.",
    "llama-2-7b-chat-hf_fact": [
      "Vitamin D may reduce the incidence of falls in older people according to clinical trials.",
      "Document 0 discusses the mechanisms of falls in older adults and the potential role of vitamin D in preventing these falls.",
      "Document 0 suggests that vitamin D has an action on postural adaptations, including muscles and the central nervous system.",
      "Document 1 identifies muscle weakness, sensory impairment, and gait disturbances as risk factors for falls.",
      "Document 1 highlights the importance of evidence-based interventions to prevent falls in older people."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nWithout access to the actual content of \"Document 0\" and \"Document 1,\" it is impossible to verify the accuracy of statements 2 through 5. The first statement is generally supported by some clinical trials, but the specifics of the documents mentioned cannot be confirmed.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 222,
    "user_query": "Is there any association between Jarid2 and miR-155 in Th17 cells?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, there is an association between Jarid2 and miR-155 in Th17 cells. According to Document 0, Jarid2 recruits PRC2, which cooperates with PRC1 to regulate the transcriptional expression of cytokine genes in Th17 cells. PRC2 is known to be involved in the regulation of gene expression by binding to specific DNA sequences and modifying histone structures, leading to changes in chromatin structure and accessibility to transcription factors.\nFurthermore, Document 1 suggests that Jarid2 associates with PRC2 in a range of different cell types, including ESCs and thymocytes. While the exact mechanisms of this association are not fully understood, it is likely that Jarid2 plays a role in regulating the expression of miR-155 and other genes involved in Th17 cell differentiation and function.\nTherefore, based on the information provided, there is evidence to suggest that Jarid2 is involved in the regulation of miR-155 expression in Th17 cells, and that this association may play a role in the regulation of cytokine gene expression and Th17 cell differentiation.",
    "llama-2-7b-chat-hf_fact_raw": "1. There is an association between Jarid2 and miR-155 in Th17 cells.\n2. Jarid2 recruits PRC2 to regulate the transcriptional expression of cytokine genes in Th17 cells.\n3. PRC2 is involved in the regulation of gene expression by binding to specific DNA sequences and modifying histone structures.\n4. Jarid2 associates with PRC2 in various cell types, including ESCs (embryonic stem cells) and thymocytes.\n5. Jarid2 is implicated in the regulation of miR-155 expression and may influence Th17 cell differentiation and function.",
    "llama-2-7b-chat-hf_fact": [
      "There is an association between Jarid2 and miR-155 in Th17 cells.",
      "Jarid2 recruits PRC2 to regulate the transcriptional expression of cytokine genes in Th17 cells.",
      "PRC2 is involved in the regulation of gene expression by binding to specific DNA sequences and modifying histone structures.",
      "Jarid2 associates with PRC2 in various cell types, including ESCs (embryonic stem cells) and thymocytes.",
      "Jarid2 is implicated in the regulation of miR-155 expression and may influence Th17 cell differentiation and function."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: There is evidence in scientific literature that suggests an association between Jarid2 and miR-155 in Th17 cells, as Jarid2 has been shown to be involved in the regulation of miR-155, which can affect Th17 cell differentiation and function.\n2. TRUE: Jarid2 is known to recruit Polycomb Repressive Complex 2 (PRC2) to target genes, which can regulate the transcriptional expression of various genes, including cytokine genes in Th17 cells.\n3. TRUE: PRC2 is indeed involved in the regulation of gene expression, but not by binding to specific DNA sequences. Instead, it modifies histone structures through methylation, which can lead to transcriptional repression. The statement is slightly misleading but essentially true regarding the role of PRC2 in gene regulation.\n4. TRUE: Jarid2 is known to associate with PRC2 in various cell types, including embryonic stem cells (ESCs) and thymocytes, among others, to regulate gene expression.\n5. TRUE: Jarid2 is implicated in the regulation of miR-155 expression, which can influence Th17 cell differentiation and function, as miR-155 has been shown to play a role in the immune response and inflammation associated with Th17 cells.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 224,
    "user_query": "How many genes does the human hoxD cluster contain?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, the human HoxD cluster contains 39 genes.",
    "llama-2-7b-chat-hf_fact_raw": "NO FACTS",
    "llama-2-7b-chat-hf_fact": [],
    "llama-2-7b-chat-hf_judge": []
  },
  {
    "id": 268,
    "user_query": "List phosphorylation consensus motifs for Casein Kinase 1 (CK1)?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Documents 0 and 1, the consensus motifs for phosphorylation by Casein Kinase 1 (CK1) are:\n1. Acidic motifs N-terminal to phosphorylation sites: CK1s typically recognize substrates with acidic motifs located N-terminal to the phosphorylation sites.\n2. Consecutive phosphoserines: CK1 family members tend to generate clusters of consecutive phosphoserines on their substrates.\nTherefore, the consensus motifs for CK1 phosphorylation are:\nX-X-S-P-X-X-S-P (where X is any amino acid and S is serine).\nFor example, the consensus motif for the phosphorylation of β-catenin by CK1 is:\nS-P-X-X-S-P-X-X-S-P (where X is any amino acid and S is serine).\nNote that this is a general consensus motif and may not be specific to β-catenin. Other substrates of CK1 may have different consensus motifs.",
    "llama-2-7b-chat-hf_fact_raw": "1. Casein Kinase 1 (CK1) recognizes substrates with acidic motifs located N-terminal to the phosphorylation sites.\n2. CK1 family members tend to generate clusters of consecutive phosphoserines on their substrates.\n3. A general consensus motif for CK1 phosphorylation is X-X-S-P-X-X-S-P (where X is any amino acid and S is serine).\n4. The consensus motif for the phosphorylation of β-catenin by CK1 is S-P-X-X-S-P-X-X-S-P (where X is any amino acid and S is serine).",
    "llama-2-7b-chat-hf_fact": [
      "Casein Kinase 1 (CK1) recognizes substrates with acidic motifs located N-terminal to the phosphorylation sites.",
      "CK1 family members tend to generate clusters of consecutive phosphoserines on their substrates.",
      "A general consensus motif for CK1 phosphorylation is X-X-S-P-X-X-S-P (where X is any amino acid and S is serine).",
      "The consensus motif for the phosphorylation of β-catenin by CK1 is S-P-X-X-S-P-X-X-S-P (where X is any amino acid and S is serine)."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: A general consensus motif for CK1 phosphorylation is S/T-X-X-S/T (where X is any amino acid, S is serine, and T is threonine).\n4. FALSE [correction]: The consensus motif for the phosphorylation of β-catenin by CK1 is S-X-S (where X is any amino acid and S is serine).",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "false"
    ]
  },
  {
    "id": 305,
    "user_query": "Which are the different proteins/isoforms encoded but the ASPH (aspartate beta-hydroxylase) gene in humans?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Documents 0 and 1, the different proteins/isoforms encoded by the ASPH gene in humans are:\n1. Aspartyl/Asparaginyl beta-hydroxylase domain-containing isoforms: These are the longest isoforms (a and f), which include a C-terminal Aspartyl/Asparaginyl beta-hydroxylase domain that hydroxylates aspartic acid or asparagine residues in the epidermal growth factor (EGF)-like domains of some proteins, including protein C, coagulation factors VII, IX, and X, and the complement factors C1R and C1S.\n2. 2-oxoglutarate dependent oxygenase aspartate/asparagine-β-hydroxylase (AspH): This enzyme catalyzes the hydroxylation of Asp/Asn-residues in epidermal growth factor-like domains (EGFDs).\nTherefore, the answer to the user's question is: The different proteins/isoforms encoded by the ASPH gene in humans are Aspartyl/Asparaginyl beta-hydroxylase domain-containing isoforms and 2-oxoglutarate dependent oxygenase aspartate/asparagine-β-hydroxylase (AspH).",
    "llama-2-7b-chat-hf_fact_raw": "1. The ASPH gene in humans encodes for Aspartyl/Asparaginyl beta-hydroxylase domain-containing isoforms.\n2. The longest isoforms encoded by the ASPH gene are isoforms a and f.\n3. The C-terminal Aspartyl/Asparaginyl beta-hydroxylase domain hydroxylates aspartic acid or asparagine residues in certain proteins.\n4. The proteins that can be hydroxylated by the domain include protein C, coagulation factors VII, IX, and X, and the complement factors C1R and C1S.\n5. The ASPH gene also encodes for an enzyme known as 2-oxoglutarate dependent oxygenase aspartate/asparagine-β-hydroxylase (AspH).",
    "llama-2-7b-chat-hf_fact": [
      "The ASPH gene in humans encodes for Aspartyl/Asparaginyl beta-hydroxylase domain-containing isoforms.",
      "The longest isoforms encoded by the ASPH gene are isoforms a and f.",
      "The C-terminal Aspartyl/Asparaginyl beta-hydroxylase domain hydroxylates aspartic acid or asparagine residues in certain proteins.",
      "The proteins that can be hydroxylated by the domain include protein C, coagulation factors VII, IX, and X, and the complement factors C1R and C1S.",
      "The ASPH gene also encodes for an enzyme known as 2-oxoglutarate dependent oxygenase aspartate/asparagine-β-hydroxylase (AspH)."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. UNKNOWN\n3. TRUE\n4. TRUE\n5. FALSE [correction]: The enzyme is known as aspartate/asparagine-β-hydroxylase (ASPH) or hydroxylysine kinase (Hylk), not 2-oxoglutarate dependent oxygenase aspartate/asparagine-β-hydroxylase (AspH). The enzyme ASPH is a 2-oxoglutarate-dependent dioxygenase, but the name provided in the statement is not accurate.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 330,
    "user_query": "When was empagliflozin FDA approved?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, empagliflozin was FDA approved on August 1, 2014, for the treatment of type 2 diabetes. However, in August 2021, the FDA approved an additional indication for empagliflozin to reduce the risk of cardiovascular death and heart failure (HF) hospitalization in adults with heart failure with reduced ejection fraction (HFrEF).",
    "llama-2-7b-chat-hf_fact_raw": "1. Empagliflozin was FDA approved on August 1, 2014.\n2. The initial FDA approval of empagliflozin was for the treatment of type 2 diabetes.\n3. In August 2021, the FDA approved an additional indication for empagliflozin.\n4. The additional indication for empagliflozin was to reduce the risk of cardiovascular death.\n5. The additional indication for empagliflozin was also to reduce the risk of hospitalization for heart failure in adults with heart failure with reduced ejection fraction (HFrEF).",
    "llama-2-7b-chat-hf_fact": [
      "Empagliflozin was FDA approved on August 1, 2014.",
      "The initial FDA approval of empagliflozin was for the treatment of type 2 diabetes.",
      "In August 2021, the FDA approved an additional indication for empagliflozin.",
      "The additional indication for empagliflozin was to reduce the risk of cardiovascular death.",
      "The additional indication for empagliflozin was also to reduce the risk of hospitalization for heart failure in adults with heart failure with reduced ejection fraction (HFrEF)."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Empagliflozin was FDA approved on August 1, 2014, for the treatment of type 2 diabetes.\n2. TRUE\n3. TRUE\n4. FALSE [correction]: The additional indication for empagliflozin approved in August 2021 was to reduce the risk of cardiovascular death and hospitalization for heart failure in adults with heart failure, but it was not limited to those with reduced ejection fraction (HFrEF).\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 350,
    "user_query": "What are the results of loss of the protein Lon1 in the plant Arabidopsis?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Documents 0 and 1, the loss of the protein Lon1 in the plant Arabidopsis leads to several changes in the plant's metabolism and growth. Specifically, the loss of Lon1 results in altered metabolite profiles and growth retardation, without an accumulation of oxidative damage.\nLon1 is an ATP-dependent protease that plays a crucial role in the mitochondrial proteome, particularly in the anaplerotic role of mitochondria in cellular carbon metabolism. The loss of Lon1 significantly modifies respiratory function and plant performance by subtly changing the steady-state protein assembly, stability, and damage of a range of components that debilitate an anaplerotic role for mitochondria in cellular carbon metabolism.\nThe alterations in the mitochondrial proteome caused by the loss of Lon1 lead to changes in the plant's metabolism, resulting in growth retardation. However, there is no accumulation of oxidative damage, suggesting that the loss of Lon1 does not lead to an increase in reactive oxygen species (ROS) production or oxidative stress.\nIn summary, the loss of Lon1 in Arabidopsis leads to altered metabolite profiles and growth retardation, without an accumulation of oxidative damage. These changes are likely due to the modifications in the mitochondrial proteome caused by the loss of Lon1, which debilitate the anaplerotic role of mitochondria in cellular carbon metabolism.",
    "llama-2-7b-chat-hf_fact_raw": "1. The loss of the protein Lon1 in Arabidopsis results in altered metabolite profiles and growth retardation.\n2. Lon1 is an ATP-dependent protease important for the mitochondrial proteome and cellular carbon metabolism.\n3. The absence of Lon1 significantly modifies respiratory function and plant performance.\n4. The loss of Lon1 in Arabidopsis does not lead to an accumulation of oxidative damage.\n5. The changes in Arabidopsis due to the loss of Lon1 are associated with the steady-state protein assembly, stability, and damage in mitochondria.",
    "llama-2-7b-chat-hf_fact": [
      "The loss of the protein Lon1 in Arabidopsis results in altered metabolite profiles and growth retardation.",
      "Lon1 is an ATP-dependent protease important for the mitochondrial proteome and cellular carbon metabolism.",
      "The absence of Lon1 significantly modifies respiratory function and plant performance.",
      "The loss of Lon1 in Arabidopsis does not lead to an accumulation of oxidative damage.",
      "The changes in Arabidopsis due to the loss of Lon1 are associated with the steady-state protein assembly, stability, and damage in mitochondria."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: The loss of Lon1 in Arabidopsis likely leads to an accumulation of oxidative damage, as Lon1 is involved in the removal of damaged and misfolded proteins from the mitochondria, which is important for preventing oxidative stress.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 409,
    "user_query": "Does a linker histone exist in the yeast genome?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Documents 0 and 1, there is no direct evidence to suggest that a linker histone exists in the yeast genome. The study in Document 0 directly observed the involvement of Hmo1 in chromatin assembly in yeast nucleoplasmic extracts, but did not find any evidence of a linker histone. Additionally, the protein with greatest sequence similarity to histone H1 in yeast is Hho1p, but the study found that Hho1p is not involved in chromatin assembly. Therefore, it can be concluded that a linker histone does not exist in the yeast genome.",
    "llama-2-7b-chat-hf_fact_raw": "1. There is no direct evidence of a linker histone in the yeast genome.\n2. The study in Document 0 observed the involvement of Hmo1 in chromatin assembly in yeast nucleoplasmic extracts.\n3. The study in Document 0 did not find evidence of a linker histone.\n4. Hho1p has the greatest sequence similarity to histone H1 in yeast.\n5. The study concluded that Hho1p is not involved in chromatin assembly.",
    "llama-2-7b-chat-hf_fact": [
      "There is no direct evidence of a linker histone in the yeast genome.",
      "The study in Document 0 observed the involvement of Hmo1 in chromatin assembly in yeast nucleoplasmic extracts.",
      "The study in Document 0 did not find evidence of a linker histone.",
      "Hho1p has the greatest sequence similarity to histone H1 in yeast.",
      "The study concluded that Hho1p is not involved in chromatin assembly."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. FALSE [correction]: The study likely concluded that Hho1p is involved in chromatin assembly, given that it has the greatest sequence similarity to histone H1, which is known to be involved in chromatin structure and function.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 418,
    "user_query": "Is there evidence that tomato juice lowers cholesterol levels?",
    "llama-2-7b-chat-hf_response": "Yes, there is evidence to suggest that tomato juice can lower cholesterol levels. According to Document 0, a high dietary intake of tomato products, including tomato juice, has been shown to reduce LDL cholesterol levels and increase LDL resistance to oxidation in healthy normocholesterolaemic adults. This is likely due to the high levels of lycopene, β-carotene, and γ-carotene found in tomatoes, which have been shown to have atheroprotective effects.\nThe 2014 study mentioned in Document 1 also supports the idea that tomato juice can help lower cholesterol levels. The study found that dietary tomato juice intake was associated with significant reductions in inflammation, insulin resistance, and high cholesterol, all of which are implicated in metabolic syndrome.\nWhile these findings are promising, it's important to note that the studies were observational in nature and more research is needed to confirm these results and establish a cause-and-effect relationship between tomato juice consumption and lowered cholesterol levels. Additionally, it's worth noting that tomato juice is just one part of a healthy diet and lifestyle, and it's important to make other heart-healthy choices, such as following a balanced diet, getting regular exercise, and managing stress, to help keep cholesterol levels in check.",
    "llama-2-7b-chat-hf_fact_raw": "1. A high dietary intake of tomato products, including tomato juice, has been shown to reduce LDL cholesterol levels in healthy normocholesterolaemic adults.\n2. Tomato juice intake has been associated with increased LDL resistance to oxidation.\n3. Tomatoes contain high levels of lycopene, β-carotene, and γ-carotene, which have atheroprotective effects.\n4. A 2014 study found that dietary tomato juice intake was associated with significant reductions in inflammation, insulin resistance, and high cholesterol.\n5. The studies mentioned were observational and more research is needed to confirm the results and establish a cause-and-effect relationship between tomato juice consumption and lowered cholesterol levels.",
    "llama-2-7b-chat-hf_fact": [
      "A high dietary intake of tomato products, including tomato juice, has been shown to reduce LDL cholesterol levels in healthy normocholesterolaemic adults.",
      "Tomato juice intake has been associated with increased LDL resistance to oxidation.",
      "Tomatoes contain high levels of lycopene, β-carotene, and γ-carotene, which have atheroprotective effects.",
      "A 2014 study found that dietary tomato juice intake was associated with significant reductions in inflammation, insulin resistance, and high cholesterol.",
      "The studies mentioned were observational and more research is needed to confirm the results and establish a cause-and-effect relationship between tomato juice consumption and lowered cholesterol levels."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: A high dietary intake of tomato products, including tomato juice, has been associated with reduced LDL cholesterol levels in some studies involving healthy normocholesterolaemic adults.\n2. TRUE: Tomato juice intake has been associated with increased LDL resistance to oxidation, which is considered beneficial for cardiovascular health.\n3. TRUE: Tomatoes are known to contain high levels of antioxidants such as lycopene, β-carotene, and γ-carotene, which are thought to have atheroprotective effects.\n4. UNKNOWN: Without access to the specific 2014 study mentioned, it is not possible to verify the accuracy of this statement.\n5. TRUE: It is a common scientific consensus that while observational studies can suggest associations, more research, including randomized controlled trials, is needed to confirm results and establish a cause-and-effect relationship.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "unknown",
      "true"
    ]
  },
  {
    "id": 472,
    "user_query": "How do Hsp70 and Hsp110 affect mRNA stability?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Documents 0 and 1, it can be concluded that Hsp70 and Hsp110 affect mRNA stability by binding to specific RNA motifs involved in mRNA degradation.\nHsp70 and Hsp110 are members of the mammalian 70-kDa heat shock protein (Hsp) family that have been shown to bind to AU-rich RNA in vitro. AU-rich RNA motifs are known to play a role in mRNA stability, as they can act as binding sites for RNA-binding proteins that regulate mRNA degradation. By binding to these RNA motifs, Hsp70 and Hsp110 may help to stabilize mRNAs that contain these motifs, leading to increased mRNA stability.\nAdditionally, Hsp70 has been shown to bind U-rich RNA, including some AU-rich elements (AREs), which are involved in the decay kinetics of select mRNAs. Hsp70 has also been shown to bind and stabilize some ARE-containing transcripts, suggesting that it may play a role in protecting these mRNAs from degradation.\nOverall, the information provided in Documents 0 and 1 suggests that Hsp70 and Hsp110 play a role in regulating mRNA stability by binding to specific RNA motifs involved in mRNA degradation.",
    "llama-2-7b-chat-hf_fact_raw": "1. Hsp70 and Hsp110 are members of the mammalian 70-kDa heat shock protein family.\n2. Hsp70 and Hsp110 have been shown to bind to AU-rich RNA motifs in vitro.\n3. AU-rich RNA motifs are associated with mRNA stability and degradation.\n4. Hsp70 has been shown to bind U-rich RNA, including some AU-rich elements (AREs).\n5. Hsp70 can stabilize ARE-containing transcripts, which may protect these mRNAs from degradation.",
    "llama-2-7b-chat-hf_fact": [
      "Hsp70 and Hsp110 are members of the mammalian 70-kDa heat shock protein family.",
      "Hsp70 and Hsp110 have been shown to bind to AU-rich RNA motifs in vitro.",
      "AU-rich RNA motifs are associated with mRNA stability and degradation.",
      "Hsp70 has been shown to bind U-rich RNA, including some AU-rich elements (AREs).",
      "Hsp70 can stabilize ARE-containing transcripts, which may protect these mRNAs from degradation."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Hsp70 and Hsp110 have not been specifically shown to bind to AU-rich RNA motifs in vitro. It is generally known that certain RNA-binding proteins interact with AU-rich elements, but this statement does not accurately represent the specificity of Hsp70 and Hsp110 without supporting evidence.\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 481,
    "user_query": "Which deiodinases are present in skeletal  muscle?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Document 1, the two deiodinases present in skeletal muscle are:\n1. Type 2 iodothyronine deiodinase (DIO2)\n2. Type 3 iodothyronine deiodinase (DIO3)\nDocument 1 specifically mentions that DIO2 expression is tightly regulated and catalyzes outer-ring cleavage of thyroxine (T4) to form triiodothyronine (T3) in skeletal muscle. DIO3, on the other hand, is also present in skeletal muscle and catalyzes inner-ring cleavage of T4 to form T3.\nTherefore, the answer to the user's question is: DIO2 and DIO3 are the two deiodinases present in skeletal muscle.",
    "llama-2-7b-chat-hf_fact_raw": "1. Type 2 iodothyronine deiodinase (DIO2) is present in skeletal muscle.\n2. Type 3 iodothyronine deiodinase (DIO3) is also present in skeletal muscle.\n3. DIO2 catalyzes the outer-ring cleavage of thyroxine (T4) to form triiodothyronine (T3) in skeletal muscle.\n4. DIO3 catalyzes the inner-ring cleavage of T4 to form reverse triiodothyronine (rT3), not T3 as stated in the answer. (This statement is included to correct a factual error in the provided answer.)",
    "llama-2-7b-chat-hf_fact": [
      "Type 2 iodothyronine deiodinase (DIO2) is present in skeletal muscle.",
      "Type 3 iodothyronine deiodinase (DIO3) is also present in skeletal muscle.",
      "DIO2 catalyzes the outer-ring cleavage of thyroxine (T4) to form triiodothyronine (T3) in skeletal muscle.",
      "DIO3 catalyzes the inner-ring cleavage of T4 to form reverse triiodothyronine (rT3), not T3 as stated in the answer. (This statement is included to correct a factual error in the provided answer.)"
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 534,
    "user_query": "List inflammatory caspase proteins?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, the inflammatory caspase proteins are:\n1. Caspase-1\n2. Caspase-4\n3. Caspase-5\n4. Caspase-11\nThese proteins are grouped as inflammatory caspases and share a CARD (caspase activation and recruitment domain) at the N-terminal end. They are involved in the regulation of inflammation and play a role in the activation of immune cells and the processing of pro-inflammatory cytokines.\nAdditionally, the document mentions that there are three main genes encoding inflammatory caspases in humans and mice, respectively:\n1. Caspase-1\n2. Caspase-4\n3. Caspase-5\nThese genes are responsible for the production of the inflammatory caspase proteins in these organisms.",
    "llama-2-7b-chat-hf_fact_raw": "1. Caspase-1 is classified as an inflammatory caspase protein.\n2. Caspase-4 is classified as an inflammatory caspase protein.\n3. Caspase-5 is classified as an inflammatory caspase protein.\n4. Caspase-11 is classified as an inflammatory caspase protein.\n5. Inflammatory caspases share a CARD (caspase activation and recruitment domain) at the N-terminal end.",
    "llama-2-7b-chat-hf_fact": [
      "Caspase-1 is classified as an inflammatory caspase protein.",
      "Caspase-4 is classified as an inflammatory caspase protein.",
      "Caspase-5 is classified as an inflammatory caspase protein.",
      "Caspase-11 is classified as an inflammatory caspase protein.",
      "Inflammatory caspases share a CARD (caspase activation and recruitment domain) at the N-terminal end."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 579,
    "user_query": "Is there any link between the aurora B kinase and the polycomb protein ring1B?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Documents 0 and 1, there is a clear link between the Aurora B kinase and the polycomb protein Ring1B. Both proteins play essential roles in regulating transcriptionally active genes in quiescent lymphocytes.\nRing1B and Aurora B bind to a wide range of active promoters in resting B and T cells, suggesting that they are involved in the regulation of gene expression in these cells. This is consistent with the idea that Ring1B and Aurora B are involved in the maintenance of quiescence, as quiescent cells have reduced transcriptional activity compared to actively dividing cells.\nFurthermore, the fact that Ring1B and Aurora B are essential for regulating transcriptionally active genes in quiescent lymphocytes suggests that they are involved in the regulation of key genes that are important for cellular quiescence.\nIn summary, based on the information provided in Documents 0 and 1, there is a clear link between the Aurora B kinase and the polycomb protein Ring1B in the regulation of transcriptionally active genes in quiescent lymphocytes.",
    "llama-2-7b-chat-hf_fact_raw": "1. Aurora B kinase and the polycomb protein Ring1B are linked in regulating transcriptionally active genes in quiescent lymphocytes.\n2. Ring1B and Aurora B bind to a wide range of active promoters in resting B and T cells.\n3. The involvement of Ring1B and Aurora B is associated with the maintenance of quiescence in cells.\n4. Quiescent cells have reduced transcriptional activity compared to actively dividing cells.\n5. Ring1B and Aurora B are essential for regulating key genes important for cellular quiescence.",
    "llama-2-7b-chat-hf_fact": [
      "Aurora B kinase and the polycomb protein Ring1B are linked in regulating transcriptionally active genes in quiescent lymphocytes.",
      "Ring1B and Aurora B bind to a wide range of active promoters in resting B and T cells.",
      "The involvement of Ring1B and Aurora B is associated with the maintenance of quiescence in cells.",
      "Quiescent cells have reduced transcriptional activity compared to actively dividing cells.",
      "Ring1B and Aurora B are essential for regulating key genes important for cellular quiescence."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. TRUE\n5. UNKNOWN\n\nThe statements regarding Aurora B kinase, Ring1B, and their specific roles in regulating transcriptionally active genes in quiescent lymphocytes, as well as their binding to active promoters in resting B and T cells, require specific scientific knowledge or evidence from research that is not provided in the context. Therefore, without additional information, the truthfulness of statements 1, 2, 3, and 5 cannot be determined. However, statement 4 is generally true as quiescent cells are known to have reduced transcriptional activity compared to actively dividing cells.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "true",
      "unknown"
    ]
  },
  {
    "id": 597,
    "user_query": "What are the most frequent non-canonical sequence motifs at the donor and acceptor splice sites in vertebrates?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Documents 0 and 1, the most frequent non-canonical sequence motifs at the donor and acceptor splice sites in vertebrates are:\nDonor splice site motifs:\n1. GU-rich motifs: These are the most common non-canonical motifs found at the donor splice site. They are typically found in the intron and are characterized by a high content of purine bases (G and A) and a low content of pyrimidine bases (C and T).\n2. AG-rich motifs: These motifs are similar to GU-rich motifs but have a higher content of A bases. They are also found in the intron and are recognized by specific transcription factors.\n3. GT-rich motifs: These motifs are found in the intron and are characterized by a high content of guanine bases (G) and a low content of other bases.\nAcceptor splice site motifs:\n1. GT-rich motifs: These motifs are found in the exon and are characterized by a high content of guanine bases (G). They are recognized by specific transcription factors and play a crucial role in the splicing process.\n2. AG-rich motifs: These motifs are found in the exon and are similar to the AG-rich motifs found at the donor splice site. They are recognized by specific transcription factors and play a role in the splicing process.\n3. GU-rich motifs: These motifs are found in the exon and are similar to the GU-rich motifs found at the donor splice site. They are recognized by specific transcription factors and play a role in the splicing process.\nIt is important to note that the specific motifs found at the donor and acceptor splice sites can vary depending on the species and the specific gene being studied. These motifs are recognized by specific transcription factors, which play a crucial role in the splicing process.",
    "llama-2-7b-chat-hf_fact_raw": "1. GU-rich motifs are the most common non-canonical motifs found at the donor splice site in vertebrates.\n2. AG-rich motifs at the donor splice site in vertebrates have a higher content of adenine bases (A) and are found in the intron.\n3. GT-rich motifs at the donor splice site in vertebrates are characterized by a high content of guanine bases (G) and are found in the intron.\n4. GT-rich motifs at the acceptor splice site in vertebrates are found in the exon and have a high content of guanine bases (G).\n5. AG-rich and GU-rich motifs at the acceptor splice site in vertebrates are found in the exon and play a role in the splicing process.",
    "llama-2-7b-chat-hf_fact": [
      "GU-rich motifs are the most common non-canonical motifs found at the donor splice site in vertebrates.",
      "AG-rich motifs at the donor splice site in vertebrates have a higher content of adenine bases (A) and are found in the intron.",
      "GT-rich motifs at the donor splice site in vertebrates are characterized by a high content of guanine bases (G) and are found in the intron.",
      "GT-rich motifs at the acceptor splice site in vertebrates are found in the exon and have a high content of guanine bases (G).",
      "AG-rich and GU-rich motifs at the acceptor splice site in vertebrates are found in the exon and play a role in the splicing process."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: GT-rich motifs, not GU-rich motifs, are the most common non-canonical motifs found at the donor splice site in vertebrates. The consensus sequence at the donor splice site is typically \"GT\" at the intron-exon boundary.\n2. FALSE [correction]: AG-rich motifs at the donor splice site in vertebrates are not specifically characterized by a higher content of adenine bases (A) and are typically found at the exon-intron boundary, not just in the intron. The consensus sequence at the donor splice site is \"GT\" rather than \"AG\".\n3. TRUE: GT-rich motifs at the donor splice site in vertebrates are characterized by a high content of guanine bases (G) and are found at the intron-exon boundary, which is consistent with the consensus sequence \"GT\" at the donor splice site.\n4. FALSE [correction]: GT-rich motifs at the acceptor splice site in vertebrates are found in the intron, not the exon, and have a high content of guanine bases (G). The consensus sequence at the acceptor splice site is typically \"AG\" at the intron-exon boundary.\n5. FALSE [correction]: AG-rich motifs at the acceptor splice site in vertebrates are found in the intron, not the exon, and play a role in the splicing process. The consensus sequence at the acceptor splice site is \"AG\" at the intron-exon boundary. GU-rich motifs are not typically associated with the acceptor splice site.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "true",
      "false",
      "false"
    ]
  },
  {
    "id": 629,
    "user_query": "Which event results in the acetylation of S6K1?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Documents 0 and 1, the event that results in the acetylation of S6K1 is autophagy.\nAccording to Document 0, S6K1 (also known as Ribosomal S6 kinase 1) is a key regulator of cellular processes such as cell size, mRNA transcription, splicing, and protein synthesis, and it also plays a pivotal role in directing cell apoptosis, metabolism, and feedback regulation.\nDocument 1 mentions that autophagy is a specific macromolecule and organelle degradation process that involves the enclosure of the target macromolecule or organelle in an autophagosome, followed by delivery along acetylated microtubules to the lysosome for degradation. Autophagy is triggered by stress and plays a crucial role in cell survival.\nGiven the information provided, it is likely that autophagy leads to the acetylation of S6K1, as the process of autophagy involves the degradation of cellular components, including proteins, which could result in the acetylation of S6K1. However, without further information, it is impossible to determine the exact mechanism by which autophagy leads to S6K1 acetylation.",
    "llama-2-7b-chat-hf_fact_raw": "1. S6K1, also known as Ribosomal S6 kinase 1, is a key regulator of cellular processes such as cell size, mRNA transcription, splicing, and protein synthesis.\n2. S6K1 plays a role in directing cell apoptosis, metabolism, and feedback regulation.\n3. Autophagy is a process that involves the degradation of macromolecules and organelles.\n4. During autophagy, the target macromolecule or organelle is enclosed in an autophagosome and delivered to the lysosome for degradation.\n5. Autophagy is triggered by stress and is important for cell survival.",
    "llama-2-7b-chat-hf_fact": [
      "S6K1, also known as Ribosomal S6 kinase 1, is a key regulator of cellular processes such as cell size, mRNA transcription, splicing, and protein synthesis.",
      "S6K1 plays a role in directing cell apoptosis, metabolism, and feedback regulation.",
      "Autophagy is a process that involves the degradation of macromolecules and organelles.",
      "During autophagy, the target macromolecule or organelle is enclosed in an autophagosome and delivered to the lysosome for degradation.",
      "Autophagy is triggered by stress and is important for cell survival."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 632,
    "user_query": "What is the cause of episodic ataxia type 6?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, the cause of episodic ataxia type 6 is not explicitly stated. However, it is mentioned that episodic ataxia (EA) is a type of ataxia that causes periods of movement and balance problems, with a clear beginning and end. The information also notes that ataxia describes poor muscle control that causes clumsy voluntary movements, which can affect various bodily functions such as walking, balance, hand coordination, speech, and swallowing.\nTherefore, it can be inferred that the cause of episodic ataxia type 6 is likely related to problems in the cerebellum and brainstem, which are the areas of the brain responsible for coordinating and regulating movement, balance, and other motor functions. The exact cause of episodic ataxia type 6 may involve genetic mutations or other factors that affect the functioning of these brain regions.\nIt is important to note that the exact cause of episodic ataxia type 6 may vary depending on the individual case, and a thorough medical evaluation and diagnosis are necessary to determine the underlying cause of the condition. A healthcare professional, such as a neurologist, can provide more information and guidance on the diagnosis and treatment of episodic ataxia type 6.",
    "llama-2-7b-chat-hf_fact_raw": "1. Episodic ataxia (EA) is a type of ataxia that causes periods of movement and balance problems.\n2. Ataxia describes poor muscle control that causes clumsy voluntary movements.\n3. Symptoms of ataxia can affect walking, balance, hand coordination, speech, and swallowing.\n4. The cerebellum and brainstem are areas of the brain responsible for coordinating and regulating movement, balance, and other motor functions.\n5. The exact cause of episodic ataxia type 6 may involve genetic mutations or other factors that affect the functioning of the cerebellum and brainstem.",
    "llama-2-7b-chat-hf_fact": [
      "Episodic ataxia (EA) is a type of ataxia that causes periods of movement and balance problems.",
      "Ataxia describes poor muscle control that causes clumsy voluntary movements.",
      "Symptoms of ataxia can affect walking, balance, hand coordination, speech, and swallowing.",
      "The cerebellum and brainstem are areas of the brain responsible for coordinating and regulating movement, balance, and other motor functions.",
      "The exact cause of episodic ataxia type 6 may involve genetic mutations or other factors that affect the functioning of the cerebellum and brainstem."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 646,
    "user_query": "Are chromomethylases present in animal genomes?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Documents 0 and 1, chromomethylases are not present in animal genomes. The definition of chromomethylases provided in Document 0 specifically states that they are plant-specific DNA methylation enzymes, and there is no mention of their presence in animal genomes. Additionally, the abstract of Document 1 states that cytosine methylation is a common modification in the bodies of active genes in animals and vascular plants, but there is no mention of chromomethylases being involved in this process. Therefore, it can be concluded that chromomethylases are not present in animal genomes.",
    "llama-2-7b-chat-hf_fact_raw": "1. Chromomethylases are plant-specific DNA methylation enzymes.\n2. Chromomethylases are not present in animal genomes.\n3. Cytosine methylation is a common modification in the bodies of active genes in animals and vascular plants.\n4. There is no mention of chromomethylases being involved in the cytosine methylation process in animals.",
    "llama-2-7b-chat-hf_fact": [
      "Chromomethylases are plant-specific DNA methylation enzymes.",
      "Chromomethylases are not present in animal genomes.",
      "Cytosine methylation is a common modification in the bodies of active genes in animals and vascular plants.",
      "There is no mention of chromomethylases being involved in the cytosine methylation process in animals."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: Cytosine methylation is commonly found in the DNA of plants and animals, but it is typically associated with gene repression in animals, not necessarily within the bodies of active genes.\n4. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 650,
    "user_query": "List packages for transcription factor binding sites' (TFBS) analysis available in R/Bioconductor",
    "llama-2-7b-chat-hf_response": "Based on the information provided, here are some packages available in R/Bioconductor for transcription factor binding site (TFBS) analysis:\n1. TFBSTools: This is the package mentioned in the document, which provides a toolkit for handling TFBS profile matrices, scanning sequences and alignments including whole genomes, and querying the JASPAR database. The latest version of this package is 1.41.0.\n2. JASPAR: This package provides a comprehensive collection of TFBS matrices from the JASPAR database, which is a widely used database of TFBS profiles. The package includes tools for downloading and manipulating TFBS matrices, as well as for generating new matrices from user-provided sequences.\n3. TRANSFAC: This package provides a comprehensive collection of TFBS matrices from a variety of sources, including the JASPAR database. It also includes tools for downloading and manipulating TFBS matrices, as well as for generating new matrices from user-provided sequences.\n4. ChIPseek: This package provides tools for the analysis of ChIP-seq data, which can be used to identify TFBSs. It includes tools for peak calling, motif discovery, and visualization of ChIP-seq data.\n5. HISAT2: This package provides tools for the analysis of ChIP-seq data, including peak calling and motif discovery. It also includes tools for visualizing ChIP-seq data and for identifying TFBSs.\n6. STAR: This package provides tools for the analysis of ChIP-seq data, including peak calling and motif discovery. It also includes tools for visualizing ChIP-seq data and for identifying TFBSs.\n7. Prodigal: This package provides tools for the analysis of ChIP-seq data, including peak calling and motif discovery. It also includes tools for visualizing ChIP-seq data and for identifying TFBSs.\n8. Bedtools: This package provides tools for manipulating and analyzing genomic data, including ChIP-seq data. It includes tools for bedfile manipulation, genomic interval analysis, and visualization of genomic data.\nThese packages can be used for various tasks related to TFBS analysis, such as motif discovery, peak calling, and visualization of ChIP-",
    "llama-2-7b-chat-hf_fact_raw": "1. TFBSTools is a package in R/Bioconductor that provides a toolkit for handling TFBS profile matrices and scanning sequences.\n2. The JASPAR package in R/Bioconductor offers a collection of TFBS matrices from the JASPAR database and includes tools for downloading and manipulating these matrices.\n3. TRANSFAC is a package in R/Bioconductor that provides a collection of TFBS matrices from various sources, including the JASPAR database.\n4. ChIPseek is an R/Bioconductor package that provides tools for the analysis of ChIP-seq data to identify TFBSs.\n5. Bedtools is an R/Bioconductor package that includes tools for manipulating and analyzing genomic data, such as ChIP-seq data.",
    "llama-2-7b-chat-hf_fact": [
      "TFBSTools is a package in R/Bioconductor that provides a toolkit for handling TFBS profile matrices and scanning sequences.",
      "The JASPAR package in R/Bioconductor offers a collection of TFBS matrices from the JASPAR database and includes tools for downloading and manipulating these matrices.",
      "TRANSFAC is a package in R/Bioconductor that provides a collection of TFBS matrices from various sources, including the JASPAR database.",
      "ChIPseek is an R/Bioconductor package that provides tools for the analysis of ChIP-seq data to identify TFBSs.",
      "Bedtools is an R/Bioconductor package that includes tools for manipulating and analyzing genomic data, such as ChIP-seq data."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: TRANSFAC is not a package in R/Bioconductor. TRANSFAC is a database of transcription factor binding sites. The R/Bioconductor package that provides a collection of TFBS matrices, including those from the JASPAR database, is called TFBSTools.\n4. FALSE [correction]: ChIPseeker is the R/Bioconductor package that provides tools for the analysis of ChIP-seq data, not ChIPseek.\n5. FALSE [correction]: Bedtools is not an R/Bioconductor package. It is a command-line toolset for genome arithmetic, but there is an R package called rtracklayer that provides an interface to Bedtools and other tools for manipulating and analyzing genomic data within the R environment.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 721,
    "user_query": "List clinical trials for prevention of sarcopenia",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Documents 0 and 1, there are several clinical trials that have investigated the prevention of sarcopenia through various interventions, including physical exercise, nutraceuticals, and pharmaceuticals. Here are some of the clinical trials that have been identified:\n1. Exercise interventions:\n* A randomized controlled trial published in the Journal of the American Medical Directors Association in 2018 found that a 12-month exercise program consisting of resistance training and aerobic exercise significantly improved muscle mass and strength in older adults at risk of sarcopenia.\n* A systematic review and meta-analysis published in the Journal of Aging Research in 2019 found that exercise interventions, including both resistance and aerobic exercise, were effective in preventing sarcopenia in older adults.\n2. Nutraceutical interventions:\n* A randomized controlled trial published in the Journal of Nutrition in 2018 found that supplementation with a combination of omega-3 fatty acids and antioxidants improved muscle mass and strength in older adults with sarcopenia.\n* A systematic review and meta-analysis published in the Journal of the American Geriatrics Society in 2019 found that nutraceutical interventions, including creatine, protein, and omega-3 fatty acids, were effective in preventing sarcopenia in older adults.\n3. Pharmaceutical interventions:\n* A randomized controlled trial published in the Journal of Clinical Interventions in Aging in 2018 found that treatment with the drug rapamycin improved muscle mass and strength in older adults with sarcopenia.\n* A systematic review and meta-analysis published in the Journal of the American Geriatrics Society in 2019 found that pharmaceutical interventions, including selective estrogen receptor modulators and insulin sensitizers, were effective in preventing sarcopenia in older adults.\nIt is important to note that while these interventions have shown promise in preventing sarcopenia, more research is needed to confirm their effectiveness and to determine",
    "llama-2-7b-chat-hf_fact_raw": "1. A 12-month exercise program consisting of resistance training and aerobic exercise was found to significantly improve muscle mass and strength in older adults at risk of sarcopenia, according to a randomized controlled trial published in the Journal of the American Medical Directors Association in 2018.\n2. A systematic review and meta-analysis published in the Journal of Aging Research in 2019 concluded that exercise interventions, including both resistance and aerobic exercise, were effective in preventing sarcopenia in older adults.\n3. A randomized controlled trial published in the Journal of Nutrition in 2018 reported that supplementation with a combination of omega-3 fatty acids and antioxidants improved muscle mass and strength in older adults with sarcopenia.\n4. A systematic review and meta-analysis published in the Journal of the American Geriatrics Society in 2019 indicated that nutraceutical interventions, including creatine, protein, and omega-3 fatty acids, were effective in preventing sarcopenia in older adults.\n5. A randomized controlled trial published in the Journal of Clinical Interventions in Aging in 2018 found that treatment with the drug rapamycin improved muscle mass and strength in older adults with sarcopenia.",
    "llama-2-7b-chat-hf_fact": [
      "A 12-month exercise program consisting of resistance training and aerobic exercise was found to significantly improve muscle mass and strength in older adults at risk of sarcopenia, according to a randomized controlled trial published in the Journal of the American Medical Directors Association in 2018.",
      "A systematic review and meta-analysis published in the Journal of Aging Research in 2019 concluded that exercise interventions, including both resistance and aerobic exercise, were effective in preventing sarcopenia in older adults.",
      "A randomized controlled trial published in the Journal of Nutrition in 2018 reported that supplementation with a combination of omega-3 fatty acids and antioxidants improved muscle mass and strength in older adults with sarcopenia.",
      "A systematic review and meta-analysis published in the Journal of the American Geriatrics Society in 2019 indicated that nutraceutical interventions, including creatine, protein, and omega-3 fatty acids, were effective in preventing sarcopenia in older adults.",
      "A randomized controlled trial published in the Journal of Clinical Interventions in Aging in 2018 found that treatment with the drug rapamycin improved muscle mass and strength in older adults with sarcopenia."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nWithout access to the specific articles from the journals mentioned, it is not possible to verify the accuracy of these statements. They are specific claims that require checking the respective journal articles for validation.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 722,
    "user_query": "Which is the database of molecular recognition features in membrane proteins?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, the database of molecular recognition features in membrane proteins is likely to be \"mpMoRFsDB\". This database was mentioned in Document 0, which is a research article titled \"mpMoRFsDB: a database of molecular recognition features in membrane proteins\". The article was published in the journal Bioinformatics in 2013 and provides information on the molecular recognition features (MoRFs) in membrane proteins. MoRFs are small, intrinsically disordered regions in proteins that undergo a disorder-to-order transition on binding to their partners, and are involved in protein-protein interactions. Therefore, the database \"mpMoRFsDB\" is likely to contain information on the molecular recognition features in membrane proteins, which is the topic of the user's question.",
    "llama-2-7b-chat-hf_fact_raw": "1. \"mpMoRFsDB\" is a database of molecular recognition features in membrane proteins.\n2. The database \"mpMoRFsDB\" was mentioned in a research article titled \"mpMoRFsDB: a database of molecular recognition features in membrane proteins\".\n3. The article about \"mpMoRFsDB\" was published in the journal Bioinformatics in 2013.\n4. Molecular recognition features (MoRFs) are small, intrinsically disordered regions in proteins.\n5. MoRFs undergo a disorder-to-order transition upon binding to their partners and are involved in protein-protein interactions.",
    "llama-2-7b-chat-hf_fact": [
      "\"mpMoRFsDB\" is a database of molecular recognition features in membrane proteins.",
      "The database \"mpMoRFsDB\" was mentioned in a research article titled \"mpMoRFsDB: a database of molecular recognition features in membrane proteins\".",
      "The article about \"mpMoRFsDB\" was published in the journal Bioinformatics in 2013.",
      "Molecular recognition features (MoRFs) are small, intrinsically disordered regions in proteins.",
      "MoRFs undergo a disorder-to-order transition upon binding to their partners and are involved in protein-protein interactions."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: The article about \"mpMoRFsDB\" was published in the journal Bioinformatics in 2021.\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 745,
    "user_query": "Is rivaroxaban metabolized in kidneys?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, rivaroxaban is not metabolized in the kidneys. According to Document 0, rivaroxaban is a selective, reversible, direct Factor Xa inhibitor that does not require cofactors for its anticoagulant effect. This suggests that the drug is metabolized primarily through other mechanisms, such as liver metabolism, rather than through the kidneys.\nAdditionally, Document 1 indicates that rivaroxaban is approved for use in 7 indications, including the prevention of stroke and systemic embolism in nonvalvular atrial fibrillation, treatment of deep vein thrombosis, treatment of pulmonary embolism, and others. However, there is no mention of the kidneys or renal metabolism in these documents.\nTherefore, based on the information provided, it can be concluded that rivaroxaban is not metabolized in the kidneys.",
    "llama-2-7b-chat-hf_fact_raw": "1. Rivaroxaban is not metabolized in the kidneys.\n2. Rivaroxaban is a selective, reversible, direct Factor Xa inhibitor.\n3. Rivaroxaban does not require cofactors for its anticoagulant effect.\n4. Rivaroxaban is approved for use in 7 indications.\n5. Rivaroxaban's indications include the prevention of stroke and systemic embolism in nonvalvular atrial fibrillation, treatment of deep vein thrombosis, and treatment of pulmonary embolism.",
    "llama-2-7b-chat-hf_fact": [
      "Rivaroxaban is not metabolized in the kidneys.",
      "Rivaroxaban is a selective, reversible, direct Factor Xa inhibitor.",
      "Rivaroxaban does not require cofactors for its anticoagulant effect.",
      "Rivaroxaban is approved for use in 7 indications.",
      "Rivaroxaban's indications include the prevention of stroke and systemic embolism in nonvalvular atrial fibrillation, treatment of deep vein thrombosis, and treatment of pulmonary embolism."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: Rivaroxaban is primarily metabolized in the liver, not the kidneys.\n2. TRUE: Rivaroxaban is indeed a selective, reversible, direct Factor Xa inhibitor.\n3. TRUE: Rivaroxaban does not require cofactors for its anticoagulant effect.\n4. UNKNOWN: The number of approved indications for rivaroxaban can vary by country and over time as new indications are approved or existing ones are modified. Without a current reference, it is not possible to confirm the exact number of approved indications.\n5. TRUE: Rivaroxaban's indications include the prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation, treatment of deep vein thrombosis (DVT), and treatment of pulmonary embolism (PE).",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "unknown",
      "true"
    ]
  },
  {
    "id": 763,
    "user_query": "Which genes are regulated by TRalpha2  in the heart?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Documents 0 and 1, TRalpha2 is involved in the regulation of several genes related to heart function, including:\n1. Genes involved in the regulation of heart rate, such as GO:0002027 (potassium channels).\n2. TTN isoforms, which are involved in the expression of functional and structural heart properties.\n3. The alternative splicing events required for functional and structural heart properties, which are regulated by RBM20 and PTBP1.\nTherefore, TRalpha2 is likely to regulate genes involved in the development, maintenance, and function of the heart, including genes involved in heart rate regulation, ion channel function, and alternative splicing events.",
    "llama-2-7b-chat-hf_fact_raw": "1. TRalpha2 is involved in the regulation of genes related to heart function.\n2. TRalpha2 regulates genes involved in the regulation of heart rate, such as those associated with potassium channels (GO:0002027).\n3. TRalpha2 is involved in the regulation of TTN isoforms, which are related to functional and structural properties of the heart.\n4. TRalpha2 is likely to regulate the alternative splicing events required for functional and structural heart properties, which involve RBM20 and PTBP1.",
    "llama-2-7b-chat-hf_fact": [
      "TRalpha2 is involved in the regulation of genes related to heart function.",
      "TRalpha2 regulates genes involved in the regulation of heart rate, such as those associated with potassium channels (GO:0002027).",
      "TRalpha2 is involved in the regulation of TTN isoforms, which are related to functional and structural properties of the heart.",
      "TRalpha2 is likely to regulate the alternative splicing events required for functional and structural heart properties, which involve RBM20 and PTBP1."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n\nThe statements provided are specific and technical, and they all relate to the role of TRalpha2 in heart function. Without additional context or specific research references, it is not possible to definitively confirm the accuracy of these statements. However, they are consistent with the types of roles that a thyroid hormone receptor like TRalpha2 could play in gene regulation related to heart function, including the regulation of heart rate through potassium channels, involvement in the regulation of TTN isoforms, and the potential regulation of alternative splicing events involving proteins like RBM20 and PTBP1. Therefore, based on the information given and the plausibility of the statements within the field of molecular biology, they are marked as true. If the context provided included specific research findings or references, a more accurate assessment could be made.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 786,
    "user_query": "List available biomedical question answering systems.",
    "llama-2-7b-chat-hf_response": "Thank you for your question! Based on the information provided, here are some available biomedical question answering systems:\n1. BioASQ 3 (Biomedical Semantic Indexing and Question Answering): As mentioned in Document 1, BioASQ 3 is a push towards highly precise biomedical information access systems through a series of evaluation campaigns.\n2. PubMed: PubMed is a comprehensive database of biomedical literature, providing access to over 29 million citations from MEDLINE, life science journals, and online books.\n3. Google Scholar: Google Scholar is a free search engine that indexes scholarly literature across many disciplines and sources, including articles, theses, books, and conference papers.\n4. Semantic Scholar: Semantic Scholar is an AI-powered academic search engine that indexes and organizes scientific literature, including biomedical research papers, to help scientists find relevant information more efficiently.\n5. Microsoft Research Open Data: Microsoft Research Open Data is a platform that provides access to a wide range of biomedical datasets, including gene expression data, protein structures, and clinical trial data.\n6. National Center for Biotechnology Information (NCBI): NCBI is a part of the National Library of Medicine, and it provides access to a vast array of biomedical databases, including GenBank, PubMed, and Entrez Gene.\n7. Biomedical Informatics Research Network (BIRN): BIRN is a network of biomedical informatics researchers and resources, including databases, tools, and services for biomedical research.\n8. Biomedical Information and Technology Initiative (BITI): BITI is a collaborative effort to develop and apply advanced information technologies to improve the efficiency and effectiveness of biomedical research.\n9. Biomedical Question Answering System (BQA): BQA is a system that uses natural language processing and machine learning techniques to answer biomedical questions based on a large corpus of biomedical text.\n10. COVID-19-related question answering systems: There has been a surge of COVID-19-related publications, and several question answering systems have been developed to help human experts keep up with the latest research in the field. Examples include the COVID-19 Question Answering System (C19",
    "llama-2-7b-chat-hf_fact_raw": "1. BioASQ 3 is a system aimed at improving biomedical information access through evaluation campaigns.\n2. PubMed is a database that provides access to over 29 million citations from MEDLINE, life science journals, and online books.\n3. Google Scholar is a search engine that indexes scholarly literature across many disciplines and sources.\n4. Semantic Scholar is an AI-powered search engine that organizes scientific literature, including biomedical research papers.\n5. The National Center for Biotechnology Information (NCBI) provides access to a variety of biomedical databases, including GenBank, PubMed, and Entrez Gene.",
    "llama-2-7b-chat-hf_fact": [
      "BioASQ 3 is a system aimed at improving biomedical information access through evaluation campaigns.",
      "PubMed is a database that provides access to over 29 million citations from MEDLINE, life science journals, and online books.",
      "Google Scholar is a search engine that indexes scholarly literature across many disciplines and sources.",
      "Semantic Scholar is an AI-powered search engine that organizes scientific literature, including biomedical research papers.",
      "The National Center for Biotechnology Information (NCBI) provides access to a variety of biomedical databases, including GenBank, PubMed, and Entrez Gene."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: PubMed is a database that provides access to over 32 million citations from MEDLINE, life science journals, and online books. (Note: The number of citations in PubMed can vary; the figure provided here may be outdated, so it's best to check the current number on the PubMed website.)\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 794,
    "user_query": "Which trancription factor activates the betalain pathway?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Documents 0 and 1, the trancription factor that activates the betalain pathway is most likely to be a transcription factor specific to the Caryophyllales order of plants.\nBetalains are a type of water-soluble and nitrogen-containing pigments that are restricted to the Caryophyllales order of plants, with the exception of Molluginaceae and Caryophyllaceae, which produce betalains as well. The production of betalains is controlled by light cues, which suggests that the regulation of betalain biosynthesis is mediated by light-responsive transcription factors.\nTherefore, the trancription factor that activates the betalain pathway is likely to be a transcription factor that is specific to the Caryophyllales order of plants and is light-responsive. However, without additional information, it is not possible to identify the specific trancription factor involved in betalain biosynthesis.\nIt is worth noting that the regulation of betalain biosynthesis is a complex process that involves multiple transcription factors and signaling pathways, and the exact mechanism by which light regulates betalain biosynthesis is not fully understood. Further research is needed to elucidate the molecular mechanisms underlying the regulation of betalain biosynthesis in plants.",
    "llama-2-7b-chat-hf_fact_raw": "1. Betalains are water-soluble and nitrogen-containing pigments.\n2. Betalains are restricted to the Caryophyllales order of plants, except for the Molluginaceae and Caryophyllaceae families.\n3. The production of betalains is controlled by light cues.\n4. The regulation of betalain biosynthesis is likely mediated by light-responsive transcription factors.\n5. The exact mechanism by which light regulates betalain biosynthesis is not fully understood.",
    "llama-2-7b-chat-hf_fact": [
      "Betalains are water-soluble and nitrogen-containing pigments.",
      "Betalains are restricted to the Caryophyllales order of plants, except for the Molluginaceae and Caryophyllaceae families.",
      "The production of betalains is controlled by light cues.",
      "The regulation of betalain biosynthesis is likely mediated by light-responsive transcription factors.",
      "The exact mechanism by which light regulates betalain biosynthesis is not fully understood."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 883,
    "user_query": "Global quantitative phosphoproteomic analyses are emerging. List the preferred technologies for the enrichment for phosphorylated peptides?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, the preferred technologies for enrichment of phosphorylated peptides for global quantitative phosphoproteomic analyses are:\n1. TiO2-based enrichment: This is a widely used method for phosphopeptide enrichment, which involves the use of titanium dioxide (TiO2) to selectively bind phosphorylated peptides.\n2. IMAC (Immobilized Metal Affinity Chromatography): This method uses metal ions, such as copper or nickel, to selectively bind phosphorylated peptides.\n3. PEG-based enrichment: This method uses polyethylene glycol (PEG) to selectively bind phosphorylated peptides.\n4. Hydrophobic interaction chromatography (HIC): This method separates peptides based on their hydrophobicity, which can help to enrich for phosphorylated peptides.\n5. Reversed-phase HPLC: This method separates peptides based on their hydrophobicity, which can help to enrich for phosphorylated peptides.\n6. Enrichment using phosphopeptide-specific antibodies: This method uses antibodies that specifically bind to phosphorylated peptides to enrich for them.\n7. Enrichment using phosphopeptide-specific ligands: This method uses ligands that specifically bind to phosphorylated peptides to enrich for them.\nIt's worth noting that the choice of technology will depend on the specific research question and the properties of the phosphorylated peptides being analyzed.",
    "llama-2-7b-chat-hf_fact_raw": "1. TiO2-based enrichment is used for phosphopeptide enrichment and involves titanium dioxide to selectively bind phosphorylated peptides.\n2. Immobilized Metal Affinity Chromatography (IMAC) uses metal ions like copper or nickel to selectively bind phosphorylated peptides.\n3. Polyethylene glycol (PEG) is used in a method to selectively bind phosphorylated peptides for enrichment.\n4. Hydrophobic interaction chromatography (HIC) separates peptides based on hydrophobicity and can enrich for phosphorylated peptides.\n5. Reversed-phase High-Performance Liquid Chromatography (HPLC) separates peptides based on hydrophobicity and can be used to enrich for phosphorylated peptides.",
    "llama-2-7b-chat-hf_fact": [
      "TiO2-based enrichment is used for phosphopeptide enrichment and involves titanium dioxide to selectively bind phosphorylated peptides.",
      "Immobilized Metal Affinity Chromatography (IMAC) uses metal ions like copper or nickel to selectively bind phosphorylated peptides.",
      "Polyethylene glycol (PEG) is used in a method to selectively bind phosphorylated peptides for enrichment.",
      "Hydrophobic interaction chromatography (HIC) separates peptides based on hydrophobicity and can enrich for phosphorylated peptides.",
      "Reversed-phase High-Performance Liquid Chromatography (HPLC) separates peptides based on hydrophobicity and can be used to enrich for phosphorylated peptides."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: Polyethylene glycol (PEG) is not typically used to selectively bind phosphorylated peptides for enrichment. It is often used in precipitation methods to separate proteins based on solubility.\n4. FALSE [correction]: Hydrophobic interaction chromatography (HIC) separates peptides based on hydrophobicity but is not specifically used to enrich for phosphorylated peptides. Phosphorylated peptides are more polar due to the addition of a phosphate group and are less likely to be enriched by HIC.\n5. FALSE [correction]: Reversed-phase High-Performance Liquid Chromatography (HPLC) separates peptides based on hydrophobicity but does not specifically enrich for phosphorylated peptides. It is a general peptide separation method and not targeted towards phosphorylated peptides.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 901,
    "user_query": "Which disorder is rated by Palmini classification?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the disorder that is rated by the Palmini classification is focal cortical dysplasia. Specifically, the classification divides focal cortical dysplasia into three groups: mild malformation of cortical development (mild MCD), type I and type II. The mild MCD is further divided into two subtypes: type I, with ectopically placed neurons in or adjacent to layer I, and type II, with microscopic neuronal heterotopia outside layer I.",
    "llama-2-7b-chat-hf_fact_raw": "1. The Palmini classification is used to rate focal cortical dysplasia.\n2. The Palmini classification divides focal cortical dysplasia into three groups.\n3. The three groups in the Palmini classification are mild malformation of cortical development (mild MCD), type I, and type II.\n4. Mild MCD is further divided into two subtypes by the Palmini classification.\n5. Type I mild MCD is characterized by ectopically placed neurons in or adjacent to layer I, and type II mild MCD is characterized by microscopic neuronal heterotopia outside layer I.",
    "llama-2-7b-chat-hf_fact": [
      "The Palmini classification is used to rate focal cortical dysplasia.",
      "The Palmini classification divides focal cortical dysplasia into three groups.",
      "The three groups in the Palmini classification are mild malformation of cortical development (mild MCD), type I, and type II.",
      "Mild MCD is further divided into two subtypes by the Palmini classification.",
      "Type I mild MCD is characterized by ectopically placed neurons in or adjacent to layer I, and type II mild MCD is characterized by microscopic neuronal heterotopia outside layer I."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: The three groups in the Palmini classification are type I, type II, and type III focal cortical dysplasia.\n4. FALSE [correction]: Mild malformation of cortical development (mild MCD) is not a category within the Palmini classification. The Palmini classification does not divide mild MCD into subtypes; it divides focal cortical dysplasia into subtypes.\n5. FALSE [correction]: This statement incorrectly describes mild MCD, which is not part of the Palmini classification. In the Palmini classification, type I and type II focal cortical dysplasia have different characteristics. Type I is characterized by isolated architectural abnormalities, while type II is characterized by architectural abnormalities plus the presence of dysmorphic neurons and, in type IIb, balloon cells.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 905,
    "user_query": "Are viruses involved in the etiology of human subacute thyroiditis?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Documents 0 and 1, there is evidence to suggest that viruses are involved in the etiology of human subacute thyroiditis. The review in Document 0 notes that viral infections are frequently cited as a major environmental factor involved in subacute thyroiditis and autoimmune thyroid diseases, and our research has been focused on human data. Table 1 in Document 1 provides a list of common thyroid disorders, including subacute thyroiditis, nonthyroidal illness syndrome, and autoimmune thyroid diseases, and notes that viral infection may represent one of the major environmental factors related to these disorders. While the review does not specifically mention viruses as the cause of subacute thyroiditis, the evidence suggests that viral infections may play a role in the development of this condition. Therefore, based on the information provided, the answer to the user's question is yes, viruses are involved in the etiology of human subacute thyroiditis.",
    "llama-2-7b-chat-hf_fact_raw": "1. Viral infections are frequently cited as a major environmental factor involved in subacute thyroiditis and autoimmune thyroid diseases.\n2. Document 0 contains a review that notes the involvement of viral infections in subacute thyroiditis.\n3. Document 1 includes a table listing common thyroid disorders, such as subacute thyroiditis, nonthyroidal illness syndrome, and autoimmune thyroid diseases.\n4. The table in Document 1 indicates that viral infection may be a major environmental factor related to these thyroid disorders.\n5. The evidence suggests that viral infections may play a role in the development of human subacute thyroiditis.",
    "llama-2-7b-chat-hf_fact": [
      "Viral infections are frequently cited as a major environmental factor involved in subacute thyroiditis and autoimmune thyroid diseases.",
      "Document 0 contains a review that notes the involvement of viral infections in subacute thyroiditis.",
      "Document 1 includes a table listing common thyroid disorders, such as subacute thyroiditis, nonthyroidal illness syndrome, and autoimmune thyroid diseases.",
      "The table in Document 1 indicates that viral infection may be a major environmental factor related to these thyroid disorders.",
      "The evidence suggests that viral infections may play a role in the development of human subacute thyroiditis."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 963,
    "user_query": "Is STAT3 involved in EIF2AK2-dependent suppression of autophagy?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Document 1, it appears that STAT3 is involved in the suppression of autophagy through its interaction with EIF2AK2. The document states that cytoplasmic STAT3 constitutively inhibits autophagy by sequestering EIF2AK2, as well as by interacting with other autophagy-related signaling molecules such as FOXO1 and FOXO3.\nTherefore, the answer to the user's question is yes, STAT3 is involved in the suppression of autophagy through its interaction with EIF2AK2, which is dependent on the activity of peIF2α and eIF2α kinases.",
    "llama-2-7b-chat-hf_fact_raw": "1. STAT3 is involved in the suppression of autophagy.\n2. STAT3 interacts with EIF2AK2.\n3. Cytoplasmic STAT3 constitutively inhibits autophagy by sequestering EIF2AK2.\n4. STAT3 also interacts with other autophagy-related signaling molecules such as FOXO1 and FOXO3.\n5. The suppression of autophagy by STAT3 is dependent on the activity of peIF2α and eIF2α kinases.",
    "llama-2-7b-chat-hf_fact": [
      "STAT3 is involved in the suppression of autophagy.",
      "STAT3 interacts with EIF2AK2.",
      "Cytoplasmic STAT3 constitutively inhibits autophagy by sequestering EIF2AK2.",
      "STAT3 also interacts with other autophagy-related signaling molecules such as FOXO1 and FOXO3.",
      "The suppression of autophagy by STAT3 is dependent on the activity of peIF2α and eIF2α kinases."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: STAT3 (Signal Transducer and Activator of Transcription 3) has been reported to be involved in the suppression of autophagy in various studies.\n2. TRUE: STAT3 can interact with EIF2AK2 (also known as PKR), which is a protein kinase involved in the cellular stress response.\n3. TRUE: Cytoplasmic STAT3 has been shown to constitutively inhibit autophagy, and one of the mechanisms proposed is the sequestration of EIF2AK2, preventing it from initiating autophagy.\n4. TRUE: STAT3 is known to interact with various signaling molecules, and there is evidence to suggest that it can interact with members of the FOXO family of transcription factors, such as FOXO1 and FOXO3, which are involved in autophagy regulation.\n5. FALSE [correction]: The suppression of autophagy by STAT3 is not directly dependent on the activity of phosphorylated eIF2α (peIF2α) and eIF2α kinases. Instead, STAT3 suppresses autophagy through various mechanisms, some of which may involve interactions with other proteins and signaling pathways, but not necessarily through the activity of peIF2α and eIF2α kinases.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 973,
    "user_query": "Describe what is the usage of the Theatre software tool for genomic analysis.",
    "llama-2-7b-chat-hf_response": "Based on the information provided, Theatre software tool is primarily used for genomic analysis, specifically for the following purposes:\n1. Determining or predicting coding regions, repetitive sequences, and transcription factor binding sites in families of DNA sequences. This is done by using Theatre as an interface to commonly used sequence analysis tools and biological sequence databases.\n2. Comparative analysis of genomic sequences, particularly with respect to motifs likely to be involved in the regulation of gene expression. Theatre can be used to identify and compare the differences in the p53 promoter region of different organisms, such as mammals and fish species.\nIn more detail, Theatre can be used to:\n1. Identify and annotate coding regions, repetitive sequences, and transcription factor binding sites in a given DNA sequence using various tools and databases.\n2. Compare the genomic sequences of different organisms to identify similarities and differences, particularly in regions that are likely to be involved in gene regulation.\n3. Predict the effects of mutations or variations in specific regions of the genome on gene expression or function.\n4. Identify potential regulatory elements, such as transcription factor binding sites, in a given genomic sequence.\n5. Analyze the evolutionary changes in the genomic sequences of different organisms, including the identification of conserved and non-conserved regions.\nOverall, Theatre is a powerful tool for genomic analysis, allowing researchers to quickly and easily analyze and compare genomic sequences, identify potential regulatory elements, and predict the effects of mutations or variations on gene expression or function.",
    "llama-2-7b-chat-hf_fact_raw": "1. Theatre software tool is used for genomic analysis.\n2. Theatre can determine or predict coding regions, repetitive sequences, and transcription factor binding sites in DNA sequences.\n3. The software allows for comparative analysis of genomic sequences to identify motifs involved in gene expression regulation.\n4. Theatre can be used to predict the effects of mutations or variations in specific regions of the genome on gene expression or function.\n5. It can analyze evolutionary changes in genomic sequences, including the identification of conserved and non-conserved regions.",
    "llama-2-7b-chat-hf_fact": [
      "Theatre software tool is used for genomic analysis.",
      "Theatre can determine or predict coding regions, repetitive sequences, and transcription factor binding sites in DNA sequences.",
      "The software allows for comparative analysis of genomic sequences to identify motifs involved in gene expression regulation.",
      "Theatre can be used to predict the effects of mutations or variations in specific regions of the genome on gene expression or function.",
      "It can analyze evolutionary changes in genomic sequences, including the identification of conserved and non-conserved regions."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The correct term is likely \"gene prediction software\" or \"bioinformatics tools\" rather than \"theatre software tool,\" which is not a recognized term for genomic analysis.\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nWithout specific information about a software named \"Theatre,\" it is not possible to accurately assess statements 2 through 5. If \"Theatre\" is a hypothetical or incorrectly named software tool for genomic analysis, the capabilities described in statements 2 through 5 are typical of many bioinformatics tools, but without the correct name or additional context, the truthfulness of these statements cannot be determined.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 997,
    "user_query": "Which  is the execution time (complexity) of the Smith-Waterman algorithm for the alignment of two sequences",
    "llama-2-7b-chat-hf_response": "Based on the information provided, the execution time (complexity) of the Smith-Waterman algorithm for the alignment of two sequences is O(n^2), where n is the length of the sequences.\nThe Smith-Waterman algorithm is a local alignment algorithm that uses dynamic programming to find the highest-scoring path between two sequences. The algorithm works by computing the score for each possible alignment between the two sequences, and then selecting the alignment with the highest score.\nThe time complexity of the Smith-Waterman algorithm is O(n^2) because it requires computing the score for each possible alignment between the two sequences, which involves comparing each element of one sequence to each element of the other sequence. Since there are n elements in each sequence, the total number of possible alignments is n x n = n^2.\nTherefore, the execution time of the Smith-Waterman algorithm is proportional to the square of the length of the sequences, which makes it a computationally expensive algorithm for large sequences. However, the algorithm is widely used in many applications, such as in bioinformatics and computational biology, because of its high accuracy and sensitivity in identifying local alignments between sequences.",
    "llama-2-7b-chat-hf_fact_raw": "1. The execution time (complexity) of the Smith-Waterman algorithm for the alignment of two sequences is O(n^2).\n2. The Smith-Waterman algorithm is a local alignment algorithm.\n3. The Smith-Waterman algorithm uses dynamic programming.\n4. The algorithm computes the score for each possible alignment between two sequences.\n5. The Smith-Waterman algorithm is used in applications such as bioinformatics and computational biology.",
    "llama-2-7b-chat-hf_fact": [
      "The execution time (complexity) of the Smith-Waterman algorithm for the alignment of two sequences is O(n^2).",
      "The Smith-Waterman algorithm is a local alignment algorithm.",
      "The Smith-Waterman algorithm uses dynamic programming.",
      "The algorithm computes the score for each possible alignment between two sequences.",
      "The Smith-Waterman algorithm is used in applications such as bioinformatics and computational biology."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1004,
    "user_query": "Which SLC family is FLVCR1 a member of?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, FLVCR1 is a member of the SLC49 family.",
    "llama-2-7b-chat-hf_fact_raw": "1. FLVCR1 is a member of the SLC49 family.",
    "llama-2-7b-chat-hf_fact": [
      "FLVCR1 is a member of the SLC49 family."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true"
    ]
  },
  {
    "id": 1047,
    "user_query": "List GATA-1 interacting partners as discovered with the help of the biotinylation tagging approach.",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Documents 0 and 1, the following are some of the known interacting partners of GATA-1:\n1. HES6: As mentioned in Document 1, HES6 is a novel GATA-1-interacting protein that is essential for human erythropoiesis. The study found that HES6 is expressed at the gene level during erythropoiesis and interacts with GATA-1 to regulate erythroid gene expression.\n2. KLF1: GATA-1 has been shown to interact with KLF1, a transcription factor that regulates the expression of genes involved in erythropoiesis. The interaction between GATA-1 and KLF1 has been suggested to play a role in the regulation of erythroid gene expression during development and disease.\n3. NF-E2: NF-E2 is a transcription factor that regulates the expression of genes involved in erythropoiesis, and has been shown to interact with GATA-1. The interaction between GATA-1 and NF-E2 has been suggested to play a role in the regulation of erythroid gene expression during development and disease.\n4. BCL11A: BCL11A is a transcription factor that regulates the expression of genes involved in erythropoiesis, and has been shown to interact with GATA-1. The interaction between GATA-1 and BCL11A has been suggested to play a role in the regulation of erythroid gene expression during development and disease.\n5. TAL1: TAL1 is a transcription factor that regulates the expression of genes involved in erythropoiesis, and has been shown to interact with GATA-1. The interaction between GATA-1 and TAL1 has been suggested to play a role in the regulation of erythroid gene expression during development and disease.\nThese are some of the known interacting partners of GATA-1, and further research may identify additional partners.",
    "llama-2-7b-chat-hf_fact_raw": "1. HES6 is a GATA-1-interacting protein that is essential for human erythropoiesis.\n2. GATA-1 has been shown to interact with KLF1, a transcription factor involved in regulating erythropoiesis.\n3. NF-E2, a transcription factor that regulates genes involved in erythropoiesis, interacts with GATA-1.\n4. BCL11A, a transcription factor that regulates genes involved in erythropoiesis, has been shown to interact with GATA-1.\n5. TAL1, a transcription factor that regulates genes involved in erythropoiesis, has been shown to interact with GATA-1.",
    "llama-2-7b-chat-hf_fact": [
      "HES6 is a GATA-1-interacting protein that is essential for human erythropoiesis.",
      "GATA-1 has been shown to interact with KLF1, a transcription factor involved in regulating erythropoiesis.",
      "NF-E2, a transcription factor that regulates genes involved in erythropoiesis, interacts with GATA-1.",
      "BCL11A, a transcription factor that regulates genes involved in erythropoiesis, has been shown to interact with GATA-1.",
      "TAL1, a transcription factor that regulates genes involved in erythropoiesis, has been shown to interact with GATA-1."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN: The statement about HES6 being a GATA-1-interacting protein essential for human erythropoiesis is specific, and without the relevant scientific literature or context, it's difficult to verify its accuracy.\n2. TRUE: GATA-1 is known to interact with KLF1 (also known as EKLF), which is a transcription factor involved in the regulation of erythropoiesis.\n3. TRUE: NF-E2 is a transcription factor that regulates genes involved in erythropoiesis and is known to interact with GATA-1.\n4. TRUE: BCL11A is a transcription factor that regulates genes involved in erythropoiesis and has been shown to interact with GATA-1.\n5. TRUE: TAL1 is a transcription factor that regulates genes involved in erythropoiesis and is known to interact with GATA-1.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1072,
    "user_query": "What is the outcome of TAF10 interacting with the GATA1 transcription factor?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Documents 0 and 1, it can be concluded that the outcome of TAF10 interacting with the GATA1 transcription factor is that it enhances the activity of GATA1 during erythroid cell differentiation and development.\nThe study in Document 0 shows that TAF10 interacts directly with GATA1 in human fetal erythroid cells, and that TAF10 is enriched on the GATA1 locus in these cells. This suggests that TAF10 plays a role in recruiting GATA1 to specific genomic regions and promoting its transcriptional activity.\nThe study in Document 1 provides further evidence for the interaction between TAF10 and GATA1, as well as the stability of TFIID and SAGA complexes during erythroid cell differentiation. The authors found that TAF10 interacts directly with GATA1 and that the composition of TFIID and SAGA complexes is maintained during erythroid cell development, despite some minor changes.\nOverall, these findings suggest that TAF10 plays a key role in regulating the activity of GATA1 during erythroid cell differentiation and development, and that the stability of TFIID and SAGA complexes is important for maintaining proper transcriptional regulation during this process.",
    "llama-2-7b-chat-hf_fact_raw": "1. TAF10 enhances the activity of GATA1 during erythroid cell differentiation and development.\n2. TAF10 interacts directly with GATA1 in human fetal erythroid cells.\n3. TAF10 is enriched on the GATA1 locus in human fetal erythroid cells.\n4. The composition of TFIID and SAGA complexes is maintained during erythroid cell development.\n5. The stability of TFIID and SAGA complexes is important for proper transcriptional regulation during erythroid cell differentiation and development.",
    "llama-2-7b-chat-hf_fact": [
      "TAF10 enhances the activity of GATA1 during erythroid cell differentiation and development.",
      "TAF10 interacts directly with GATA1 in human fetal erythroid cells.",
      "TAF10 is enriched on the GATA1 locus in human fetal erythroid cells.",
      "The composition of TFIID and SAGA complexes is maintained during erythroid cell development.",
      "The stability of TFIID and SAGA complexes is important for proper transcriptional regulation during erythroid cell differentiation and development."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. TRUE\n\nThe statements provided are highly specific and pertain to molecular biology, specifically the interactions between transcription factors and other proteins during cell differentiation. Without the specific context or research findings, it is not possible to accurately determine the truthfulness of statements 1, 2, and 3. These would require specific experimental evidence to confirm.\n\nStatement 4 is vague because it does not specify which stage of erythroid cell development is being referred to, and the composition of TFIID and SAGA complexes can vary depending on the cell type and developmental stage. Therefore, without additional context, it is difficult to determine the truthfulness of this statement.\n\nStatement 5 is generally true in the context of cell biology, as the stability of transcriptional complexes like TFIID and SAGA is crucial for proper transcriptional regulation during cell differentiation and development. However, this is a broad statement, and the specifics can vary depending on the cell type and context.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 1082,
    "user_query": "Are there any Decision support systems for chronic pain management ?",
    "llama-2-7b-chat-hf_response": "Yes, there are decision support systems available for chronic pain management. According to Document 1, computerized decision-support systems (CDSSs) have great potential for improving chronic pain management, particularly in the primary care setting. These systems can provide healthcare professionals with evidence-based recommendations and guidelines for managing chronic pain, which can help improve patient outcomes and reduce healthcare costs.\nSome examples of decision support systems for chronic pain management include:\n1. The Chronic Pain Management Decision Support System (CPM-DSS): This system was developed by the University of Washington and provides healthcare professionals with a comprehensive framework for managing chronic pain. It includes a range of tools and resources, such as clinical guidelines, pain assessment scales, and communication strategies.\n2. The Pain Management Collaborative (PMC): This is a web-based decision support system that provides healthcare professionals with access to a range of resources and tools for managing chronic pain. It includes a library of clinical guidelines and protocols, as well as a community of practice for sharing knowledge and best practices.\n3. The Chronic Pain Center (CPC): This is a decision support system that provides healthcare professionals with a comprehensive framework for managing chronic pain. It includes a range of tools and resources, such as clinical guidelines, pain assessment scales, and communication strategies.\n4. The Pain Management and Education (PME): This is a decision support system that provides healthcare professionals with a range of resources and tools for managing chronic pain. It includes a library of clinical guidelines and protocols, as well as a community of practice for sharing knowledge and best practices.\nIt is important to note that these are just a few examples of decision support systems available for chronic pain management, and there may be others available depending on the specific needs and requirements of the healthcare professionals and patients.",
    "llama-2-7b-chat-hf_fact_raw": "1. Computerized decision-support systems (CDSSs) are used to improve chronic pain management, especially in primary care settings.\n2. The Chronic Pain Management Decision Support System (CPM-DSS) was developed by the University of Washington.\n3. The Pain Management Collaborative (PMC) is a web-based decision support system for chronic pain management.\n4. The Chronic Pain Center (CPC) provides a comprehensive framework for managing chronic pain, including tools and resources.\n5. The Pain Management and Education (PME) system offers resources and tools for chronic pain management, including a community of practice for knowledge sharing.",
    "llama-2-7b-chat-hf_fact": [
      "Computerized decision-support systems (CDSSs) are used to improve chronic pain management, especially in primary care settings.",
      "The Chronic Pain Management Decision Support System (CPM-DSS) was developed by the University of Washington.",
      "The Pain Management Collaborative (PMC) is a web-based decision support system for chronic pain management.",
      "The Chronic Pain Center (CPC) provides a comprehensive framework for managing chronic pain, including tools and resources.",
      "The Pain Management and Education (PME) system offers resources and tools for chronic pain management, including a community of practice for knowledge sharing."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: Computerized decision-support systems (CDSSs) are indeed used to improve various aspects of healthcare, including chronic pain management in primary care settings.\n2. UNKNOWN: Without specific information about the development of the Chronic Pain Management Decision Support System (CPM-DSS), it is not possible to confirm or deny whether it was developed by the University of Washington.\n3. UNKNOWN: The statement about the Pain Management Collaborative (PMC) being a web-based decision support system for chronic pain management cannot be verified without additional context or information.\n4. UNKNOWN: The statement regarding the Chronic Pain Center (CPC) providing a comprehensive framework for managing chronic pain, including tools and resources, cannot be verified without further information.\n5. UNKNOWN: The statement about the Pain Management and Education (PME) system offering resources and tools for chronic pain management, including a community of practice for knowledge sharing, cannot be verified without additional context or information.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1149,
    "user_query": "Which is the subcellular localization of the protein angiogenin?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Documents 0 and 1, angiogenin is localized to the cytoplasm.\nDocument 0 mentions that angiogenin is a member of the vertebrate-specific secreted ribonucleases, which suggests that it is secreted from cells and present in the extracellular space. However, the document also highlights the importance of angiogenin in regulating cell proliferation, survival, migration, and invasion, which are all processes that occur within the cytoplasm. Therefore, it is likely that angiogenin is localized to the cytoplasm, where it can interact with other proteins and play a role in these cellular processes.\nDocument 1 provides additional context for the localization of angiogenin. The document mentions that protein synthesis is an energy-expensive process, and that the proteome of a cell is extremely dynamic. This suggests that cells have to constantly adjust their proteome in response to changing conditions, including the presence of nutrients and stress. Since angiogenin is involved in regulating cell proliferation and survival, it is likely that it is localized to the cytoplasm, where it can interact with other proteins involved in these processes and respond to changes in the cellular environment.\nIn summary, based on the information provided in Documents 0 and 1, angiogenin is localized to the cytoplasm.",
    "llama-2-7b-chat-hf_fact_raw": "1. Angiogenin is localized to the cytoplasm.\n2. Angiogenin is a member of the vertebrate-specific secreted ribonucleases.\n3. Angiogenin is involved in regulating cell proliferation, survival, migration, and invasion.\n4. Angiogenin can interact with other proteins within the cytoplasm.\n5. The proteome of a cell is extremely dynamic, requiring constant adjustment in response to changing conditions.",
    "llama-2-7b-chat-hf_fact": [
      "Angiogenin is localized to the cytoplasm.",
      "Angiogenin is a member of the vertebrate-specific secreted ribonucleases.",
      "Angiogenin is involved in regulating cell proliferation, survival, migration, and invasion.",
      "Angiogenin can interact with other proteins within the cytoplasm.",
      "The proteome of a cell is extremely dynamic, requiring constant adjustment in response to changing conditions."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1161,
    "user_query": "How does ranolazine affect kinase signaling activation in the heart?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, ranolazine appears to affect kinase signaling activation in the heart by reducing intracellular calcium overload and associated diastolic contractile dysfunction. This is achieved through the inhibition of the late phase of the inward sodium current in ventricular myocardial cells, which reduces the amount of calcium that enters the cell during the diastolic phase of the cardiac cycle. This, in turn, can help to alleviate diastolic contractile dysfunction, which is a common feature of heart failure.\nKinase signaling plays a crucial role in regulating various cellular processes, including cell survival, proliferation, and contractility. In the heart, kinase signaling is involved in the regulation of cardiac contractility, and dysregulation of these signals can contribute to the development of heart failure. By reducing intracellular calcium overload and associated diastolic contractile dysfunction, ranolazine may help to improve kinase signaling activation in the heart and alleviate some of the symptoms of heart failure.\nHowever, it is important to note that the effects of ranolazine on kinase signaling activation in the heart are still being studied, and further research is needed to fully understand its mechanisms of action. The recently reported effect of ranolazine on heart rate and rate pressure product in humans is a novel finding that will need to be further evaluated in clinical trials.",
    "llama-2-7b-chat-hf_fact_raw": "1. Ranolazine reduces intracellular calcium overload in ventricular myocardial cells.\n2. Ranolazine inhibits the late phase of the inward sodium current in ventricular myocardial cells.\n3. Reduction of calcium entry during the diastolic phase of the cardiac cycle can alleviate diastolic contractile dysfunction.\n4. Diastolic contractile dysfunction is a common feature of heart failure.\n5. The effects of ranolazine on kinase signaling activation in the heart are still being studied.",
    "llama-2-7b-chat-hf_fact": [
      "Ranolazine reduces intracellular calcium overload in ventricular myocardial cells.",
      "Ranolazine inhibits the late phase of the inward sodium current in ventricular myocardial cells.",
      "Reduction of calcium entry during the diastolic phase of the cardiac cycle can alleviate diastolic contractile dysfunction.",
      "Diastolic contractile dysfunction is a common feature of heart failure.",
      "The effects of ranolazine on kinase signaling activation in the heart are still being studied."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Ranolazine is thought to reduce intracellular sodium overload in ventricular myocardial cells, which indirectly reduces calcium overload.\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1225,
    "user_query": "Is the regulation of Vsr endonuclease independent of the growth phase of bacteria?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Documents 0 and 1, the regulation of Vsr endonuclease appears to be growth phase dependent. The studies shown in these documents demonstrate that the levels of Vsr endonuclease are decreased relative to Dcm cytosine methylase during the log phase of bacterial growth. This suggests that the regulation of Vsr endonuclease is linked to the growth phase of the bacteria, with lower levels of Vsr endonuclease observed during the log phase.",
    "llama-2-7b-chat-hf_fact_raw": "1. The regulation of Vsr endonuclease is growth phase dependent.\n2. Levels of Vsr endonuclease decrease relative to Dcm cytosine methylase during the log phase of bacterial growth.\n3. Lower levels of Vsr endonuclease are observed during the log phase of bacterial growth.",
    "llama-2-7b-chat-hf_fact": [
      "The regulation of Vsr endonuclease is growth phase dependent.",
      "Levels of Vsr endonuclease decrease relative to Dcm cytosine methylase during the log phase of bacterial growth.",
      "Lower levels of Vsr endonuclease are observed during the log phase of bacterial growth."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Levels of Vsr endonuclease increase relative to Dcm cytosine methylase during the log phase of bacterial growth.\n3. FALSE [correction]: Higher levels of Vsr endonuclease are observed during the log phase of bacterial growth.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "false"
    ]
  },
  {
    "id": 1233,
    "user_query": "What are the computational tools for the prediction of beta-barrel transmembrane proteins?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, there are several computational tools available for the prediction of beta-barrel transmembrane proteins:\n1. TMBHMM: This is a hidden Markov model-based method that predicts both the transmembrane beta-barrel structure and the exposure status of residues predicted to be in the membrane. It has been compared to other methods in the literature and is available as a web server.\n2. BetAware-Deep: This is a deep learning-based method that predicts the topology of beta-barrel transmembrane proteins. According to the information provided, BetAware-Deep outperforms two other state-of-the-art methods for topology prediction, predicting correct topologies for 10 out of 15 proteins in a test set.\nThese are some of the computational tools available for predicting beta-barrel transmembrane proteins. It is important to note that the accuracy of these tools can vary depending on the specific method used and the quality of the input data. Therefore, it is recommended to use multiple tools and compare their predictions to obtain the most accurate results.",
    "llama-2-7b-chat-hf_fact_raw": "1. TMBHMM is a computational tool that uses a hidden Markov model to predict the structure and exposure status of residues in beta-barrel transmembrane proteins.\n2. TMBHMM is available as a web server for users.\n3. BetAware-Deep is a deep learning-based computational tool for predicting the topology of beta-barrel transmembrane proteins.\n4. BetAware-Deep has been reported to outperform two other state-of-the-art methods in topology prediction for beta-barrel transmembrane proteins.\n5. BetAware-Deep correctly predicted the topologies for 10 out of 15 proteins in a test set, according to the provided information.",
    "llama-2-7b-chat-hf_fact": [
      "TMBHMM is a computational tool that uses a hidden Markov model to predict the structure and exposure status of residues in beta-barrel transmembrane proteins.",
      "TMBHMM is available as a web server for users.",
      "BetAware-Deep is a deep learning-based computational tool for predicting the topology of beta-barrel transmembrane proteins.",
      "BetAware-Deep has been reported to outperform two other state-of-the-art methods in topology prediction for beta-barrel transmembrane proteins.",
      "BetAware-Deep correctly predicted the topologies for 10 out of 15 proteins in a test set, according to the provided information."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: The correct name of the tool is BetAware, not BetAware-Deep.\n4. UNKNOWN\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1251,
    "user_query": "Galassi classification is used for which disorder?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, the Galassi classification is used to classify arachnoid cysts in the middle cranial fossa, which account for 50-60% of all arachnoid cysts.",
    "llama-2-7b-chat-hf_fact_raw": "1. The Galassi classification is used to classify arachnoid cysts in the middle cranial fossa.\n2. Arachnoid cysts in the middle cranial fossa account for 50-60% of all arachnoid cysts.",
    "llama-2-7b-chat-hf_fact": [
      "The Galassi classification is used to classify arachnoid cysts in the middle cranial fossa.",
      "Arachnoid cysts in the middle cranial fossa account for 50-60% of all arachnoid cysts."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true"
    ]
  },
  {
    "id": 1304,
    "user_query": "List common features of Shapiro syndrome",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Documents 0 and 1, the common features of Shapiro syndrome are:\n1. Spontaneous periodic hypothermia: This is the most distinctive feature of Shapiro syndrome, and it occurs in patients regardless of age or sex.\n2. Limited number of cases: To date, fewer than 60 cases of Shapiro syndrome have been reported worldwide, indicating that it is a rare condition.\n3. Limited knowledge of disease: The pathogenesis and etiology of Shapiro syndrome are still not well understood, and current knowledge is limited to clinical features.\n4. Clinical characteristics: The clinical characteristics of Shapiro syndrome include recurrent episodes of hypothermia, which can last for several hours or days, and are often accompanied by other symptoms such as confusion, disorientation, and seizures.\n5. Possible etiology: The possible etiology of Shapiro syndrome is still controversial, but it is thought to be related to abnormalities in the brain's temperature regulation mechanisms.\nBased on this information, it is important to note that Shapiro syndrome is a rare and poorly understood condition, and further research is needed to determine its causes and develop effective treatments.",
    "llama-2-7b-chat-hf_fact_raw": "1. Shapiro syndrome is characterized by spontaneous periodic hypothermia.\n2. Fewer than 60 cases of Shapiro syndrome have been reported worldwide.\n3. The pathogenesis and etiology of Shapiro syndrome are not well understood.\n4. Clinical characteristics of Shapiro syndrome include recurrent episodes of hypothermia, confusion, disorientation, and seizures.\n5. Shapiro syndrome may be related to abnormalities in the brain's temperature regulation mechanisms.",
    "llama-2-7b-chat-hf_fact": [
      "Shapiro syndrome is characterized by spontaneous periodic hypothermia.",
      "Fewer than 60 cases of Shapiro syndrome have been reported worldwide.",
      "The pathogenesis and etiology of Shapiro syndrome are not well understood.",
      "Clinical characteristics of Shapiro syndrome include recurrent episodes of hypothermia, confusion, disorientation, and seizures.",
      "Shapiro syndrome may be related to abnormalities in the brain's temperature regulation mechanisms."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE (As of my knowledge cutoff in 2023, fewer than 60 cases have been reported. However, the exact number may have changed since then.)\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1320,
    "user_query": "Which disease is linked to mutations within BRAG1?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, the disease that is linked to mutations within the BRAG1 gene is nonsyndromic X-chromosome-linked intellectual disability (XLID).",
    "llama-2-7b-chat-hf_fact_raw": "1. Mutations within the BRAG1 gene are linked to nonsyndromic X-chromosome-linked intellectual disability (XLID).",
    "llama-2-7b-chat-hf_fact": [
      "Mutations within the BRAG1 gene are linked to nonsyndromic X-chromosome-linked intellectual disability (XLID)."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n\n[Note: The statement refers to a specific gene, BRAG1, and its association with nonsyndromic X-linked intellectual disability (XLID). Without access to current and specific genetic research data or literature, it is not possible to verify the accuracy of this statement. The correct gene associated with XLID might be ARX or another gene entirely, but without the proper context or reference, the truthfulness of the statement cannot be determined.]",
    "llama-2-7b-chat-hf_judge": [
      "unknown"
    ]
  },
  {
    "id": 1362,
    "user_query": "Which protein is the main inhibitor of protein phosphatase 1 (PP1)?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Documents 0 and 1, the main inhibitor of protein phosphatase 1 (PP1) is Inhibitor-3. The study in Document 0 describes the identification of Inhibitor-3 as a metal binding dynamic protein-protein interaction that inhibits PP1. The authors use structural reverse genetics to identify the PP1-dependent phenotypes of genetically engineered mice of 49 PP1-interacting proteins (PIPs), and find that Inhibitor-3 is one of the main inhibitors of PP1.\nTherefore, based on the information provided in the two documents, the answer to the user's question is: Inhibitor-3 is the main inhibitor of protein phosphatase 1 (PP1).",
    "llama-2-7b-chat-hf_fact_raw": "1. Inhibitor-3 is identified as the main inhibitor of protein phosphatase 1 (PP1).\n2. The identification of Inhibitor-3 involved a study that used structural reverse genetics.\n3. The study included genetically engineered mice of 49 PP1-interacting proteins (PIPs).\n4. Inhibitor-3 was found to be one of the main inhibitors of PP1 through the study mentioned.",
    "llama-2-7b-chat-hf_fact": [
      "Inhibitor-3 is identified as the main inhibitor of protein phosphatase 1 (PP1).",
      "The identification of Inhibitor-3 involved a study that used structural reverse genetics.",
      "The study included genetically engineered mice of 49 PP1-interacting proteins (PIPs).",
      "Inhibitor-3 was found to be one of the main inhibitors of PP1 through the study mentioned."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n\nWithout specific information from the passage or scientific literature to confirm or refute these statements, it is not possible to determine their accuracy. The statements are very specific to a particular study and its findings, which would require access to that study or related scientific publications to verify.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1374,
    "user_query": "Which mechanisms underlie adaptive mutagenesis (stationary-phase mutagenesis) in Bacillus subtilis?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Documents 0 and 1, the mechanisms that underlie adaptive mutagenesis (stationary-phase mutagenesis) in Bacillus subtilis are:\n1. Nonlethal selective pressure: The production of mutations in nondividing or stationary-phase bacteria when the cells are subjected to nonlethal selective pressure, such as nutrient-limited environments.\n2. Lack of division: The absence of cell division in stationary phase bacteria can lead to an increase in mutation rates due to the reduced DNA replication and repair processes (Hall, 1998; Martinez and Baquero, 2000).\n3. Aging of the cell population: The accumulation of mutations over time in the stationary phase bacteria can lead to the selection of mutants with increased fitness (Rosenberg, 2001).\n4. Phase variation: The phenomenon of phase variation in bacterial pathogens, where the expression of certain genes is turned on or off in response to changes in the environment, can also contribute to the development of antibiotic resistance mutations (Rosenberg, 2001).\nTherefore, the mechanisms that underlie adaptive mutagenesis in Bacillus subtilis are related to the reduction in DNA repair and replication processes during stationary phase, the aging of the cell population, and the ability of bacteria to switch between different gene expression patterns in response to changes in the environment.",
    "llama-2-7b-chat-hf_fact_raw": "1. Nonlethal selective pressure can induce mutations in nondividing or stationary-phase Bacillus subtilis when subjected to nutrient-limited environments.\n2. The absence of cell division in stationary phase Bacillus subtilis can lead to an increase in mutation rates due to reduced DNA replication and repair processes.\n3. The accumulation of mutations over time in stationary phase Bacillus subtilis can lead to the selection of mutants with increased fitness.\n4. Phase variation, where the expression of certain genes in bacterial pathogens is turned on or off in response to environmental changes, can contribute to the development of antibiotic resistance mutations.\n5. Adaptive mutagenesis in Bacillus subtilis is related to the reduction in DNA repair and replication processes during the stationary phase.",
    "llama-2-7b-chat-hf_fact": [
      "Nonlethal selective pressure can induce mutations in nondividing or stationary-phase Bacillus subtilis when subjected to nutrient-limited environments.",
      "The absence of cell division in stationary phase Bacillus subtilis can lead to an increase in mutation rates due to reduced DNA replication and repair processes.",
      "The accumulation of mutations over time in stationary phase Bacillus subtilis can lead to the selection of mutants with increased fitness.",
      "Phase variation, where the expression of certain genes in bacterial pathogens is turned on or off in response to environmental changes, can contribute to the development of antibiotic resistance mutations.",
      "Adaptive mutagenesis in Bacillus subtilis is related to the reduction in DNA repair and replication processes during the stationary phase."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: The absence of cell division in stationary phase Bacillus subtilis can lead to an increase in mutation rates, but this is not due to reduced DNA replication and repair processes. Instead, it is thought that the stress of nutrient limitation can induce a hypermutation state, which increases the mutation rate.\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1399,
    "user_query": "What causes erucism?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, erucism is caused by the toxins released by the bristles of moth larvae when they penetrate the skin. The toxins contain thermolabile proteins, proteolytic enzymes, and histamine, which can cause various skin and systemic reactions in humans.",
    "llama-2-7b-chat-hf_fact_raw": "1. Erucism is caused by toxins released by the bristles of moth larvae.\n2. The toxins that cause erucism penetrate the skin.\n3. The toxins responsible for erucism contain thermolabile proteins.\n4. Proteolytic enzymes are present in the toxins that cause erucism.\n5. Histamine is a component of the toxins that lead to erucism.",
    "llama-2-7b-chat-hf_fact": [
      "Erucism is caused by toxins released by the bristles of moth larvae.",
      "The toxins that cause erucism penetrate the skin.",
      "The toxins responsible for erucism contain thermolabile proteins.",
      "Proteolytic enzymes are present in the toxins that cause erucism.",
      "Histamine is a component of the toxins that lead to erucism."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. UNKNOWN\n4. UNKNOWN\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 1413,
    "user_query": "What are the indications for hydrochlorothiazide?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, the indications for hydrochlorothiazide are:\n1. High blood pressure (hypertension)\n2. Fluid retention (edema) in people with congestive heart failure, cirrhosis of the liver, or kidney disorders\n3. Edema caused by taking steroids or estrogen.\nIt is important to note that hydrochlorothiazide should not be used in individuals who are unable to urinate.",
    "llama-2-7b-chat-hf_fact_raw": "1. Hydrochlorothiazide is indicated for the treatment of high blood pressure (hypertension).\n2. Hydrochlorothiazide is used to treat fluid retention (edema) in people with congestive heart failure.\n3. Hydrochlorothiazide is used to treat fluid retention (edema) in people with cirrhosis of the liver.\n4. Hydrochlorothiazide is used to treat fluid retention (edema) in people with kidney disorders.\n5. Hydrochlorothiazide is indicated for treating edema caused by taking steroids or estrogen.",
    "llama-2-7b-chat-hf_fact": [
      "Hydrochlorothiazide is indicated for the treatment of high blood pressure (hypertension).",
      "Hydrochlorothiazide is used to treat fluid retention (edema) in people with congestive heart failure.",
      "Hydrochlorothiazide is used to treat fluid retention (edema) in people with cirrhosis of the liver.",
      "Hydrochlorothiazide is used to treat fluid retention (edema) in people with kidney disorders.",
      "Hydrochlorothiazide is indicated for treating edema caused by taking steroids or estrogen."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE\n\nHydrochlorothiazide is a diuretic medication often used to treat high blood pressure and edema, including that caused by congestive heart failure, cirrhosis of the liver, kidney disorders, and in some cases, from taking steroids or estrogen.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1447,
    "user_query": "Has silicon been used in treatment of  incontinence ?",
    "llama-2-7b-chat-hf_response": "Yes, silicon has been used in the treatment of incontinence, specifically in the form of bulking agents injected periurethrally or transurethrally. According to Document 0, this minimally invasive procedure has been shown to be effective in curing or improving stress urinary incontinence (SUI) in adult women. The bulking agents used are typically made of silicon and are designed to increase the volume of the urethral wall, thereby strengthening the muscles and improving bladder control.\nDocument 1 also mentions the use of vaginal pessaries as a conservative treatment for incontinence. Pessaries are devices that are inserted into the vagina to support the urethra and bladder, helping to prevent leakage. While not made of silicon, pessaries can also provide symptomatic improvement for women with incontinence.\nIn summary, silicon has been used in the treatment of incontinence through the injection of bulking agents, and vaginal pessaries are another conservative treatment option that can provide symptomatic improvement.",
    "llama-2-7b-chat-hf_fact_raw": "1. Silicon has been used in the treatment of incontinence.\n2. Bulking agents made of silicon are injected periurethrally or transurethrally to treat incontinence.\n3. The procedure using silicon bulking agents has been effective in curing or improving stress urinary incontinence in adult women.\n4. The purpose of the silicon bulking agents is to increase the volume of the urethral wall and strengthen the muscles.\n5. Vaginal pessaries are used as a conservative treatment for incontinence to support the urethra and bladder.",
    "llama-2-7b-chat-hf_fact": [
      "Silicon has been used in the treatment of incontinence.",
      "Bulking agents made of silicon are injected periurethrally or transurethrally to treat incontinence.",
      "The procedure using silicon bulking agents has been effective in curing or improving stress urinary incontinence in adult women.",
      "The purpose of the silicon bulking agents is to increase the volume of the urethral wall and strengthen the muscles.",
      "Vaginal pessaries are used as a conservative treatment for incontinence to support the urethra and bladder."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Silicone, not silicon, has been used in the treatment of incontinence. Silicon is a chemical element, while silicone is a polymer used in medical treatments.\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1454,
    "user_query": "What is the association between moon cycle and rupture risk of intracranial aneurysms?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, there is no established association between the moon cycle and the risk of intracranial aneurysm rupture. The document states that \"Moon phases are not associated with incidence of intracranial aneurysm rupture,\" and encourages further research to investigate this topic using more sensitive approaches. Therefore, the answer to the user's question is that there is no known association between the moon cycle and the risk of intracranial aneurysm rupture.",
    "llama-2-7b-chat-hf_fact_raw": "1. There is no established association between the moon cycle and the risk of intracranial aneurysm rupture.\n2. The document referenced states, \"Moon phases are not associated with incidence of intracranial aneurysm rupture.\"\n3. Further research is encouraged to investigate the topic of moon cycle and intracranial aneurysm rupture risk using more sensitive approaches.",
    "llama-2-7b-chat-hf_fact": [
      "There is no established association between the moon cycle and the risk of intracranial aneurysm rupture.",
      "The document referenced states, \"Moon phases are not associated with incidence of intracranial aneurysm rupture.\"",
      "Further research is encouraged to investigate the topic of moon cycle and intracranial aneurysm rupture risk using more sensitive approaches."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. TRUE\n3. UNKNOWN\n\nWithout the actual document or scientific evidence provided, the veracity of the first and third statements cannot be determined. The second statement is accepted as true based on the direct quote from the referenced document.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "true",
      "unknown"
    ]
  },
  {
    "id": 1477,
    "user_query": "Does HuR protein regulate the splicing process?",
    "llama-2-7b-chat-hf_response": "Yes, HuR protein does regulate the splicing process. According to Document 0, HuR regulates the splicing and abundance of mRNAs required for entry into and transition through the S phase of the cell cycle, and it modulates a gene signature associated with cell cycle progression. Document 1 also supports this conclusion, as it shows that HuR regulates Fas splicing in vivo and in vitro through antagonism with TIA-1/TIAR. These findings suggest that HuR plays a role in regulating the splicing process, which is an essential step in the expression of genes involved in various cellular processes, including the cell cycle.",
    "llama-2-7b-chat-hf_fact_raw": "1. HuR protein regulates the splicing and abundance of mRNAs required for entry into and transition through the S phase of the cell cycle.\n2. HuR modulates a gene signature associated with cell cycle progression.\n3. HuR regulates Fas splicing in vivo and in vitro.\n4. HuR's regulation of splicing involves antagonism with TIA-1/TIAR.\n5. The splicing process regulated by HuR is an essential step in the expression of genes involved in various cellular processes.",
    "llama-2-7b-chat-hf_fact": [
      "HuR protein regulates the splicing and abundance of mRNAs required for entry into and transition through the S phase of the cell cycle.",
      "HuR modulates a gene signature associated with cell cycle progression.",
      "HuR regulates Fas splicing in vivo and in vitro.",
      "HuR's regulation of splicing involves antagonism with TIA-1/TIAR.",
      "The splicing process regulated by HuR is an essential step in the expression of genes involved in various cellular processes."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE\n\nThe statements provided are consistent with the known functions of the HuR protein, which is involved in the regulation of mRNA stability and splicing, affecting various cellular processes including the cell cycle. HuR's interaction with TIA-1/TIAR and its role in Fas splicing are specific details that are accurate based on scientific literature. However, without specific references to the original passage, these responses are based on general knowledge about the HuR protein up to the knowledge cutoff date.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1492,
    "user_query": "Describe the known functions for the prothymosin alpha c-terminal peptide?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Documents 0 and 1, prothymosin alpha c-terminal peptide (ProTα) has the following known functions:\n1. Interaction with the Keap1 Kelch domain: ProTα and Neh2 have nearly identical Kelch-binding domains, which have been investigated using crystallographic and NMR methods. The Kelch-binding domain of ProTα (NEENGE) is similar to that of Neh2, DEETGE.\n2. Protease proteolytic modifications: ProTMA undergoes two types of protease proteolytic modifications, which can provide insight into its interactions with other molecules and help elucidate its roles in cells.\n3. Cell type, cell status, and localization: The function of ProTMA appears to be determined by the cell type, cell status, and specific localization within cells.\nOverall, ProTMA seems to play a complex role in cells, with its function depending on various factors such as the cell type, cell status, and localization. Its interaction with the Keap1 Kelch domain and protease proteolytic modifications may also play a crucial role in its function.",
    "llama-2-7b-chat-hf_fact_raw": "1. Prothymosin alpha c-terminal peptide (ProTα) interacts with the Keap1 Kelch domain.\n2. The Kelch-binding domain of ProTα is similar to that of Neh2, with the sequences NEENGE and DEETGE respectively.\n3. Prothymosin alpha c-terminal peptide undergoes protease proteolytic modifications.\n4. The function of Prothymosin alpha c-terminal peptide is influenced by the cell type, cell status, and specific localization within cells.",
    "llama-2-7b-chat-hf_fact": [
      "Prothymosin alpha c-terminal peptide (ProTα) interacts with the Keap1 Kelch domain.",
      "The Kelch-binding domain of ProTα is similar to that of Neh2, with the sequences NEENGE and DEETGE respectively.",
      "Prothymosin alpha c-terminal peptide undergoes protease proteolytic modifications.",
      "The function of Prothymosin alpha c-terminal peptide is influenced by the cell type, cell status, and specific localization within cells."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. UNKNOWN\n4. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "unknown",
      "true"
    ]
  },
  {
    "id": 1516,
    "user_query": "Which peptide plays a pivotal role in human cystatin C fibrillization?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Document 0, the peptide that plays a pivotal role in human cystatin C fibrillization is LQVVR.",
    "llama-2-7b-chat-hf_fact_raw": "1. The peptide LQVVR plays a pivotal role in human cystatin C fibrillization.",
    "llama-2-7b-chat-hf_fact": [
      "The peptide LQVVR plays a pivotal role in human cystatin C fibrillization."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n\nWithout additional context or a specific reference to scientific literature, it is not possible to verify the accuracy of the statement regarding the role of the peptide LQVVR in human cystatin C fibrillization.",
    "llama-2-7b-chat-hf_judge": [
      "unknown"
    ]
  },
  {
    "id": 1574,
    "user_query": "Does the concentration of protein HIF-1α increase after the administration of the cytoprotective prodrug\"amifostine\" (ethyol) ?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, it appears that the concentration of protein HIF-1α may increase after the administration of the cytoprotective prodrug \"amifostine\" (ethyol).\nDocument 0 suggests that HIF-1α protein levels transiently increase during the G1 phase of the cell cycle in an AMP-activated protein kinase (AMPK)-dependent manner. This suggests that HIF-1α is involved in cellular processes that are important for cell survival and proliferation, and that its levels may be regulated by various cellular signaling pathways.\nDocument 1 highlights the HIF-1 α pathway as a crucial survival pathway for cancer cells, and suggests that targeting this pathway could be a promising strategy for cancer therapy. However, it also acknowledges that targeting HIF-1 α has been challenging due to its role in maintaining cellular homeostasis.\nGiven these findings, it is possible that the administration of amifostine (ethyol) may increase the concentration of HIF-1α protein in cancer cells, potentially leading to enhanced cellular survival and proliferation. However, further research is needed to confirm this hypothesis and to fully understand the mechanisms underlying the effects of amifostine on HIF-1α protein levels.",
    "llama-2-7b-chat-hf_fact_raw": "1. The concentration of protein HIF-1α may increase after the administration of the cytoprotective prodrug \"amifostine\" (ethyol).\n2. HIF-1α protein levels transiently increase during the G1 phase of the cell cycle in an AMP-activated protein kinase (AMPK)-dependent manner.\n3. HIF-1α is involved in cellular processes important for cell survival and proliferation.\n4. The HIF-1α pathway is a crucial survival pathway for cancer cells.\n5. Targeting the HIF-1α pathway could be a promising strategy for cancer therapy.",
    "llama-2-7b-chat-hf_fact": [
      "The concentration of protein HIF-1α may increase after the administration of the cytoprotective prodrug \"amifostine\" (ethyol).",
      "HIF-1α protein levels transiently increase during the G1 phase of the cell cycle in an AMP-activated protein kinase (AMPK)-dependent manner.",
      "HIF-1α is involved in cellular processes important for cell survival and proliferation.",
      "The HIF-1α pathway is a crucial survival pathway for cancer cells.",
      "Targeting the HIF-1α pathway could be a promising strategy for cancer therapy."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN: The statement about the effect of amifostine on HIF-1α concentration is specific and would require scientific data or research to confirm its accuracy.\n2. UNKNOWN: The statement about HIF-1α protein levels increasing during the G1 phase in an AMPK-dependent manner is also specific and requires scientific evidence to verify.\n3. TRUE: HIF-1α (Hypoxia-inducible factor 1-alpha) is indeed involved in cellular processes that are important for cell survival and proliferation, such as response to hypoxia.\n4. TRUE: The HIF-1α pathway is known to be important for the survival of cancer cells, particularly under hypoxic conditions which are common in the tumor microenvironment.\n5. TRUE: Targeting the HIF-1α pathway is considered a promising strategy for cancer therapy, as it is involved in the adaptation of cancer cells to hypoxic conditions and supports their survival and proliferation.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1588,
    "user_query": "Which histone marks are deposited by Set7?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Document 0, Set7 deposits H3K4 methylation.",
    "llama-2-7b-chat-hf_fact_raw": "1. Set7 is responsible for depositing H3K4 methylation.",
    "llama-2-7b-chat-hf_fact": [
      "Set7 is responsible for depositing H3K4 methylation."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true"
    ]
  },
  {
    "id": 1620,
    "user_query": "How many disulfide bridges has the protein hepcidin got?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, the protein hepcidin has 4 disulfide bridges.",
    "llama-2-7b-chat-hf_fact_raw": "1. The protein hepcidin has 4 disulfide bridges.",
    "llama-2-7b-chat-hf_fact": [
      "The protein hepcidin has 4 disulfide bridges."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true"
    ]
  },
  {
    "id": 1643,
    "user_query": "What is the localization of the protein encoded by the gene DNAJC11?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Documents 0 and 1, the localization of the protein encoded by the gene DNAJC11 is likely in the nucleus.\nDocument 0 mentions that Alzheimer's disease (AD) is characterized by the accumulation of tau neurofibrillary tangles in the hippocampus and associated neocortex, which suggests that the protein encoded by DNAJC11 is involved in the process of protein aggregation and deposition in the brain. However, the document does not provide any information about the subcellular localization of DNAJC11.\nDocument 1 provides a schematic model for nuclear protein import through the nuclear pore complex (NPC), which suggests that the protein encoded by DNAJC11 may be imported into the nucleus through this process. The document also mentions that NLS-dependent protein trafficking from the cytoplasm into the nucleus is mediated by members of the importin (also referred to as karyopherin) family, which includes importins 1-5 and karyopherin-1. Since DNAJC11 is a nuclear protein, it is likely to be imported into the nucleus through this pathway.\nTherefore, based on the information provided in Documents 0 and 1, the localization of the protein encoded by DNAJC11 is likely in the nucleus.",
    "llama-2-7b-chat-hf_fact_raw": "1. The protein encoded by the gene DNAJC11 is likely localized in the nucleus.\n2. Alzheimer's disease is characterized by the accumulation of tau neurofibrillary tangles in the hippocampus and associated neocortex.\n3. The protein encoded by DNAJC11 may be involved in the process of protein aggregation and deposition in the brain.\n4. Nuclear protein import through the nuclear pore complex (NPC) is a process that could involve the protein encoded by DNAJC11.\n5. NLS-dependent protein trafficking from the cytoplasm into the nucleus is mediated by members of the importin family, which includes importins 1-5 and karyopherin-1.",
    "llama-2-7b-chat-hf_fact": [
      "The protein encoded by the gene DNAJC11 is likely localized in the nucleus.",
      "Alzheimer's disease is characterized by the accumulation of tau neurofibrillary tangles in the hippocampus and associated neocortex.",
      "The protein encoded by DNAJC11 may be involved in the process of protein aggregation and deposition in the brain.",
      "Nuclear protein import through the nuclear pore complex (NPC) is a process that could involve the protein encoded by DNAJC11.",
      "NLS-dependent protein trafficking from the cytoplasm into the nucleus is mediated by members of the importin family, which includes importins 1-5 and karyopherin-1."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The protein encoded by the gene DNAJC11 is not typically localized in the nucleus; it is primarily associated with the mitochondria.\n2. TRUE\n3. UNKNOWN: Without specific information on the function of DNAJC11, it is not possible to determine whether it is involved in protein aggregation and deposition in the brain.\n4. FALSE [correction]: Given that DNAJC11 is primarily associated with the mitochondria, it is unlikely to be involved in nuclear protein import through the nuclear pore complex (NPC), which is a process typically associated with nuclear-localized proteins.\n5. FALSE [correction]: NLS-dependent protein trafficking from the cytoplasm into the nucleus is mediated by members of the importin family, which includes importins α and β (not numerically labeled 1-5) and karyopherins, among others. Karyopherin-1 is not a recognized member of the importin family; instead, karyopherin β1 (also known as importin β1) is a well-known member of this family.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "unknown",
      "false",
      "false"
    ]
  },
  {
    "id": 1655,
    "user_query": "Are ultraconserved elements depleted among copy number variants (CNVs)?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Document 0, it appears that ultraconserved elements are depleted among copy number variants (CNVs). The study found that mammalian ultraconserved elements are strongly depleted among segmental duplications and CNVs. This suggests that CNVs, which are regions of the genome that have undergone duplication, are less likely to contain ultraconserved elements compared to other regions of the genome.",
    "llama-2-7b-chat-hf_fact_raw": "1. Ultraconserved elements are depleted among copy number variants (CNVs).\n2. The study found that mammalian ultraconserved elements are strongly depleted among segmental duplications and CNVs.\n3. CNVs are regions of the genome that have undergone duplication.\n4. CNVs are less likely to contain ultraconserved elements compared to other regions of the genome.",
    "llama-2-7b-chat-hf_fact": [
      "Ultraconserved elements are depleted among copy number variants (CNVs).",
      "The study found that mammalian ultraconserved elements are strongly depleted among segmental duplications and CNVs.",
      "CNVs are regions of the genome that have undergone duplication.",
      "CNVs are less likely to contain ultraconserved elements compared to other regions of the genome."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: CNVs are regions of the genome where there are copy number differences, which can include duplications but also deletions or complex multi-site variants.\n4. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 1665,
    "user_query": "Which is the substrate of the haspin kinase during mitosis?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Documents 0 and 1, the substrate of the Haspin kinase during mitosis is Thr-3 in histone H3 (H3T3).",
    "llama-2-7b-chat-hf_fact_raw": "1. The substrate of the Haspin kinase during mitosis is Thr-3 in histone H3 (H3T3).",
    "llama-2-7b-chat-hf_fact": [
      "The substrate of the Haspin kinase during mitosis is Thr-3 in histone H3 (H3T3)."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true"
    ]
  },
  {
    "id": 1696,
    "user_query": "What is the mechanism of viroid replication?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Documents 0 and 1, the mechanism of viroid replication appears to involve an RNA-based rolling-circle mechanism with three steps that operate in both polarity strands. Here is a simplified explanation of the mechanism:\nStep 1: Synthesis of longer-than-unit strands\nIn this step, either the nuclear RNA polymerase II or a nuclear-encoded chloroplastic RNA polymerase synthesizes longer-than-unit strands of viroid RNA. This is possible due to the presence of specific sequences in the viroid RNA that can act as templates for RNA synthesis.\nStep 2: Redirection of host machinery\nOnce the longer-than-unit strands are synthesized, they are redirected to transcribe RNA templates. This is achieved through the use of specific sequences in the viroid RNA that interact with host machinery, such as RNA polymerase, to redirect the synthesis of new RNA molecules.\nStep 3: Replication of the viroid genome\nIn the final step, the newly synthesized RNA templates are used to replicate the viroid genome through an RNA-dependent RNA polymerase activity. This results in the amplification of the viroid genome, which is necessary for the virus to infect and replicate in the host plant.\nOverall, the mechanism of viroid replication involves the use of specific sequences in the viroid RNA to redirect host machinery for infection, allowing the virus to replicate and infect the host plant.",
    "llama-2-7b-chat-hf_fact_raw": "1. Viroid replication involves an RNA-based rolling-circle mechanism.\n2. The replication process includes the synthesis of longer-than-unit strands of viroid RNA.\n3. Nuclear RNA polymerase II or a nuclear-encoded chloroplastic RNA polymerase can synthesize these longer-than-unit strands.\n4. Specific sequences in the viroid RNA interact with host machinery to redirect the synthesis of new RNA molecules.\n5. RNA-dependent RNA polymerase activity is used in the final step to replicate the viroid genome.",
    "llama-2-7b-chat-hf_fact": [
      "Viroid replication involves an RNA-based rolling-circle mechanism.",
      "The replication process includes the synthesis of longer-than-unit strands of viroid RNA.",
      "Nuclear RNA polymerase II or a nuclear-encoded chloroplastic RNA polymerase can synthesize these longer-than-unit strands.",
      "Specific sequences in the viroid RNA interact with host machinery to redirect the synthesis of new RNA molecules.",
      "RNA-dependent RNA polymerase activity is used in the final step to replicate the viroid genome."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. FALSE [correction]: RNA-dependent RNA polymerase activity is not used in the final step to replicate the viroid genome; instead, RNA polymerase II, which is normally associated with DNA transcription, is involved in the replication of viroids.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 1723,
    "user_query": "Does fibronectin constitute a serum biomarker for Duchenne muscular dystrophy?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, fibronectin can be considered a potential serum biomarker for Duchenne muscular dystrophy (DMD).\nDocument 0 suggests that fibronectin levels differ between the DMD and control groups, which could indicate a potential biomarker for DMD. Additionally, Document 1 suggests that serum fibronectin levels may constitute a promising biomarker to monitor disease progression in DMD patients.\nWhile the study does not specifically mention fibronectin as a biomarker for DMD, the findings suggest that it may be a useful marker for monitoring the progression of the disease. Further research is needed to confirm this finding and to determine the sensitivity and specificity of fibronectin as a biomarker for DMD.\nIn summary, based on the information provided, fibronectin appears to be a potential serum biomarker for Duchenne muscular dystrophy, and further research is warranted to confirm this finding.",
    "llama-2-7b-chat-hf_fact_raw": "1. Fibronectin is considered a potential serum biomarker for Duchenne muscular dystrophy (DMD).\n2. Document 0 indicates that fibronectin levels differ between the DMD and control groups.\n3. Document 1 suggests that serum fibronectin levels may be a promising biomarker to monitor disease progression in DMD patients.\n4. The study referenced does not definitively confirm fibronectin as a biomarker for DMD.\n5. Further research is needed to determine the sensitivity and specificity of fibronectin as a biomarker for DMD.",
    "llama-2-7b-chat-hf_fact": [
      "Fibronectin is considered a potential serum biomarker for Duchenne muscular dystrophy (DMD).",
      "Document 0 indicates that fibronectin levels differ between the DMD and control groups.",
      "Document 1 suggests that serum fibronectin levels may be a promising biomarker to monitor disease progression in DMD patients.",
      "The study referenced does not definitively confirm fibronectin as a biomarker for DMD.",
      "Further research is needed to determine the sensitivity and specificity of fibronectin as a biomarker for DMD."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE\n\nWithout the actual documents or studies to review, I can only assume that the statements provided are summaries or interpretations of the findings. Therefore, based on the context given, all statements seem to align with common scientific reporting where potential biomarkers are identified, their levels are compared between groups, their promise is suggested, definitive confirmation is often lacking in early studies, and further research is typically called for.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1763,
    "user_query": "Data from which major epigenome projects are contained in the DeepBlue epigenomic data server?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Documents 0 and 1, the major epigenome projects whose data are contained in the DeepBlue epigenomic data server are:\n1. ENCODE (Encyclopedia of DNA Elements)\n2. ROADMAP (Roadmap Epigenomics Consortium)\n3. BLUEPRINT (Blueprint Epigenomics Project)\n4. DEEP (Deep Epigenomics Project)\nDeepBlue is a data server that provides access to a comprehensive collection of epigenomic data from these projects, including data on DNA methylation, histone modifications, and other epigenetic marks. The server comes with a user manual, examples, and a well-documented application programming interface (API) that can be accessed via the XML-RPC protocol, which is supported by many programming languages.",
    "llama-2-7b-chat-hf_fact_raw": "1. The DeepBlue epigenomic data server contains data from the ENCODE (Encyclopedia of DNA Elements) project.\n2. The DeepBlue epigenomic data server contains data from the ROADMAP (Roadmap Epigenomics Consortium) project.\n3. The DeepBlue epigenomic data server contains data from the BLUEPRINT (Blueprint Epigenomics Project).\n4. The DeepBlue epigenomic data server contains data from the DEEP (Deep Epigenomics Project).\n5. The DeepBlue server provides access to epigenomic data including DNA methylation, histone modifications, and other epigenetic marks.",
    "llama-2-7b-chat-hf_fact": [
      "The DeepBlue epigenomic data server contains data from the ENCODE (Encyclopedia of DNA Elements) project.",
      "The DeepBlue epigenomic data server contains data from the ROADMAP (Roadmap Epigenomics Consortium) project.",
      "The DeepBlue epigenomic data server contains data from the BLUEPRINT (Blueprint Epigenomics Project).",
      "The DeepBlue epigenomic data server contains data from the DEEP (Deep Epigenomics Project).",
      "The DeepBlue server provides access to epigenomic data including DNA methylation, histone modifications, and other epigenetic marks."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. UNKNOWN\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "unknown",
      "true"
    ]
  },
  {
    "id": 1792,
    "user_query": "Which tool employs self organizing maps for analyzing synonymous codon usage?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, the tool that employs self-organizing maps for analyzing synonymous codon usage is CUBAP. According to Document 1, CUBAP is an interactive web portal for analyzing codon usage biases across populations, and it uses self-organizing maps to visualize and analyze codon usage data.",
    "llama-2-7b-chat-hf_fact_raw": "1. CUBAP is a tool that employs self-organizing maps for analyzing synonymous codon usage.\n2. CUBAP is an interactive web portal designed for analyzing codon usage biases across populations.\n3. CUBAP uses self-organizing maps to visualize and analyze codon usage data.",
    "llama-2-7b-chat-hf_fact": [
      "CUBAP is a tool that employs self-organizing maps for analyzing synonymous codon usage.",
      "CUBAP is an interactive web portal designed for analyzing codon usage biases across populations.",
      "CUBAP uses self-organizing maps to visualize and analyze codon usage data."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: CUBAP is not specifically described as an interactive web portal designed for analyzing codon usage biases across populations. It is a tool that employs self-organizing maps for analyzing synonymous codon usage, but without additional context, it's unclear whether it is an interactive web portal or has the specific function of analyzing biases across populations.\n3. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 1793,
    "user_query": "What is MINDY-1?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, MINDY-1 appears to be a deubiquitinating enzyme, specifically a member of a new family of enzymes that are evolutionarily conserved and structurally distinct. According to Document 1, MINDY-1 is a protein that is involved in the deubiquitination of various target proteins, which is a post-translational modification that can affect protein function. The document does not provide any information about MINDY-1's relationship to a character named Mindy Chen, who is mentioned in Document 1 as a nanny and pop star. Therefore, I cannot provide an answer to the user's question based on the information provided.",
    "llama-2-7b-chat-hf_fact_raw": "1. MINDY-1 is a deubiquitinating enzyme.\n2. MINDY-1 belongs to a new family of enzymes that are evolutionarily conserved.\n3. MINDY-1 is structurally distinct from other enzymes.\n4. MINDY-1 is involved in the deubiquitination of various target proteins.\n5. Deubiquitination is a post-translational modification that can affect protein function.",
    "llama-2-7b-chat-hf_fact": [
      "MINDY-1 is a deubiquitinating enzyme.",
      "MINDY-1 belongs to a new family of enzymes that are evolutionarily conserved.",
      "MINDY-1 is structurally distinct from other enzymes.",
      "MINDY-1 is involved in the deubiquitination of various target proteins.",
      "Deubiquitination is a post-translational modification that can affect protein function."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1810,
    "user_query": "Which software package is available for the analysis of conserved genomic loci?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, the software package available for the analysis of conserved genomic loci is PHYLUCE. According to Document 0, PHYLUCE is a software package for the analysis of conserved genomic loci, and it was published in 2016 in the journal Bioinformatics. Additionally, Document 1 confirms that PHYLUCE is a software package for the analysis of conserved genomic loci. Therefore, the answer to the user's question is PHYLUCE.",
    "llama-2-7b-chat-hf_fact_raw": "1. PHYLUCE is a software package for the analysis of conserved genomic loci.\n2. PHYLUCE was published in 2016.\n3. The journal Bioinformatics published information about PHYLUCE in 2016.",
    "llama-2-7b-chat-hf_fact": [
      "PHYLUCE is a software package for the analysis of conserved genomic loci.",
      "PHYLUCE was published in 2016.",
      "The journal Bioinformatics published information about PHYLUCE in 2016."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: PHYLUCE was first published in 2013.\n3. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 1860,
    "user_query": "Please list 3 diseases associated with the PIEZO2 gene.",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Documents 0 and 1, the three diseases associated with the PIEZO2 gene are:\n1. Autosomal recessive syndrome of muscular atrophy with perinatal respiratory distress, arthrogryposis, and scoliosis (caused by loss-of-function mutations in the PIEZO2 gene).\n2. Autosomal dominant distal arthrogryposis (caused by gain-of-function mutations in the PIEZO2 gene). There are three clinical types of autosomal dominant distal arthrogryposis associated with PIEZO2 gene mutations:\n\t* Type 1: Characterized by muscle weakness and stiffness, particularly in the distal limbs.\n\t* Type 2: Features a more severe form of muscle weakness and stiffness, as well as joint contractures and scoliosis.\n\t* Type 3: Presents with a milder form of muscle weakness and stiffness, as well as mild joint contractures.\nIt is important to note that these are the diseases associated with the PIEZO2 gene based on the information provided in the documents, and there may be additional diseases associated with this gene that are not mentioned in the provided documents.",
    "llama-2-7b-chat-hf_fact_raw": "1. The PIEZO2 gene is associated with an autosomal recessive syndrome of muscular atrophy with perinatal respiratory distress, arthrogryposis, and scoliosis caused by loss-of-function mutations.\n2. Gain-of-function mutations in the PIEZO2 gene can cause autosomal dominant distal arthrogryposis.\n3. There are three clinical types of autosomal dominant distal arthrogryposis associated with PIEZO2 gene mutations: Type 1, Type 2, and Type 3, each with varying degrees of muscle weakness, stiffness, joint contractures, and scoliosis.",
    "llama-2-7b-chat-hf_fact": [
      "The PIEZO2 gene is associated with an autosomal recessive syndrome of muscular atrophy with perinatal respiratory distress, arthrogryposis, and scoliosis caused by loss-of-function mutations.",
      "Gain-of-function mutations in the PIEZO2 gene can cause autosomal dominant distal arthrogryposis.",
      "There are three clinical types of autosomal dominant distal arthrogryposis associated with PIEZO2 gene mutations: Type 1, Type 2, and Type 3, each with varying degrees of muscle weakness, stiffness, joint contractures, and scoliosis."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: There are two clinical types of autosomal dominant distal arthrogryposis associated with PIEZO2 gene mutations: Type 5 and Type 9, each with varying degrees of muscle weakness, stiffness, joint contractures, and scoliosis.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 1867,
    "user_query": "What is promoted by ERAP1-ERAP2 dimerization?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Documents 0 and 1, ERAP1-ERAP2 dimerization is promoted to modulate the activity of ERAP1 and ERAP2, which are enzymes involved in the immune response. The dimerization of these enzymes is thought to allow for access to the active site of both enzymes, which is important for their proper functioning. This information suggests that ERAP1-ERAP2 dimerization plays a role in the regulation of the immune response, and may be a novel immunological strategy for cancer immunotherapy.",
    "llama-2-7b-chat-hf_fact_raw": "1. ERAP1 and ERAP2 are enzymes involved in the immune response.\n2. Dimerization of ERAP1 and ERAP2 is thought to allow access to the active sites of both enzymes.\n3. ERAP1-ERAP2 dimerization is promoted to modulate the activity of both enzymes.\n4. ERAP1-ERAP2 dimerization plays a role in the regulation of the immune response.\n5. ERAP1-ERAP2 dimerization may be a strategy for cancer immunotherapy.",
    "llama-2-7b-chat-hf_fact": [
      "ERAP1 and ERAP2 are enzymes involved in the immune response.",
      "Dimerization of ERAP1 and ERAP2 is thought to allow access to the active sites of both enzymes.",
      "ERAP1-ERAP2 dimerization is promoted to modulate the activity of both enzymes.",
      "ERAP1-ERAP2 dimerization plays a role in the regulation of the immune response.",
      "ERAP1-ERAP2 dimerization may be a strategy for cancer immunotherapy."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE\n\nAll statements are generally consistent with the known functions of ERAP1 and ERAP2 in the immune response. ERAP1 and ERAP2 are indeed involved in the immune response, particularly in antigen processing. Dimerization can affect the access to active sites and modulate enzyme activity. This dimerization is known to play a role in the regulation of the immune response, and manipulating such interactions could potentially be a strategy for cancer immunotherapy. However, the specifics of how ERAP1-ERAP2 dimerization may be used in cancer immunotherapy would depend on ongoing research and are not detailed here, so while the statement is plausible, it is somewhat speculative without additional context.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1890,
    "user_query": "What is the function of R-spondin 1 and noggin in non-damaged gallbladders?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, R-spondin 1 and noggin play a role in the function of non-damaged gallbladders by stimulating the growth of gallbladder-derived organoids. These growth factors promote partial differentiation toward the hepatocyte fate, suggesting that they may play a role in the maintenance and proliferation of gallbladder stem/progenitor cells. The presence of these factors in non-damaged gallbladders may help to ensure the proper functioning of the organ.\nIt is worth noting that other studies have reported that RSPO2, the gene encoding R-spondin 1, is amplified or overexpressed in certain subtypes of hepatocellular carcinoma (HCC), a type of liver cancer that can arise from the dysregulation of the Wnt/β-catenin signaling pathway. This suggests that R-spondin 1 may play a role in the development and progression of HCC, although the exact mechanisms are not yet fully understood.\nIn summary, the function of R-spondin 1 and noggin in non-damaged gallbladders is to promote the growth and differentiation of gallbladder-derived organoids, which may help to maintain the proper functioning of the organ. However, further research is needed to fully understand the role of these factors in gallbladder development and disease.",
    "llama-2-7b-chat-hf_fact_raw": "1. R-spondin 1 and noggin stimulate the growth of gallbladder-derived organoids in non-damaged gallbladders.\n2. These growth factors promote partial differentiation toward the hepatocyte fate.\n3. R-spondin 1 and noggin may play a role in the maintenance and proliferation of gallbladder stem/progenitor cells.\n4. RSPO2, the gene encoding R-spondin 1, is amplified or overexpressed in certain subtypes of hepatocellular carcinoma (HCC).\n5. Dysregulation of the Wnt/β-catenin signaling pathway can lead to the development of hepatocellular carcinoma (HCC).",
    "llama-2-7b-chat-hf_fact": [
      "R-spondin 1 and noggin stimulate the growth of gallbladder-derived organoids in non-damaged gallbladders.",
      "These growth factors promote partial differentiation toward the hepatocyte fate.",
      "R-spondin 1 and noggin may play a role in the maintenance and proliferation of gallbladder stem/progenitor cells.",
      "RSPO2, the gene encoding R-spondin 1, is amplified or overexpressed in certain subtypes of hepatocellular carcinoma (HCC).",
      "Dysregulation of the Wnt/β-catenin signaling pathway can lead to the development of hepatocellular carcinoma (HCC)."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. FALSE [correction]: RSPO2 is a gene that encodes R-spondin 2, not R-spondin 1. RSPO1 is the gene that encodes R-spondin 1.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "false",
      "true"
    ]
  },
  {
    "id": 1937,
    "user_query": "Does NADPH oxidase 5 require any subunit for function?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Documents 0 and 1, it is clear that NOX5, also known as NADPH oxidase 5, is a multisubunit enzyme complex that requires at least five essential subunits for its function. The information in Document 0 suggests that NOX5 contains four Ca2+ binding domains at the N-terminus, which suggests that it may have a different structure and function compared to other members of the NADPH oxidase (NOXs) family.\nOn the other hand, Document 1 states that NOX5 is a multisubunit enzyme complex composed of five essential subunits, with two subunits localized in the membrane and three subunits localized in the cytosol. This suggests that NOX5 requires at least five subunits to function properly.\nTherefore, based on the information provided, it can be concluded that NOX5 does require subunits for its function, and the exact number of subunits required is at least five.",
    "llama-2-7b-chat-hf_fact_raw": "1. NADPH oxidase 5 (NOX5) is a multisubunit enzyme complex.\n2. NOX5 requires at least five essential subunits for its function.\n3. NOX5 contains four Ca2+ binding domains at the N-terminus.\n4. Two subunits of NOX5 are localized in the membrane.\n5. Three subunits of NOX5 are localized in the cytosol.",
    "llama-2-7b-chat-hf_fact": [
      "NADPH oxidase 5 (NOX5) is a multisubunit enzyme complex.",
      "NOX5 requires at least five essential subunits for its function.",
      "NOX5 contains four Ca2+ binding domains at the N-terminus.",
      "Two subunits of NOX5 are localized in the membrane.",
      "Three subunits of NOX5 are localized in the cytosol."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: NADPH oxidase 5 (NOX5) is not a multisubunit enzyme complex; it is a single enzyme that does not require additional subunits for its function.\n2. FALSE [correction]: NOX5 does not require at least five essential subunits for its function as it is a single enzyme.\n3. TRUE\n4. FALSE [correction]: NOX5 is a single enzyme and does not have separate subunits; therefore, it cannot have two subunits localized in the membrane.\n5. FALSE [correction]: NOX5 is a single enzyme and does not have separate subunits; therefore, it cannot have three subunits localized in the cytosol.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "true",
      "false",
      "false"
    ]
  },
  {
    "id": 1944,
    "user_query": "What is the connection between furin and hepcidin?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, there appears to be a connection between furin and hepcidin in the regulation of iron metabolism.\nFurin is a protease enzyme that is involved in the processing and activation of various proteins in the body. Document 0 mentions that hepcidin binds to ferroportin, an iron export protein, and induces its internalization and degradation. This suggests that furin may play a role in the processing and activation of hepcidin, which in turn regulates the export of iron from the body.\nDocument 1 further supports this connection by stating that hepcidin is thought to be the key regulator of iron metabolism in humans through its inhibition of ferroportin. This suggests that furin may be involved in the regulation of hepcidin activity, which in turn affects the amount of iron that is available for use by the body's cells.\nTherefore, based on the information provided, it can be inferred that there is a connection between furin and hepcidin in the regulation of iron metabolism in the body.",
    "llama-2-7b-chat-hf_fact_raw": "1. Furin is a protease enzyme involved in the processing and activation of various proteins in the body.\n2. Hepcidin binds to ferroportin, an iron export protein, and induces its internalization and degradation.\n3. Hepcidin is considered the key regulator of iron metabolism in humans.\n4. Hepcidin regulates iron metabolism through its inhibition of ferroportin.\n5. Furin may play a role in the processing and activation of hepcidin.",
    "llama-2-7b-chat-hf_fact": [
      "Furin is a protease enzyme involved in the processing and activation of various proteins in the body.",
      "Hepcidin binds to ferroportin, an iron export protein, and induces its internalization and degradation.",
      "Hepcidin is considered the key regulator of iron metabolism in humans.",
      "Hepcidin regulates iron metabolism through its inhibition of ferroportin.",
      "Furin may play a role in the processing and activation of hepcidin."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 1956,
    "user_query": "Which is the largest metabolic gene cluster in yeast?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Documents 0 and 1, the largest metabolic gene cluster in yeast is the DAL cluster. The DAL cluster consists of six adjacent genes that encode proteins that enable Saccharomyces cerevisiae to use allantoin as a nitrogen source. This cluster is the largest metabolic gene cluster in yeast and is an example of a physical cluster of genes that are related in function despite being unrelated in sequence.",
    "llama-2-7b-chat-hf_fact_raw": "1. The largest metabolic gene cluster in yeast is the DAL cluster.\n2. The DAL cluster consists of six adjacent genes.\n3. These genes encode proteins that allow Saccharomyces cerevisiae to utilize allantoin as a nitrogen source.\n4. The DAL cluster is an example of a physical cluster of functionally related genes that are unrelated in sequence.",
    "llama-2-7b-chat-hf_fact": [
      "The largest metabolic gene cluster in yeast is the DAL cluster.",
      "The DAL cluster consists of six adjacent genes.",
      "These genes encode proteins that allow Saccharomyces cerevisiae to utilize allantoin as a nitrogen source.",
      "The DAL cluster is an example of a physical cluster of functionally related genes that are unrelated in sequence."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: The DAL cluster consists of seven adjacent genes, not six.\n3. TRUE\n4. FALSE [correction]: The DAL cluster is an example of a physical cluster of functionally related genes that are related in sequence, as they are involved in the same metabolic pathway.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "false"
    ]
  },
  {
    "id": 1967,
    "user_query": "What is the role of LIMT lncRNA?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, the role of LIMT lncRNA is likely related to telomere maintenance. Document 0 mentions that TERC, a lncRNA, is required for telomere maintenance, and Document 1 highlights the importance of lncRNAs in the human genome, including their role in telomere maintenance.\nTelomeres are repetitive DNA sequences at the ends of chromosomes that shorten with each cell division. To maintain telomere length, the telomerase enzyme adds nucleotides to the telomeres, and TERC is a critical component of the telomerase complex. The size and sequence of TERC vary widely among different species, but it has a conserved structural organization.\nThe fact that lncRNAs represent the largest group of non-coding RNAs produced from the genome and are defined as transcripts longer than 200 nucleotides in length, without protein-coding potential, suggests that they play important roles in various cellular processes, including telomere maintenance.\nTherefore, based on the information provided, it is likely that LIMT lncRNA plays a role in telomere maintenance, possibly by acting as a template for the telomerase enzyme to add nucleotides to the telomeres.",
    "llama-2-7b-chat-hf_fact_raw": "1. LIMT lncRNA is likely related to telomere maintenance.\n2. TERC, a lncRNA, is required for telomere maintenance.\n3. Telomeres are repetitive DNA sequences at the ends of chromosomes that shorten with each cell division.\n4. The telomerase enzyme adds nucleotides to telomeres to maintain their length, and TERC is a critical component of the telomerase complex.\n5. lncRNAs are defined as transcripts longer than 200 nucleotides in length, without protein-coding potential.",
    "llama-2-7b-chat-hf_fact": [
      "LIMT lncRNA is likely related to telomere maintenance.",
      "TERC, a lncRNA, is required for telomere maintenance.",
      "Telomeres are repetitive DNA sequences at the ends of chromosomes that shorten with each cell division.",
      "The telomerase enzyme adds nucleotides to telomeres to maintain their length, and TERC is a critical component of the telomerase complex.",
      "lncRNAs are defined as transcripts longer than 200 nucleotides in length, without protein-coding potential."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN: Without specific scientific context or research data, it is not possible to confirm or refute the relationship of LIMT lncRNA to telomere maintenance.\n2. TRUE: TERC, which stands for Telomerase RNA Component, is indeed a long non-coding RNA (lncRNA) that serves as a template for telomere maintenance by the telomerase enzyme.\n3. TRUE: Telomeres are indeed repetitive nucleotide sequences at the ends of chromosomes, and they typically shorten with each round of cell division, which is a part of the normal aging process.\n4. TRUE: The telomerase enzyme does add nucleotides to the ends of telomeres to maintain their length during cell division, and TERC is an essential RNA component of the telomerase complex, providing a template for the addition of telomere repeats.\n5. TRUE: lncRNAs are defined as RNA molecules longer than 200 nucleotides that do not have the potential to code for proteins.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1984,
    "user_query": "Which R / bioconductor package is used for performing SNP enrichment analysis?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, the R/Bioconductor package used for performing SNP enrichment analysis is traseR.",
    "llama-2-7b-chat-hf_fact_raw": "1. The R/Bioconductor package traseR is used for performing SNP enrichment analysis.",
    "llama-2-7b-chat-hf_fact": [
      "The R/Bioconductor package traseR is used for performing SNP enrichment analysis."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n\n[Explanation]: Without specific information about the R/Bioconductor package traseR, it is not possible to confirm whether it is used for performing SNP enrichment analysis. A search in the current R/Bioconductor repository or package documentation would be required to verify the purpose and functionality of the traseR package.",
    "llama-2-7b-chat-hf_judge": [
      "unknown"
    ]
  },
  {
    "id": 2015,
    "user_query": "Which are the key players on radial glial specification to ependymal cells?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Documents 0 and 1, the key players in radial glial specification to ependymal cells are Mcidas and GemC1/Lynkeas. These two proteins were initially described as cell cycle regulators and have been found to play a crucial role in the specification of radial glial cells to ependymal cells. They share sequence similarity with Geminin, a protein that has been implicated in cell cycle regulation and neural development.",
    "llama-2-7b-chat-hf_fact_raw": "1. Mcidas and GemC1/Lynkeas are key players in radial glial specification to ependymal cells.\n2. Mcidas and GemC1/Lynkeas were initially described as cell cycle regulators.\n3. These proteins play a crucial role in the specification of radial glial cells to ependymal cells.\n4. Mcidas and GemC1/Lynkeas share sequence similarity with Geminin.\n5. Geminin is a protein implicated in cell cycle regulation and neural development.",
    "llama-2-7b-chat-hf_fact": [
      "Mcidas and GemC1/Lynkeas are key players in radial glial specification to ependymal cells.",
      "Mcidas and GemC1/Lynkeas were initially described as cell cycle regulators.",
      "These proteins play a crucial role in the specification of radial glial cells to ependymal cells.",
      "Mcidas and GemC1/Lynkeas share sequence similarity with Geminin.",
      "Geminin is a protein implicated in cell cycle regulation and neural development."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE\n\nBased on the context provided, all statements seem to be consistent with the roles of Mcidas and GemC1/Lynkeas in cell specification and their relationship to Geminin. However, without specific scientific literature or detailed context to reference, it is not possible to fact-check these statements with absolute certainty. The responses are based on the assumption that the statements are derived from accurate scientific information.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2065,
    "user_query": "How are triple negative gliomas characterized?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Documents 0 and 1, triple negative gliomas are characterized as follows:\n1. Lack of alterations in the TP53 gene, EGFR gene, and PD-1/PD-L1 pathway.\n2. These tumors are referred to as \"triple-negative\" because they do not have any of the three commonly identified molecular alterations that are targeted by specific therapies in glioblastoma.\n3. Triple negative gliomas are considered to be enigmatic tumors with a poor prognosis, as they do not fit into any of the established molecular subtypes of glioblastoma.\n4. The tumors are characterized by abnormalities in the MYB gene, which is a transcription factor that plays a role in cell growth and differentiation.\n5. Integrated genomic analysis has identified clinically relevant subtypes of glioblastoma, including those characterized by abnormalities in the TP53 gene, EGFR gene, and PD-1/PD-L1 pathway.\nIn summary, triple negative gliomas are a type of glioblastoma that lack the three commonly identified molecular alterations, and are characterized by abnormalities in the MYB gene. They are considered to be enigmatic tumors with a poor prognosis, and further research is needed to understand their molecular mechanisms and develop effective treatments.",
    "llama-2-7b-chat-hf_fact_raw": "1. Triple negative gliomas lack alterations in the TP53 gene, EGFR gene, and PD-1/PD-L1 pathway.\n2. These tumors do not fit into any of the established molecular subtypes of glioblastoma.\n3. Triple negative gliomas have a poor prognosis.\n4. Abnormalities in the MYB gene characterize triple negative gliomas.\n5. Integrated genomic analysis has identified clinically relevant subtypes of glioblastoma, including those with abnormalities in the TP53 gene, EGFR gene, and PD-1/PD-L1 pathway.",
    "llama-2-7b-chat-hf_fact": [
      "Triple negative gliomas lack alterations in the TP53 gene, EGFR gene, and PD-1/PD-L1 pathway.",
      "These tumors do not fit into any of the established molecular subtypes of glioblastoma.",
      "Triple negative gliomas have a poor prognosis.",
      "Abnormalities in the MYB gene characterize triple negative gliomas.",
      "Integrated genomic analysis has identified clinically relevant subtypes of glioblastoma, including those with abnormalities in the TP53 gene, EGFR gene, and PD-1/PD-L1 pathway."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Triple negative gliomas are characterized by the lack of alterations in the IDH gene, 1p/19q co-deletion, and the absence of EGFR amplification, not the TP53 gene, EGFR gene, and PD-1/PD-L1 pathway.\n2. TRUE\n3. TRUE\n4. FALSE [correction]: Abnormalities in the MYB gene are not a characteristic feature of triple negative gliomas; instead, they are more commonly associated with other types of tumors, such as certain leukemias.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 2069,
    "user_query": "What is TOPAZ1?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, TOPAZ1 appears to be a clinical trial evaluating the use of durvalumab, a monoclonal antibody, in combination with chemotherapy, for the treatment of advanced biliary tract cancer. The trial is being conducted at 145 centers across 17 countries, including the United States, Europe, South America, Korea, Thailand, Japan, Taiwan, and China. The primary endpoint of the trial is overall survival, with secondary endpoints including progression-free survival, objective response rate, and safety. The trial was first presented at the 2022 ASCO GI meeting, and the latest data cutoff was August 11, 2021, with 685 patients enrolled.",
    "llama-2-7b-chat-hf_fact_raw": "1. TOPAZ1 is a clinical trial evaluating the use of durvalumab in combination with chemotherapy for the treatment of advanced biliary tract cancer.\n2. The trial is being conducted at 145 centers across 17 countries.\n3. The countries involved in the trial include the United States, Europe, South America, Korea, Thailand, Japan, Taiwan, and China.\n4. The primary endpoint of the TOPAZ1 trial is overall survival.\n5. The trial was first presented at the 2022 ASCO GI meeting.",
    "llama-2-7b-chat-hf_fact": [
      "TOPAZ1 is a clinical trial evaluating the use of durvalumab in combination with chemotherapy for the treatment of advanced biliary tract cancer.",
      "The trial is being conducted at 145 centers across 17 countries.",
      "The countries involved in the trial include the United States, Europe, South America, Korea, Thailand, Japan, Taiwan, and China.",
      "The primary endpoint of the TOPAZ1 trial is overall survival.",
      "The trial was first presented at the 2022 ASCO GI meeting."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. UNKNOWN\n3. UNKNOWN\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "unknown",
      "true",
      "true"
    ]
  },
  {
    "id": 2075,
    "user_query": "Which gene controls the expression of GATA-1 isoforms?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, the gene that controls the expression of GATA-1 isoforms is likely to be GATA1 itself.\nDocument 0 mentions that hematopoietic development is regulated by the combinatorial actions of transcription factors, including GATA-1. This suggests that GATA-1 plays a critical role in regulating the expression of genes involved in hematopoietic development.\nDocument 1 further supports this conclusion by showing that K562 cells, which express GATA1s or GATA1FL transgenes, can be used to model the effects of the two isoforms on in vitro haematopoietic differentiation. This suggests that the expression of GATA-1 isoforms has a significant impact on the differentiation of hematopoietic cells.\nGiven this information, it is likely that the gene that controls the expression of GATA-1 isoforms is GATA1 itself, as it is the only gene mentioned in the documents that is involved in regulating hematopoietic development and the expression of GATA-1 isoforms.",
    "llama-2-7b-chat-hf_fact_raw": "1. The gene that controls the expression of GATA-1 isoforms is likely GATA1 itself.\n2. GATA-1 plays a critical role in regulating the expression of genes involved in hematopoietic development.\n3. K562 cells can express GATA1s or GATA1FL transgenes.\n4. The expression of GATA-1 isoforms impacts the differentiation of hematopoietic cells.",
    "llama-2-7b-chat-hf_fact": [
      "The gene that controls the expression of GATA-1 isoforms is likely GATA1 itself.",
      "GATA-1 plays a critical role in regulating the expression of genes involved in hematopoietic development.",
      "K562 cells can express GATA1s or GATA1FL transgenes.",
      "The expression of GATA-1 isoforms impacts the differentiation of hematopoietic cells."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2076,
    "user_query": "What is MIRA-seq?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Documents 0 and 1, MIRA-seq is a genome-scale DNA methylation analysis platform that uses the high affinity of a methylated-CpG-binding protein complex (MBD2B and MBD3L1) to enrich regions with methylated CpG dinucleotides. This approach can be applied to both array-based DNA analysis and next-generation sequencing (NGS) technologies, which are sometimes distinguished as MIRA-chip and MIRA-Seq, respectively.\nThe MIRA procedure involves fragmenting genomic DNA, followed by the enrichment of methylated CpG dinucleotides using the MBD2B and MBD3L1 complex. The resulting enriched DNA is then subjected to high-throughput sequencing, which allows for the detection of DNA methylation differences at CpG-rich genomic regions.\nOne of the advantages of MIRA-seq is that it is not limited by primer or probe design, making it a cost-effective and reliable method for DNA methylation analysis. Additionally, the method can be used to score DNA methylation differences at CpG-rich genomic regions, providing valuable insights into the epigenetic regulation of gene expression.\nIn summary, MIRA-seq is a powerful tool for genome-scale DNA methylation analysis that leverages the high affinity of a methylated-CpG-binding protein complex to enrich methylated CpG dinucleotides and enable high-throughput sequencing.",
    "llama-2-7b-chat-hf_fact_raw": "1. MIRA-seq is a genome-scale DNA methylation analysis platform.\n2. MIRA-seq uses a methylated-CpG-binding protein complex (MBD2B and MBD3L1) to enrich regions with methylated CpG dinucleotides.\n3. MIRA-seq can be applied to both array-based DNA analysis and next-generation sequencing technologies.\n4. The MIRA procedure involves fragmenting genomic DNA and enriching methylated CpG dinucleotides using the MBD2B and MBD3L1 complex.\n5. MIRA-seq allows for the detection of DNA methylation differences at CpG-rich genomic regions.",
    "llama-2-7b-chat-hf_fact": [
      "MIRA-seq is a genome-scale DNA methylation analysis platform.",
      "MIRA-seq uses a methylated-CpG-binding protein complex (MBD2B and MBD3L1) to enrich regions with methylated CpG dinucleotides.",
      "MIRA-seq can be applied to both array-based DNA analysis and next-generation sequencing technologies.",
      "The MIRA procedure involves fragmenting genomic DNA and enriching methylated CpG dinucleotides using the MBD2B and MBD3L1 complex.",
      "MIRA-seq allows for the detection of DNA methylation differences at CpG-rich genomic regions."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE\n\nMIRA-seq, which stands for Methylated CpG Island Recovery Assay sequencing, is indeed a platform used for genome-scale DNA methylation analysis. It utilizes the methylated-CpG-binding protein complex, specifically MBD2B and MBD3L1, to enrich for regions of the genome that contain methylated CpG dinucleotides. This technique can be applied to various DNA analysis technologies, including array-based platforms and next-generation sequencing. The MIRA procedure does involve fragmenting genomic DNA and then enriching for methylated CpG dinucleotides using the specified protein complex. Lastly, MIRA-seq is designed to detect DNA methylation differences, particularly in CpG-rich regions of the genome.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2108,
    "user_query": "What is the indication of ARCALYST?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, the indication of ARCALYST is:\nARCALYST ® (rilonacept) is an interleukin-1 blocker indicated for:\n* Treatment of Recurrent Pericarditis (RP) in adults and pediatric patients 12 years and older.\n* Reduction in risk of recurrence in adults and pediatric patients 12 years and older with a history of RP.\nIn particular, ARCALYST is used to treat some of the symptoms of rare genetic conditions such as Familial Cold Auto-inflammatory Syndrome (FCAS) or Muckle-Wells Syndrome (MWS), which are inflammatory disorders that cause symptoms in response to cold, heat, stress, or tiredness. However, the primary indication of ARCALYST is for the treatment of Recurrent Pericarditis (RP) and reduction in risk of recurrence in adults and pediatric patients 12 years and older.",
    "llama-2-7b-chat-hf_fact_raw": "1. ARCALYST (rilonacept) is indicated for the treatment of Recurrent Pericarditis (RP) in adults and pediatric patients 12 years and older.\n2. ARCALYST is indicated for the reduction in risk of recurrence of RP in adults and pediatric patients 12 years and older.\n3. ARCALYST is used to treat symptoms of Familial Cold Auto-inflammatory Syndrome (FCAS).\n4. ARCALYST is used to treat symptoms of Muckle-Wells Syndrome (MWS).\n5. FCAS and MWS are inflammatory disorders that can cause symptoms in response to cold, heat, stress, or tiredness.",
    "llama-2-7b-chat-hf_fact": [
      "ARCALYST (rilonacept) is indicated for the treatment of Recurrent Pericarditis (RP) in adults and pediatric patients 12 years and older.",
      "ARCALYST is indicated for the reduction in risk of recurrence of RP in adults and pediatric patients 12 years and older.",
      "ARCALYST is used to treat symptoms of Familial Cold Auto-inflammatory Syndrome (FCAS).",
      "ARCALYST is used to treat symptoms of Muckle-Wells Syndrome (MWS).",
      "FCAS and MWS are inflammatory disorders that can cause symptoms in response to cold, heat, stress, or tiredness."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. FALSE [correction]: FCAS and MWS are inflammatory disorders that can cause symptoms in response to cold or stress, but not specifically heat or tiredness. FCAS is characterized by episodes of fever, skin rash, and joint pain triggered by cold temperatures. MWS includes symptoms like fever, rash, and joint pain, but can also involve hearing loss and amyloidosis. Heat and tiredness are not typically triggers for these syndromes.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 2170,
    "user_query": "List the human acrocentric chromosomes that are involved in Robertsonian translocation.",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Documents 0 and 1, the human acrocentric chromosomes involved in Robertsonian translocations are:\n1. Chromosome 13 (der(13q14q))\n2. Chromosome 14 (der(14q21q))\n3. Chromosome 15 (der(15q11q))\n4. Chromosome 21 (der(21q22q))\n5. Chromosome 22 (der(22q11q))\nThese chromosomes are acrocentric, meaning they have a short arm that is much shorter than their long arm. The short arms of these chromosomes contain numerous copies of genes coding for ribosomal RNA. Robertsonian translocations involve the exchange of a segment of chromosomal material between two acrocentric chromosomes, resulting in a chromosome with an abnormal number of copies of the genes on the short arm.",
    "llama-2-7b-chat-hf_fact_raw": "1. Chromosome 13 is involved in Robertsonian translocations.\n2. Chromosome 14 is involved in Robertsonian translocations.\n3. Chromosome 15 is involved in Robertsonian translocations.\n4. Chromosome 21 is involved in Robertsonian translocations.\n5. Chromosome 22 is involved in Robertsonian translocations.",
    "llama-2-7b-chat-hf_fact": [
      "Chromosome 13 is involved in Robertsonian translocations.",
      "Chromosome 14 is involved in Robertsonian translocations.",
      "Chromosome 15 is involved in Robertsonian translocations.",
      "Chromosome 21 is involved in Robertsonian translocations.",
      "Chromosome 22 is involved in Robertsonian translocations."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE\n\nRobertsonian translocations are a type of chromosomal rearrangement that involves the fusion of two acrocentric chromosomes. Acrocentric chromosomes in humans include chromosomes 13, 14, 15, 21, and 22. Therefore, all of these chromosomes can be involved in Robertsonian translocations.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2237,
    "user_query": "Which R package could be used for the identification of pediatric brain tumors?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, the R package that could be used for the identification of pediatric brain tumors is \"MethPed\". The package is available via Bioconductor and efficiently classifies pediatric brain tumors using a developed classifier called MethPed. The classifier is based on DNA methylation data from 450K BeadChips and uses a Random Forest algorithm to identify tumor specific gene and protein signatures.\nThe package documentation highlights the importance of DNA methylation in carcinogenesis and how the MethPed classifier can be used to identify pediatric brain tumors with high accuracy. The package also includes tools for data preprocessing, visualization, and interpretation of the results.\nTherefore, based on the information provided, the R package \"MethPed\" is the most suitable choice for identifying pediatric brain tumors using DNA methylation data.",
    "llama-2-7b-chat-hf_fact_raw": "1. The R package \"MethPed\" can be used for the identification of pediatric brain tumors.\n2. \"MethPed\" is available via Bioconductor.\n3. The MethPed classifier uses DNA methylation data from 450K BeadChips.\n4. The MethPed classifier employs a Random Forest algorithm.\n5. The MethPed package includes tools for data preprocessing, visualization, and interpretation of results.",
    "llama-2-7b-chat-hf_fact": [
      "The R package \"MethPed\" can be used for the identification of pediatric brain tumors.",
      "\"MethPed\" is available via Bioconductor.",
      "The MethPed classifier uses DNA methylation data from 450K BeadChips.",
      "The MethPed classifier employs a Random Forest algorithm.",
      "The MethPed package includes tools for data preprocessing, visualization, and interpretation of results."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: \"MethPed\" is available via CRAN, not Bioconductor.\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2246,
    "user_query": "Is NEMO a zinc finger protein?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Documents 0 and 1, it is possible to conclude that NEMO is a zinc finger protein.\nThe article in Document 0 states that the zinc finger of NEMO is a functional ubiquitin-binding domain. This suggests that NEMO contains a specific structural motif that is capable of binding to ubiquitin, which is a protein modification that plays a role in protein degradation and signal transduction.\nAdditionally, the article in Document 1 mentions that IKKγ (NEMO) is a key component of the NF-κB pathway, which is involved in regulating inflammation and immune responses. Zinc finger proteins are known to play a role in protein-protein interactions and signal transduction, which aligns with the function of NEMO in the NF-κB pathway.\nTherefore, based on the information provided, it is reasonable to conclude that NEMO is a zinc finger protein.",
    "llama-2-7b-chat-hf_fact_raw": "1. NEMO contains a zinc finger that is a functional ubiquitin-binding domain.\n2. The zinc finger of NEMO plays a role in protein degradation and signal transduction.\n3. NEMO, also known as IKKγ, is a key component of the NF-κB pathway.\n4. The NF-κB pathway is involved in regulating inflammation and immune responses.\n5. Zinc finger proteins are involved in protein-protein interactions and signal transduction.",
    "llama-2-7b-chat-hf_fact": [
      "NEMO contains a zinc finger that is a functional ubiquitin-binding domain.",
      "The zinc finger of NEMO plays a role in protein degradation and signal transduction.",
      "NEMO, also known as IKKγ, is a key component of the NF-κB pathway.",
      "The NF-κB pathway is involved in regulating inflammation and immune responses.",
      "Zinc finger proteins are involved in protein-protein interactions and signal transduction."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2247,
    "user_query": "Does TFIIS affect nucleosome positioning?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, it appears that TFIIS does affect nucleosome positioning.\nDocument 0 suggests that lack of TFIIS influences nucleosome occupancy across the genome, with a particular focus on genes that contain a canonical TATA box (TATA genes). This suggests that TFIIS plays a role in regulating the positioning of nucleosomes in these genes.\nDocument 1 further supports this conclusion by stating that TFIIS generally contributes to nucleosome positioning in both gene promoters and bodies. This suggests that TFIIS is involved in the process of nucleosome positioning, which is important for regulating gene expression.\nOverall, the information provided suggests that TFIIS plays a role in regulating nucleosome positioning, which in turn can affect gene expression.",
    "llama-2-7b-chat-hf_fact_raw": "1. TFIIS influences nucleosome occupancy across the genome.\n2. The lack of TFIIS has a notable impact on genes that contain a canonical TATA box.\n3. TFIIS is involved in regulating the positioning of nucleosomes in gene promoters and bodies.\n4. Nucleosome positioning is important for regulating gene expression.\n5. TFIIS plays a role in the process of nucleosome positioning.",
    "llama-2-7b-chat-hf_fact": [
      "TFIIS influences nucleosome occupancy across the genome.",
      "The lack of TFIIS has a notable impact on genes that contain a canonical TATA box.",
      "TFIIS is involved in regulating the positioning of nucleosomes in gene promoters and bodies.",
      "Nucleosome positioning is important for regulating gene expression.",
      "TFIIS plays a role in the process of nucleosome positioning."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE\n\nNote: The statements provided are consistent with the general understanding of the role of TFIIS in transcription and chromatin structure. TFIIS is known to influence transcription elongation by RNA polymerase II, which can affect nucleosome occupancy and positioning. However, without specific experimental evidence or a detailed passage to reference, the responses are based on general knowledge in the field of molecular biology.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2262,
    "user_query": "Do origins of replication close to yeast centromeres fire early or late?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Documents 0 and 1, it can be inferred that origins of replication close to yeast centromeres fire early.\nDocument 0 states that eukaryotic DNA replication begins with multiple origins of replication (ORIs), and identifying these ORIs is essential for understanding the DNA replication process. Since centromeres are genetic elements essential for proper segregation of chromosomes during cell division, it is likely that the origins of replication close to these centromeres would fire early in the replication process.\nDocument 1 also supports this conclusion by mentioning that the early replication of baker's yeast centromeres is one frequently cited example of temporal regulation. While the biological significance of early centromere replication remains speculative, the fact that it is a well-documented phenomenon suggests that it is an important aspect of the DNA replication process.\nTherefore, based on the information provided, it can be concluded that origins of replication close to yeast centromeres fire early during the DNA replication process.",
    "llama-2-7b-chat-hf_fact_raw": "1. Eukaryotic DNA replication begins with multiple origins of replication.\n2. Origins of replication close to yeast centromeres fire early in the replication process.\n3. Centromeres are essential for proper segregation of chromosomes during cell division.\n4. Early replication of baker's yeast centromeres is an example of temporal regulation in the DNA replication process.\n5. The biological significance of early centromere replication in yeast is considered speculative.",
    "llama-2-7b-chat-hf_fact": [
      "Eukaryotic DNA replication begins with multiple origins of replication.",
      "Origins of replication close to yeast centromeres fire early in the replication process.",
      "Centromeres are essential for proper segregation of chromosomes during cell division.",
      "Early replication of baker's yeast centromeres is an example of temporal regulation in the DNA replication process.",
      "The biological significance of early centromere replication in yeast is considered speculative."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 2268,
    "user_query": "Which are the properties of mammalian GA-sequences?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Document 0, the properties of mammalian GA-sequences are:\n1. Length: Mammalian GA-sequences are longer than 50 bases, but consist exclusively of G's and A's.\n2. Frequency: Although their frequency of incidence should be 10^-16 or smaller, the chromosomes of human, chimpanzee, dog, cat, rat, and mouse contained many tens of thousands of them ubiquitously located along the chromosomes with a species-dependent distribution.\n3. Species-dependent distribution: The distribution of GA-sequences varies among different mammalian species.\nIt is important to note that the information provided in Document 1 is related to the properties and distribution of pure GA-sequences of mammalian genomes, but it does not provide additional information about the properties of mammalian GA-sequences.",
    "llama-2-7b-chat-hf_fact_raw": "1. Mammalian GA-sequences are longer than 50 bases and consist exclusively of G's and A's.\n2. The expected frequency of incidence for mammalian GA-sequences should be 10^-16 or smaller.\n3. Human, chimpanzee, dog, cat, rat, and mouse chromosomes contain many tens of thousands of GA-sequences.\n4. GA-sequences are ubiquitously located along the chromosomes of the mentioned mammals.\n5. The distribution of GA-sequences varies among different mammalian species.",
    "llama-2-7b-chat-hf_fact": [
      "Mammalian GA-sequences are longer than 50 bases and consist exclusively of G's and A's.",
      "The expected frequency of incidence for mammalian GA-sequences should be 10^-16 or smaller.",
      "Human, chimpanzee, dog, cat, rat, and mouse chromosomes contain many tens of thousands of GA-sequences.",
      "GA-sequences are ubiquitously located along the chromosomes of the mentioned mammals.",
      "The distribution of GA-sequences varies among different mammalian species."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Mammalian GA-sequences, also known as GA-rich sequences or GA-repeats, do not have a strict length requirement of being longer than 50 bases and can consist of various combinations of G's and A's, not exclusively G's and A's.\n2. UNKNOWN: Without specific information on the definition of GA-sequences being used and the context of the calculation, it is not possible to confirm the expected frequency of incidence for mammalian GA-sequences.\n3. TRUE: Human, chimpanzee, dog, cat, rat, and mouse chromosomes do contain many GA-sequences, although the exact number can vary and may not be in the tens of thousands for all species.\n4. TRUE: GA-sequences are commonly found throughout the chromosomes of the mentioned mammals, although their exact ubiquity can vary.\n5. TRUE: The distribution and frequency of GA-sequences can indeed vary among different mammalian species due to evolutionary divergence and genetic variability.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2291,
    "user_query": "How many Groucho-related genes (GRG) are contained in the mouse genome?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, there is only one Groucho-related gene (GRG) contained in the mouse genome, specifically GRG5. This is mentioned in Document 0, which states that GRG5 is a multifunctional protein that has been implicated in late embryonic and postnatal mouse development.",
    "llama-2-7b-chat-hf_fact_raw": "1. There is only one Groucho-related gene (GRG) in the mouse genome.\n2. The Groucho-related gene in the mouse genome is specifically GRG5.\n3. GRG5 is a multifunctional protein.\n4. GRG5 has been implicated in late embryonic and postnatal mouse development.",
    "llama-2-7b-chat-hf_fact": [
      "There is only one Groucho-related gene (GRG) in the mouse genome.",
      "The Groucho-related gene in the mouse genome is specifically GRG5.",
      "GRG5 is a multifunctional protein.",
      "GRG5 has been implicated in late embryonic and postnatal mouse development."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: There are multiple Groucho-related genes (GRGs) in the mouse genome, not just one.\n2. FALSE [correction]: The Groucho-related genes in the mouse genome include GRG1, GRG2, GRG3, GRG4, and GRG5 (also known as TLE1, TLE2, TLE3, TLE4, and TLE5 respectively).\n3. TRUE: GRG5, like other Groucho/TLE family members, is considered a multifunctional protein involved in various cellular processes.\n4. TRUE: GRG5, as part of the Groucho/TLE family, has been implicated in various developmental processes, including late embryonic and postnatal development.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 2304,
    "user_query": "Which RNA polymerase II subunit carries RNA cleavage activity?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Document 0, RNA polymerase II subunit 6 (Rpb6) carries RNA cleavage activity.",
    "llama-2-7b-chat-hf_fact_raw": "NO FACTS",
    "llama-2-7b-chat-hf_fact": [],
    "llama-2-7b-chat-hf_judge": []
  },
  {
    "id": 2321,
    "user_query": "What is the genetic basis of Ohdo syndrome?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, the genetic basis of Ohdo syndrome is a mutation in a gene or genes that are responsible for the development and function of various body systems, including the reproductive, skeletal, and nervous systems. The specific genetic cause of Ohdo syndrome can vary depending on the type of Ohdo syndrome present, with the SBBYS variant being caused by a mutation in the PTEN gene and the Maat-Kievit-Brunner type being caused by a mutation in the TCF4 gene.\nThe PTEN gene is a tumor suppressor gene that plays a critical role in regulating cell growth and division. Mutations in the PTEN gene have been identified as the cause of several rare genetic disorders, including Cowden syndrome and Bannayan-Riley-Ruvalcaba syndrome, which are characterized by similar symptoms to Ohdo syndrome, including genital abnormalities, intellectual disability, and distinctive facial features.\nThe TCF4 gene is a transcription factor that plays a critical role in regulating the expression of genes involved in the development and function of various body systems. Mutations in the TCF4 gene have been identified as the cause of several rare genetic disorders, including Waardenburg syndrome and Hirschsprung disease, which are characterized by similar symptoms to Ohdo syndrome, including intellectual disability and distinctive facial features.\nIn summary, the genetic basis of Ohdo syndrome is a mutation in a gene or genes that are responsible for the development and function of various body systems, including the reproductive, skeletal, and nervous systems. The specific genetic cause of Ohdo syndrome can vary depending on the type of Ohdo syndrome present.",
    "llama-2-7b-chat-hf_fact_raw": "1. Ohdo syndrome can be caused by a mutation in the PTEN gene, which is associated with the SBBYS variant of the syndrome.\n2. The Maat-Kievit-Brunner type of Ohdo syndrome is caused by a mutation in the TCF4 gene.\n3. The PTEN gene is a tumor suppressor gene that regulates cell growth and division.\n4. Mutations in the PTEN gene can also lead to Cowden syndrome and Bannayan-Riley-Ruvalcaba syndrome.\n5. Mutations in the TCF4 gene can lead to Waardenburg syndrome and Hirschsprung disease.",
    "llama-2-7b-chat-hf_fact": [
      "Ohdo syndrome can be caused by a mutation in the PTEN gene, which is associated with the SBBYS variant of the syndrome.",
      "The Maat-Kievit-Brunner type of Ohdo syndrome is caused by a mutation in the TCF4 gene.",
      "The PTEN gene is a tumor suppressor gene that regulates cell growth and division.",
      "Mutations in the PTEN gene can also lead to Cowden syndrome and Bannayan-Riley-Ruvalcaba syndrome.",
      "Mutations in the TCF4 gene can lead to Waardenburg syndrome and Hirschsprung disease."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Ohdo syndrome, SBBYS variant, is caused by a mutation in the KAT6B gene, not the PTEN gene.\n2. TRUE\n3. TRUE\n4. TRUE\n5. FALSE [correction]: Mutations in the TCF4 gene can lead to Pitt-Hopkins syndrome, not Waardenburg syndrome and Hirschsprung disease. Waardenburg syndrome is associated with mutations in genes such as PAX3 and MITF, while Hirschsprung disease is commonly associated with mutations in the RET gene.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 2331,
    "user_query": "Which R/Bioconductor package has been developed for the analysis of psychiatric disease genes?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, the R/Bioconductor package that has been developed for the analysis of psychiatric disease genes is Psygenet2r. According to Document 0, Psygenet2r is especially suited for network medicine analysis of psychiatric disorders, and it is implemented in R and available under MIT license from Bioconductor.",
    "llama-2-7b-chat-hf_fact_raw": "1. The R/Bioconductor package developed for the analysis of psychiatric disease genes is called Psygenet2r.\n2. Psygenet2r is particularly designed for network medicine analysis of psychiatric disorders.\n3. Psygenet2r is implemented in the R programming language.\n4. Psygenet2r is available under the MIT license.\n5. Psygenet2r can be obtained from Bioconductor.",
    "llama-2-7b-chat-hf_fact": [
      "The R/Bioconductor package developed for the analysis of psychiatric disease genes is called Psygenet2r.",
      "Psygenet2r is particularly designed for network medicine analysis of psychiatric disorders.",
      "Psygenet2r is implemented in the R programming language.",
      "Psygenet2r is available under the MIT license.",
      "Psygenet2r can be obtained from Bioconductor."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. UNKNOWN\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "unknown",
      "true"
    ]
  },
  {
    "id": 2360,
    "user_query": "Describe swirl sign in intracerebral hemorrhage.",
    "llama-2-7b-chat-hf_response": "Thank you for providing the necessary information. Based on the provided documents, the swirl sign in intracerebral hemorrhage (ICH) refers to the non-contrast CT appearance of acute extravasation of blood into a hematoma. It represents unclotted fresh blood that is of lower attenuation than the clotted blood that surrounds it. The swirl sign is typically seen in areas of low attenuation, radiolucency, or irregular density on CT scans.\nThe study you mentioned aimed to describe the prevalence and reliability of the subjective evaluation of the swirl sign in ICH, as well as its prognostic value. The study found that the swirl sign was present in 70% of patients with ICH and was more common in those with larger hematomas. The authors also found that the subjective evaluation of the swirl sign was reliable and could be used to predict poor outcomes in patients with ICH.\nIn summary, the swirl sign in ICH is a non-contrast CT appearance of acute extravasation of blood into a hematoma, representing unclotted fresh blood that is of lower attenuation than the clotted blood that surrounds it. The swirl sign is a reliable indicator of poor outcomes in patients with ICH and can be used to predict poor prognosis.",
    "llama-2-7b-chat-hf_fact_raw": "1. The swirl sign in intracerebral hemorrhage refers to the non-contrast CT appearance of acute extravasation of blood into a hematoma.\n2. The swirl sign represents unclotted fresh blood that is of lower attenuation than the clotted blood that surrounds it.\n3. The swirl sign is typically seen in areas of low attenuation, radiolucency, or irregular density on CT scans.\n4. A study found that the swirl sign was present in 70% of patients with intracerebral hemorrhage.\n5. The subjective evaluation of the swirl sign was found to be reliable and could be used to predict poor outcomes in patients with intracerebral hemorrhage.",
    "llama-2-7b-chat-hf_fact": [
      "The swirl sign in intracerebral hemorrhage refers to the non-contrast CT appearance of acute extravasation of blood into a hematoma.",
      "The swirl sign represents unclotted fresh blood that is of lower attenuation than the clotted blood that surrounds it.",
      "The swirl sign is typically seen in areas of low attenuation, radiolucency, or irregular density on CT scans.",
      "A study found that the swirl sign was present in 70% of patients with intracerebral hemorrhage.",
      "The subjective evaluation of the swirl sign was found to be reliable and could be used to predict poor outcomes in patients with intracerebral hemorrhage."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: The prevalence of the swirl sign in patients with intracerebral hemorrhage varies among studies, and there is no specific study mentioned here to verify the 70% figure. Without a specific reference, the exact percentage cannot be confirmed.\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "false",
      "unknown"
    ]
  },
  {
    "id": 2392,
    "user_query": "What induces Arabidopsis ROF1 expression?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Documents 0 and 1, it can be inferred that Arabidopsis ROF1 expression is induced by heat stress. The study in Document 0 shows that ROF1 binds to heat shock proteins HSP90.1 via its tetratricopeptide repeat domain, which suggests that ROF1 plays a role in responding to heat stress. Additionally, the study in Document 1 reports the characterization of the Arabidopsis large FKBPs ROF1 and ROF2 expression and protein accumulation, which suggests that these proteins may also play a role in heat stress response.\nTherefore, based on the information provided, it can be concluded that Arabidopsis ROF1 expression is induced by heat stress.",
    "llama-2-7b-chat-hf_fact_raw": "1. Arabidopsis ROF1 expression is induced by heat stress.\n2. ROF1 binds to heat shock proteins HSP90.1 via its tetratricopeptide repeat domain.\n3. The binding of ROF1 to HSP90.1 suggests a role for ROF1 in responding to heat stress.\n4. The characterization of Arabidopsis large FKBPs ROF1 and ROF2 includes their expression and protein accumulation.\n5. The expression and protein accumulation of ROF1 and ROF2 suggest a role in heat stress response.",
    "llama-2-7b-chat-hf_fact": [
      "Arabidopsis ROF1 expression is induced by heat stress.",
      "ROF1 binds to heat shock proteins HSP90.1 via its tetratricopeptide repeat domain.",
      "The binding of ROF1 to HSP90.1 suggests a role for ROF1 in responding to heat stress.",
      "The characterization of Arabidopsis large FKBPs ROF1 and ROF2 includes their expression and protein accumulation.",
      "The expression and protein accumulation of ROF1 and ROF2 suggest a role in heat stress response."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: Arabidopsis ROF1 (AtFKBP62) expression is known to be induced by heat stress.\n2. TRUE: ROF1 (AtFKBP62) has been reported to interact with HSP90.1 through its tetratricopeptide repeat (TPR) domain.\n3. TRUE: The binding of ROF1 to HSP90.1 does suggest a role for ROF1 in the cellular response to heat stress, as HSP90.1 is a heat shock protein involved in protecting cells from stress.\n4. TRUE: The characterization of Arabidopsis large FKBPs like ROF1 and ROF2 typically includes studies of their expression patterns and protein accumulation under various conditions, including heat stress.\n5. TRUE: The expression and protein accumulation of ROF1 and ROF2 under heat stress conditions suggest that they may play a role in the plant's response to heat stress.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2398,
    "user_query": "What protein is the most common cause of hereditary  renal amyloidosis?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, the most common cause of hereditary renal amyloidosis is Leukocyte cell-derived chemotaxin 2 (LECT2) amyloidosis. According to Document 1, LECT2 amyloidosis is a recently discovered form of amyloidosis that most often affects the kidneys and liver, and can be passed down from a parent to a child through rare gene mutations. Therefore, it is the most likely protein to be associated with hereditary renal amyloidosis.",
    "llama-2-7b-chat-hf_fact_raw": "1. Leukocyte cell-derived chemotaxin 2 (LECT2) amyloidosis is the most common cause of hereditary renal amyloidosis.\n2. LECT2 amyloidosis often affects the kidneys and liver.\n3. LECT2 amyloidosis can be inherited from a parent to a child through rare gene mutations.",
    "llama-2-7b-chat-hf_fact": [
      "Leukocyte cell-derived chemotaxin 2 (LECT2) amyloidosis is the most common cause of hereditary renal amyloidosis.",
      "LECT2 amyloidosis often affects the kidneys and liver.",
      "LECT2 amyloidosis can be inherited from a parent to a child through rare gene mutations."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Leukocyte cell-derived chemotaxin 2 (LECT2) amyloidosis is not the most common cause of hereditary renal amyloidosis. The most common form of hereditary renal amyloidosis is typically associated with mutations in the genes encoding for transthyretin (ATTR), fibrinogen A alpha-chain (AFib), apolipoprotein AI (AApoAI), and lysozyme (ALys).\n2. TRUE\n3. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 2407,
    "user_query": "Has the proteome of mice hippocampus been analysed?",
    "llama-2-7b-chat-hf_response": "Yes, the proteome of the mouse hippocampus has been analyzed in several studies. The information provided in the documents you provided suggests that the hippocampal proteome has been analyzed at two different ages, 5 and 10 months, to investigate the relationship between proteomic changes and the progression of amyloid plaque deposition in the hippocampus.\nOne such study published in the journal Nature Communications in 2018 analyzed the hippocampal proteome of aged mice (12-14 months) and found that the proteome was significantly altered compared to younger mice (3-4 months). The study identified several proteins that were differentially expressed between the two age groups, including proteins involved in synaptic function, neurotransmission, and protein degradation.\nAnother study published in the journal Molecular Psychiatry in 2017 analyzed the hippocampal proteome of mice with Alzheimer's disease-like pathology and found that the proteome was altered in response to the accumulation of amyloid-β peptides. The study identified several proteins that were differentially expressed between the Alzheimer's disease-like mice and control mice, including proteins involved in inflammation, oxidative stress, and protein degradation.\nOverall, these studies suggest that the proteome of the mouse hippocampus is dynamic and can be altered in response to various factors, including aging and the accumulation of amyloid-β peptides. Further research is needed to fully understand the changes in the hippocampal proteome and their implications for brain function and disease.",
    "llama-2-7b-chat-hf_fact_raw": "1. The proteome of the mouse hippocampus has been analyzed in several studies.\n2. One study published in Nature Communications in 2018 analyzed the hippocampal proteome of aged mice (12-14 months) and compared it to younger mice (3-4 months).\n3. The 2018 study identified proteins that were differentially expressed between the two age groups, including those involved in synaptic function, neurotransmission, and protein degradation.\n4. A study published in Molecular Psychiatry in 2017 analyzed the hippocampal proteome of mice with Alzheimer's disease-like pathology.\n5. The 2017 study found that the hippocampal proteome was altered in response to the accumulation of amyloid-β peptides and identified proteins involved in inflammation, oxidative stress, and protein degradation.",
    "llama-2-7b-chat-hf_fact": [
      "The proteome of the mouse hippocampus has been analyzed in several studies.",
      "One study published in Nature Communications in 2018 analyzed the hippocampal proteome of aged mice (12-14 months) and compared it to younger mice (3-4 months).",
      "The 2018 study identified proteins that were differentially expressed between the two age groups, including those involved in synaptic function, neurotransmission, and protein degradation.",
      "A study published in Molecular Psychiatry in 2017 analyzed the hippocampal proteome of mice with Alzheimer's disease-like pathology.",
      "The 2017 study found that the hippocampal proteome was altered in response to the accumulation of amyloid-β peptides and identified proteins involved in inflammation, oxidative stress, and protein degradation."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE\n\nThese statements are consistent with the types of findings that would be reported in studies analyzing the proteome of the mouse hippocampus, particularly in relation to aging and disease models such as Alzheimer's disease. However, without access to the specific articles from Nature Communications and Molecular Psychiatry, I cannot verify the exact details of the findings. The statements are plausible based on common scientific knowledge in the field of proteomics and neurodegenerative diseases.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2409,
    "user_query": "Are mouse chromosomes acrocentric?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, the answer to the user's question is:\nYes, mouse chromosomes are acrocentric. According to Document 0, all chromosomes in mice are acrocentric, while other mammalian species carry a mixture of acrocentric and metacentric chromosomes. Additionally, Document 1 confirms that all mouse chromosomes are acrocentric, unlike the mostly metacentric chromosomes of humans.",
    "llama-2-7b-chat-hf_fact_raw": "1. Mouse chromosomes are acrocentric.\n2. Other mammalian species have a mixture of acrocentric and metacentric chromosomes.\n3. Human chromosomes are mostly metacentric.",
    "llama-2-7b-chat-hf_fact": [
      "Mouse chromosomes are acrocentric.",
      "Other mammalian species have a mixture of acrocentric and metacentric chromosomes.",
      "Human chromosomes are mostly metacentric."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: Human chromosomes are a mixture of metacentric, submetacentric, and acrocentric chromosomes.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 2417,
    "user_query": "Which siRNA based drug is in clinical trials for the treatment of pancreatic cancer?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Document 0, the siRNA-based drug that is in clinical trials for the treatment of pancreatic cancer is ALN-VSP02. According to the document, ALN-VSP02 was shown to achieve partial stabilization in patients receiving treatment, indicating that it has shown some clinical response in the treatment of pancreatic cancer.",
    "llama-2-7b-chat-hf_fact_raw": "1. ALN-VSP02 is an siRNA-based drug that is in clinical trials for the treatment of pancreatic cancer.\n2. ALN-VSP02 has achieved partial stabilization in patients receiving treatment for pancreatic cancer.",
    "llama-2-7b-chat-hf_fact": [
      "ALN-VSP02 is an siRNA-based drug that is in clinical trials for the treatment of pancreatic cancer.",
      "ALN-VSP02 has achieved partial stabilization in patients receiving treatment for pancreatic cancer."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown"
    ]
  },
  {
    "id": 2419,
    "user_query": "What is the HPG pore?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, the HPG pore appears to be a toolkit for exploring and analyzing nanopore sequencing data. Nanopore sequencing is a single-molecule sequencing technique that uses a nanopore to read the sequence of nucleotides in a DNA molecule. The HPG pore toolkit is designed to help researchers analyze and manage the large amounts of data generated by nanopore sequencing technologies.\nThe toolkit can run on both individual computers and in the Hadoop distributed computing framework, which allows for easy scale-up to manage large amounts of data. This suggests that the HPG pore toolkit is designed to be flexible and scalable, allowing researchers to analyze large datasets generated by nanopore sequencing technologies.\nBased on the information provided, the HPG pore toolkit appears to be a useful tool for researchers working with nanopore sequencing data, as it provides a way to efficiently and effectively analyze and manage large datasets.",
    "llama-2-7b-chat-hf_fact_raw": "1. The HPG pore is a toolkit for exploring and analyzing nanopore sequencing data.\n2. Nanopore sequencing is a single-molecule sequencing technique.\n3. The HPG pore toolkit helps researchers analyze and manage data from nanopore sequencing technologies.\n4. The toolkit can run on individual computers and in the Hadoop distributed computing framework.\n5. The HPG pore toolkit is designed to be flexible and scalable for analyzing large datasets.",
    "llama-2-7b-chat-hf_fact": [
      "The HPG pore is a toolkit for exploring and analyzing nanopore sequencing data.",
      "Nanopore sequencing is a single-molecule sequencing technique.",
      "The HPG pore toolkit helps researchers analyze and manage data from nanopore sequencing technologies.",
      "The toolkit can run on individual computers and in the Hadoop distributed computing framework.",
      "The HPG pore toolkit is designed to be flexible and scalable for analyzing large datasets."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The HPG Pore is not a toolkit; it is a hypothetical protein or gene (HPG) associated with pores, and the statement seems to be a mix-up with a bioinformatics tool. If referring to a bioinformatics tool, it might be a confusion with a different tool for analyzing nanopore sequencing data.\n2. TRUE\n3. UNKNOWN: Without specific information about the \"HPG pore toolkit,\" it is unclear whether such a toolkit exists or helps researchers analyze and manage data from nanopore sequencing technologies. If the statement refers to a real toolkit, the name might be incorrect or misspelled.\n4. UNKNOWN: As the existence and details of the \"HPG pore toolkit\" are not confirmed, it is not possible to determine whether it can run on individual computers and in the Hadoop distributed computing framework.\n5. UNKNOWN: Without confirmation of the \"HPG pore toolkit\" and its features, it is not possible to determine if it is designed to be flexible and scalable for analyzing large datasets.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2472,
    "user_query": "What is the 959 Nematode Genomes initiative?",
    "llama-2-7b-chat-hf_response": "The 959 Nematode Genomes initiative is a community-curated semantic wiki that aims to coordinate the sequencing efforts of individual labs to collectively sequence 959 genomes spanning the phylum Nematoda. The initiative was launched to build upon the success of the Caenorhabditis elegans genome sequencing project, which ushered in a new era of whole-organism, systems analyses of this powerful model organism.\nThe main goal of the 959 Nematode Genomes wiki is to track sequencing projects that have been proposed, are in progress, or have been completed, and to provide a central hub for sharing information, resources, and data among researchers. By pooling their efforts, the participating labs hope to generate a wealth of new data and insights into the biology of nematodes, which are a diverse and important group of organisms that include parasitic and beneficial species.\nThe wiki is open to anyone who wants to contribute, and it provides a range of tools and resources for participants, including a database of sequencing projects, a calendar of events, and a discussion forum. By working together through this initiative, the participating labs aim to accelerate the pace of nematode genome sequencing and to foster collaboration and knowledge-sharing among researchers in the field.",
    "llama-2-7b-chat-hf_fact_raw": "1. The 959 Nematode Genomes initiative is a community-curated semantic wiki.\n2. The initiative's aim is to coordinate the sequencing of 959 genomes across the phylum Nematoda.\n3. The initiative was launched following the success of the Caenorhabditis elegans genome sequencing project.\n4. The wiki tracks proposed, in-progress, and completed sequencing projects.\n5. The 959 Nematode Genomes initiative is designed to facilitate information and resource sharing among researchers.",
    "llama-2-7b-chat-hf_fact": [
      "The 959 Nematode Genomes initiative is a community-curated semantic wiki.",
      "The initiative's aim is to coordinate the sequencing of 959 genomes across the phylum Nematoda.",
      "The initiative was launched following the success of the Caenorhabditis elegans genome sequencing project.",
      "The wiki tracks proposed, in-progress, and completed sequencing projects.",
      "The 959 Nematode Genomes initiative is designed to facilitate information and resource sharing among researchers."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The 959 Nematode Genomes initiative is not a wiki; it is a scientific project aimed at sequencing the genomes of 959 nematode species.\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2557,
    "user_query": "Which R package has been developed for analyzing Non-invasive prenatal testing (NIPT) data?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, the R package that has been developed for analyzing Non-invasive prenatal testing (NIPT) data is NIPTeR. According to Document 0, NIPTeR is an open-source R Package that enables fast NIPT analysis and simple but flexible workflow creation, including variation reduction, trisomy prediction algorithms, and quality control. This package allows users to account for variability in NIPT data, calculate control group statistics, and predict the presence of trisomies. Therefore, NIPTeR is the recommended package for analyzing NIPT data.",
    "llama-2-7b-chat-hf_fact_raw": "1. The R package developed for analyzing Non-invasive prenatal testing (NIPT) data is called NIPTeR.\n2. NIPTeR is an open-source R Package.\n3. NIPTeR enables fast NIPT analysis.\n4. NIPTeR includes features for variation reduction, trisomy prediction algorithms, and quality control.\n5. NIPTeR allows users to calculate control group statistics and predict the presence of trisomies.",
    "llama-2-7b-chat-hf_fact": [
      "The R package developed for analyzing Non-invasive prenatal testing (NIPT) data is called NIPTeR.",
      "NIPTeR is an open-source R Package.",
      "NIPTeR enables fast NIPT analysis.",
      "NIPTeR includes features for variation reduction, trisomy prediction algorithms, and quality control.",
      "NIPTeR allows users to calculate control group statistics and predict the presence of trisomies."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2560,
    "user_query": "Describe Achenbach’s syndrome.",
    "llama-2-7b-chat-hf_response": "Thank you for asking! Based on the information provided in Documents 0 and 1, Achenbach's syndrome is a rare condition characterized by recurring and painful bruising of the fingers or palm, without any underlying serious conditions. The syndrome is more common in middle-aged females, with a median age of onset of 48-50 years (range 22-76 years).\nThe symptoms of Achenbach's syndrome typically include a blue-purple discoloration of the volar aspect of one or more digits, associated with pain and paresthesia. The bruising can occur spontaneously and can recur multiple times, causing significant distress and discomfort for the affected individual.\nIt is important to note that Achenbach's syndrome is an underdiagnosed condition, and patients may be hesitant to seek medical attention due to the alarming appearance of the bruising. However, early diagnosis and treatment can help alleviate symptoms and improve quality of life for individuals affected by this condition.\nIf you or someone you know is experiencing recurring and painful bruising of the fingers or palm, it is essential to consult with a healthcare professional for proper evaluation and management.",
    "llama-2-7b-chat-hf_fact_raw": "1. Achenbach's syndrome is characterized by recurring and painful bruising of the fingers or palm.\n2. The condition is more common in middle-aged females.\n3. The median age of onset for Achenbach's syndrome is between 48-50 years.\n4. Symptoms of Achenbach's syndrome include blue-purple discoloration of the volar aspect of one or more digits, pain, and paresthesia.\n5. Achenbach's syndrome is considered an underdiagnosed condition.",
    "llama-2-7b-chat-hf_fact": [
      "Achenbach's syndrome is characterized by recurring and painful bruising of the fingers or palm.",
      "The condition is more common in middle-aged females.",
      "The median age of onset for Achenbach's syndrome is between 48-50 years.",
      "Symptoms of Achenbach's syndrome include blue-purple discoloration of the volar aspect of one or more digits, pain, and paresthesia.",
      "Achenbach's syndrome is considered an underdiagnosed condition."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. UNKNOWN\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "unknown",
      "true",
      "true"
    ]
  },
  {
    "id": 2581,
    "user_query": "Which algorithm is used for detection of long repeat expansions?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Document 1, the algorithm used for detection of long repeat expansions is ExpansionHunter.",
    "llama-2-7b-chat-hf_fact_raw": "1. ExpansionHunter is an algorithm used for the detection of long repeat expansions.",
    "llama-2-7b-chat-hf_fact": [
      "ExpansionHunter is an algorithm used for the detection of long repeat expansions."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true"
    ]
  },
  {
    "id": 2582,
    "user_query": "Which brain tumors does neuroligin-3 promote?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Documents 0 and 1, neuroligin-3 appears to promote the growth and proliferation of glioblastoma (GBM) cells. The documents suggest that activity-dependent cleavage and secretion of neuroligin-3 (NLGN3) plays an important role in the regulation of brain cancer, and that NLGN3 is a leading candidate mitogen that promotes the proliferation of GBM cells. Specifically, the documents state that soluble NLGN3 is sufficient and necessary to promote robust HGG cell proliferation, and that NLGN3 induces the PI3K-mTOR signaling pathway activity and feedforward expression of NLGN3 in glioma cells. Therefore, based on the information provided, it can be concluded that neuroligin-3 promotes the growth and proliferation of glioblastoma cells.",
    "llama-2-7b-chat-hf_fact_raw": "1. Neuroligin-3 promotes the growth and proliferation of glioblastoma (GBM) cells.\n2. Activity-dependent cleavage and secretion of neuroligin-3 (NLGN3) is important in the regulation of brain cancer.\n3. Soluble NLGN3 is sufficient and necessary to promote robust high-grade glioma (HGG) cell proliferation.\n4. Neuroligin-3 induces the PI3K-mTOR signaling pathway activity in glioma cells.\n5. Neuroligin-3 promotes feedforward expression of itself in glioma cells.",
    "llama-2-7b-chat-hf_fact": [
      "Neuroligin-3 promotes the growth and proliferation of glioblastoma (GBM) cells.",
      "Activity-dependent cleavage and secretion of neuroligin-3 (NLGN3) is important in the regulation of brain cancer.",
      "Soluble NLGN3 is sufficient and necessary to promote robust high-grade glioma (HGG) cell proliferation.",
      "Neuroligin-3 induces the PI3K-mTOR signaling pathway activity in glioma cells.",
      "Neuroligin-3 promotes feedforward expression of itself in glioma cells."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: Neuroligin-3 has been shown to promote the growth and proliferation of glioblastoma (GBM) cells in various studies.\n2. TRUE: Activity-dependent cleavage and secretion of neuroligin-3 (NLGN3) have been implicated in the regulation of brain cancer, including glioblastoma.\n3. TRUE: Research suggests that soluble NLGN3 is both sufficient and necessary to promote robust high-grade glioma (HGG) cell proliferation.\n4. TRUE: Neuroligin-3 has been reported to induce the PI3K-mTOR signaling pathway activity in glioma cells, which is a pathway known for its role in cell growth and proliferation.\n5. UNKNOWN: Without specific evidence or studies to support the statement that neuroligin-3 promotes feedforward expression of itself in glioma cells, the truth of this statement cannot be determined.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 2586,
    "user_query": "What is the approximate size of gas vesicles?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Documents 0 and 1, the approximate size of gas vesicles can be estimated to be:\nThe width of gas vesicles ranges from 45 to > 200 nm, which is approximately 0.000045 to 0.0002 micrometers (μm).\nThe length of gas vesicles ranges from 0.1 to 2 μm, which is approximately 0.000001 to 0.000002 micrometers (μm).\nTherefore, the volume of a gas vesicle can be estimated to be:\nVolume of gas vesicle = width x length x number of gas vesicles\nThe number of gas vesicles in a given organelle or cell can vary depending on the organism and the specific conditions. However, for the purpose of this calculation, let's assume an average number of 10 gas vesicles per organelle or cell.\nVolume of gas vesicle = 0.000045 x 0.00001 x 10 = 4.5 x 10^-12 cubic micrometers (μm^3)\nSo, the approximate size of gas vesicles is around 4.5 x 10^-12 μm^3.\nPlease note that this is a rough estimate based on the information provided, and the actual size of gas vesicles can vary depending on various factors such as the organism, the stage of gas vesicle formation, and the specific conditions.",
    "llama-2-7b-chat-hf_fact_raw": "1. The width of gas vesicles ranges from 45 to over 200 nanometers (nm).\n2. The length of gas vesicles ranges from 0.1 to 2 micrometers (μm).\n3. The volume of a gas vesicle can be estimated using the formula: volume = width x length x number of gas vesicles.\n4. An average number of 10 gas vesicles per organelle or cell is assumed for the purpose of the calculation provided.\n5. The approximate volume of a gas vesicle is around 4.5 x 10^-12 cubic micrometers (μm^3) based on the given calculation.",
    "llama-2-7b-chat-hf_fact": [
      "The width of gas vesicles ranges from 45 to over 200 nanometers (nm).",
      "The length of gas vesicles ranges from 0.1 to 2 micrometers (μm).",
      "The volume of a gas vesicle can be estimated using the formula: volume = width x length x number of gas vesicles.",
      "An average number of 10 gas vesicles per organelle or cell is assumed for the purpose of the calculation provided.",
      "The approximate volume of a gas vesicle is around 4.5 x 10^-12 cubic micrometers (μm^3) based on the given calculation."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: The volume of a gas vesicle can be estimated using the formula for the volume of a cylinder (volume = π x (radius)^2 x length), not simply width x length x number of gas vesicles.\n4. UNKNOWN\n5. FALSE [correction]: Without specific values for the width, length, and number of gas vesicles, it is not possible to confirm the approximate volume of a gas vesicle. Additionally, the correct formula for the volume of a cylinder should be used, which includes π and the square of the radius.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "unknown",
      "false"
    ]
  },
  {
    "id": 2589,
    "user_query": "List BET proteins.",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Documents 0 and 1, here are some of the BET proteins that have been identified:\n1. BRD2 (Bromodomain-Containing Protein 2)\n2. BRD3 (Bromodomain-Containing Protein 3)\n3. BRD4 (Bromodomain-Containing Protein 4)\n4. BRDT (Bromodomain-Containing Protein T)\nThese proteins are part of the BET family and play crucial roles in regulating various cellular processes, including cell cycle progression, neurogenesis, differentiation, and maturation of erythroids and spermatogenesis. Research has shown that BET proteins, particularly BRD4, are associated with various pathological conditions, including cancer, inflammation, infections, and renal disease.\nIt is important to note that this list may not be exhaustive, as there may be other BET proteins that have been identified in scientific literature. However, based on the information provided in Documents 0 and 1, these are some of the most well-known and well-studied BET proteins.",
    "llama-2-7b-chat-hf_fact_raw": "1. BRD2 is identified as a BET protein.\n2. BRD3 is identified as a BET protein.\n3. BRD4 is identified as a BET protein.\n4. BRDT is identified as a BET protein.\n5. BET proteins are associated with various pathological conditions, including cancer, inflammation, infections, and renal disease.",
    "llama-2-7b-chat-hf_fact": [
      "BRD2 is identified as a BET protein.",
      "BRD3 is identified as a BET protein.",
      "BRD4 is identified as a BET protein.",
      "BRDT is identified as a BET protein.",
      "BET proteins are associated with various pathological conditions, including cancer, inflammation, infections, and renal disease."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2610,
    "user_query": "Which algorithm has been developed for prediction of protein subcellular localization using deep learning?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the two documents, the algorithm that has been developed for prediction of protein subcellular localization using deep learning is called DeepPSL. This algorithm uses Stacked Auto-Encoder (SAE) networks to predict protein subcellular locations.",
    "llama-2-7b-chat-hf_fact_raw": "1. DeepPSL is an algorithm developed for prediction of protein subcellular localization using deep learning.\n2. DeepPSL utilizes Stacked Auto-Encoder (SAE) networks for its predictions.",
    "llama-2-7b-chat-hf_fact": [
      "DeepPSL is an algorithm developed for prediction of protein subcellular localization using deep learning.",
      "DeepPSL utilizes Stacked Auto-Encoder (SAE) networks for its predictions."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true"
    ]
  },
  {
    "id": 2634,
    "user_query": "What is MULTOVL?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, MULTOVL appears to be an application suite designed to detect and analyze multiple overlaps of genomic regions in a fast and efficient manner. The package supports the detection of multiple region intersections, unions, and solitary genomic regions. The significance of actually observed overlaps is also analyzed. MULTOVL is a useful tool for bioinformatics researchers and analysts who need to identify and analyze multiple genomic regions in large datasets.",
    "llama-2-7b-chat-hf_fact_raw": "1. MULTOVL is an application suite designed for detecting and analyzing multiple overlaps of genomic regions.\n2. MULTOVL supports the detection of multiple region intersections, unions, and solitary genomic regions.\n3. The application analyzes the significance of observed overlaps.\n4. MULTOVL is intended for use by bioinformatics researchers and analysts.\n5. The tool is designed to handle large datasets in genomic research.",
    "llama-2-7b-chat-hf_fact": [
      "MULTOVL is an application suite designed for detecting and analyzing multiple overlaps of genomic regions.",
      "MULTOVL supports the detection of multiple region intersections, unions, and solitary genomic regions.",
      "The application analyzes the significance of observed overlaps.",
      "MULTOVL is intended for use by bioinformatics researchers and analysts.",
      "The tool is designed to handle large datasets in genomic research."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. UNKNOWN\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "unknown",
      "true",
      "true"
    ]
  },
  {
    "id": 2660,
    "user_query": "Can GDF15 be a biomarker for metformin treatment?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, it is possible that GDF15 could be used as a biomarker for metformin treatment. Document 0 mentions that GDF15 is expressed in multiple cell types and can be increased by cellular stressors, including hypoxia, mitochondrial dysfunction, and metformin. This suggests that GDF15 levels may be affected by metformin treatment, and could potentially serve as a biomarker for its effectiveness.\nDocument 1 provides further evidence for this possibility, as it suggests that the weight-lowering effects of metformin might involve GDF15. This suggests that GDF15 levels may be a useful indicator of metformin's effectiveness in weight loss, and could potentially be used as a biomarker for metformin treatment.\nHowever, it is important to note that more research is needed to fully understand the relationship between GDF15 and metformin treatment, and to determine the accuracy and reliability of GDF15 as a biomarker for metformin treatment. Further studies are needed to confirm these findings and to establish the clinical utility of GDF15 as a biomarker for metformin treatment.",
    "llama-2-7b-chat-hf_fact_raw": "1. GDF15 is expressed in multiple cell types.\n2. GDF15 levels can be increased by cellular stressors such as hypoxia, mitochondrial dysfunction, and metformin.\n3. GDF15 levels may be affected by metformin treatment.\n4. The weight-lowering effects of metformin might involve GDF15.\n5. More research is needed to fully understand the relationship between GDF15 and metformin treatment.",
    "llama-2-7b-chat-hf_fact": [
      "GDF15 is expressed in multiple cell types.",
      "GDF15 levels can be increased by cellular stressors such as hypoxia, mitochondrial dysfunction, and metformin.",
      "GDF15 levels may be affected by metformin treatment.",
      "The weight-lowering effects of metformin might involve GDF15.",
      "More research is needed to fully understand the relationship between GDF15 and metformin treatment."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2664,
    "user_query": "Is recursive splicing more common in short introns?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Documents 0 and 1, it is more common for recursive splicing to occur in short introns.\nDocument 0 explains that recursive splicing often involves non-canonical splicing elements positioned deep within introns, which suggests that the process is more prevalent in introns that are shorter in length. Additionally, the document proposes different mechanisms for the deployment of recursive splicing, which may be more relevant in shorter introns.\nDocument 1 also supports the idea that recursive splicing is more common in short introns. The document states that eukaryotic genomes have evolved to host genes carrying multiple exons separated by increasingly larger intronic sequences, which suggests that the longer introns are less likely to undergo recursive splicing.\nTherefore, based on the information provided, it can be concluded that recursive splicing is more common in short introns than in longer introns.",
    "llama-2-7b-chat-hf_fact_raw": "1. Recursive splicing often involves non-canonical splicing elements positioned deep within introns.\n2. Recursive splicing is suggested to be more prevalent in introns that are shorter in length.\n3. Different mechanisms for the deployment of recursive splicing may be more relevant in shorter introns.\n4. Eukaryotic genomes have evolved to host genes with multiple exons separated by increasingly larger intronic sequences.\n5. Longer introns are less likely to undergo recursive splicing compared to shorter introns.",
    "llama-2-7b-chat-hf_fact": [
      "Recursive splicing often involves non-canonical splicing elements positioned deep within introns.",
      "Recursive splicing is suggested to be more prevalent in introns that are shorter in length.",
      "Different mechanisms for the deployment of recursive splicing may be more relevant in shorter introns.",
      "Eukaryotic genomes have evolved to host genes with multiple exons separated by increasingly larger intronic sequences.",
      "Longer introns are less likely to undergo recursive splicing compared to shorter introns."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Recursive splicing is suggested to be more prevalent in introns that are longer in length.\n3. FALSE [correction]: Different mechanisms for the deployment of recursive splicing may be more relevant in longer introns.\n4. TRUE\n5. FALSE [correction]: Longer introns are more likely to undergo recursive splicing compared to shorter introns.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "false",
      "true",
      "false"
    ]
  },
  {
    "id": 2679,
    "user_query": "What is the TALE-iD method used for?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Documents 0 and 1, the TALE-iD method is used for genome editing and modifying the epigenome. TALE nucleases, activators, transposases, recombinases, and epigenomic modifiers are all types of genome editing tools that use the TALE-iD method. These tools are designed to be easy to use and have been used to achieve significant advancements in both agriculture and medicine.\nThe TALE-iD method involves the use of a Cys 2-His 2 zinc-finger protein domain, which is a common DNA-binding motif found in eukaryotes. This domain is composed of approximately 30 amino acids in a conserved ββα configuration, and is used to recognize and bind to specific DNA sequences. By using the TALE-iD method, researchers can design and create genome editing tools that can be used to modify specific genes or sequences in an organism's genome.\nThe TALEN technology, which is a type of genome editing tool that uses the TALE-iD method, was the first easy-to-use genome editing technology to be developed and has been instrumental in sparking the genome editing revolution. TALENs have been used to achieve significant advancements in both agriculture and medicine, including the development of new crop varieties and the treatment of genetic diseases.\nIn summary, the TALE-iD method is a powerful tool for genome editing and epigenomic modification, and has been used to achieve significant advancements in both agriculture and medicine.",
    "llama-2-7b-chat-hf_fact_raw": "1. The TALE-iD method is used for genome editing and modifying the epigenome.\n2. TALE nucleases, activators, transposases, recombinases, and epigenomic modifiers are tools that use the TALE-iD method.\n3. The TALE-iD method involves the use of a Cys 2-His 2 zinc-finger protein domain to recognize and bind to specific DNA sequences.\n4. TALEN technology, which uses the TALE-iD method, was the first easy-to-use genome editing technology to be developed.\n5. TALENs have been used in the development of new crop varieties and the treatment of genetic diseases.",
    "llama-2-7b-chat-hf_fact": [
      "The TALE-iD method is used for genome editing and modifying the epigenome.",
      "TALE nucleases, activators, transposases, recombinases, and epigenomic modifiers are tools that use the TALE-iD method.",
      "The TALE-iD method involves the use of a Cys 2-His 2 zinc-finger protein domain to recognize and bind to specific DNA sequences.",
      "TALEN technology, which uses the TALE-iD method, was the first easy-to-use genome editing technology to be developed.",
      "TALENs have been used in the development of new crop varieties and the treatment of genetic diseases."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: The TALE-iD method involves the use of transcription activator-like effector (TALE) proteins to recognize and bind to specific DNA sequences, not Cys2-His2 zinc-finger protein domains.\n4. FALSE [correction]: TALEN technology was not the first easy-to-use genome editing technology to be developed; zinc-finger nucleases (ZFNs) were developed earlier.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "false",
      "true"
    ]
  },
  {
    "id": 2747,
    "user_query": "Which Lisp framework has been developed for image processing?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, the Lisp framework that has been developed for image processing is FunImageJ.",
    "llama-2-7b-chat-hf_fact_raw": "1. FunImageJ is a Lisp framework developed for image processing.",
    "llama-2-7b-chat-hf_fact": [
      "FunImageJ is a Lisp framework developed for image processing."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true"
    ]
  },
  {
    "id": 2759,
    "user_query": "How many genes in S. cerevisiae are the result of an ancient whole genome duplication?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the documents, it is difficult to give an exact number of genes in Saccharomyces cerevisiae that are the result of an ancient whole genome duplication. However, we can make an estimate based on the information provided.\nDocument 0 mentions that many duplicate genes have been found in S. cerevisiae, and these often seem to be phenotypically redundant. This suggests that a significant portion of the genes in S. cerevisiae are the result of an ancient whole genome duplication.\nDocument 1 provides information on the number of single nucleotide polymorphisms (SNPs) detected across 1,011 genomes of S. cerevisiae. The document states that a total of 1,625,809 high-quality reference-based SNPs were detected, with 31.3% of the polymorphic positions being present at very low frequencies.\nUsing these numbers, we can estimate the number of genes in S. cerevisiae that are the result of an ancient whole genome duplication. Let's assume that the 1,625,809 SNPs detected in the document are evenly distributed across the genes in S. cerevisiae, which is unlikely but simplifies the calculation.\nIf we assume that each gene in S. cerevisiae has an average of 100 SNPs, which is a rough estimate based on the document, then the total number of genes in S. cerevisiae would be:\n1,625,809 SNPs / 100 SNPs per gene = 16,258 genes\nHowever, this estimate may be too high, as some of the SNPs may be present in non-coding regions or may affect multiple genes. Therefore, a more realistic estimate of the number of genes in S. cerevisiae that are the result of an ancient whole genome duplication may be lower, around 10,000 to 15,000 genes.\nIn conclusion, while we cannot give an exact number of genes in S. cerevisiae that are the result of an ancient whole genome duplication, based on the information provided in the documents,",
    "llama-2-7b-chat-hf_fact_raw": "1. Many duplicate genes have been found in Saccharomyces cerevisiae.\n2. These duplicate genes in S. cerevisiae often seem to be phenotypically redundant.\n3. A total of 1,625,809 high-quality reference-based single nucleotide polymorphisms (SNPs) were detected across 1,011 genomes of S. cerevisiae.\n4. 31.3% of the polymorphic positions in S. cerevisiae were present at very low frequencies.\n5. An estimate suggests that there may be around 10,000 to 15,000 genes in S. cerevisiae that are the result of an ancient whole genome duplication.",
    "llama-2-7b-chat-hf_fact": [
      "Many duplicate genes have been found in Saccharomyces cerevisiae.",
      "These duplicate genes in S. cerevisiae often seem to be phenotypically redundant.",
      "A total of 1,625,809 high-quality reference-based single nucleotide polymorphisms (SNPs) were detected across 1,011 genomes of S. cerevisiae.",
      "31.3% of the polymorphic positions in S. cerevisiae were present at very low frequencies.",
      "An estimate suggests that there may be around 10,000 to 15,000 genes in S. cerevisiae that are the result of an ancient whole genome duplication."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: Saccharomyces cerevisiae, commonly known as baker's yeast, is known to have many duplicate genes, which is consistent with its evolutionary history of whole-genome duplication.\n2. TRUE: The duplicate genes in S. cerevisiae are often considered to be phenotypically redundant, meaning that the loss of one copy may not have a significant effect on the organism's phenotype because the other copy can compensate.\n3. UNKNOWN: Without a specific reference to a study or database, it is not possible to confirm the exact number of high-quality reference-based single nucleotide polymorphisms (SNPs) detected across 1,011 genomes of S. cerevisiae.\n4. UNKNOWN: Similar to statement 3, without a specific reference, it is not possible to confirm the percentage of polymorphic positions present at very low frequencies in S. cerevisiae.\n5. FALSE [correction]: The estimated number of genes in S. cerevisiae is around 6,000, not 10,000 to 15,000. The reference to an ancient whole genome duplication is correct, but the number of genes resulting from that event is not as high as 10,000 to 15,000.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "unknown",
      "unknown",
      "false"
    ]
  },
  {
    "id": 2763,
    "user_query": "Which complex is bound by estrogen-related receptor β (Esrrb)?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Documents 0 and 1, the complex that is bound by estrogen-related receptor β (Esrrb) is the extra-embryonic markers.\nDocument 0 states that genetic inactivation of Esrrb leads to illegitimate expression of mesendoderm and extra-embryonic markers, impaired formative expression, and failure to self-organize in 3D. This suggests that Esrrb plays a critical role in regulating the expression of genes involved in the development of the extra-embryonic tissues, such as the mesoderm and ectoderm.\nDocument 1 provides additional information on the role of ERRs in cellular metabolism and oncogenesis. ERRs are founding members of the orphan nuclear receptor (ONR) subgroup of the nuclear receptor superfamily, and despite extensive research, no cognate ligands have been identified for the ERRs. However, the document highlights the importance of ERRα (ESRRA) and ERRγ (ESRRG) in cellular metabolism and oncogenesis.\nGiven the information provided in these documents, it can be inferred that Esrrb is involved in regulating the expression of genes involved in the development of extra-embryonic tissues, and that the complex bound by Esrrb is likely to include genes involved in these tissues.",
    "llama-2-7b-chat-hf_fact_raw": "1. Genetic inactivation of Esrrb leads to illegitimate expression of mesendoderm and extra-embryonic markers.\n2. Esrrb impairment results in failed self-organization in 3D.\n3. Esrrb is involved in regulating the expression of genes related to the development of extra-embryonic tissues.\n4. Estrogen-related receptors (ERRs) are part of the orphan nuclear receptor (ONR) subgroup of the nuclear receptor superfamily.\n5. No cognate ligands have been identified for the estrogen-related receptors (ERRs).",
    "llama-2-7b-chat-hf_fact": [
      "Genetic inactivation of Esrrb leads to illegitimate expression of mesendoderm and extra-embryonic markers.",
      "Esrrb impairment results in failed self-organization in 3D.",
      "Esrrb is involved in regulating the expression of genes related to the development of extra-embryonic tissues.",
      "Estrogen-related receptors (ERRs) are part of the orphan nuclear receptor (ONR) subgroup of the nuclear receptor superfamily.",
      "No cognate ligands have been identified for the estrogen-related receptors (ERRs)."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: Genetic inactivation of Esrrb can lead to the misexpression of genes, including those associated with mesendoderm and extra-embryonic markers, as Esrrb is known to play a role in maintaining the pluripotency of embryonic stem cells and regulating gene expression during development.\n2. TRUE: Impairment of Esrrb function can result in failed self-organization in 3D cultures, as Esrrb is important for the maintenance of stem cell properties and proper cellular organization during development.\n3. TRUE: Esrrb is indeed involved in regulating the expression of genes related to the development of extra-embryonic tissues, which is consistent with its role in embryonic stem cell pluripotency and differentiation.\n4. TRUE: Estrogen-related receptors (ERRs) are indeed part of the orphan nuclear receptor (ONR) subgroup of the nuclear receptor superfamily. They are called \"orphan\" receptors because they have no identified endogenous ligands.\n5. TRUE: As of the last update, no cognate ligands have been conclusively identified for the estrogen-related receptors (ERRs), which is why they are classified as orphan receptors.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2842,
    "user_query": "What is the role of ZCCHC17?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, ZCCHC17 appears to play a role in regulating the transcription of ribosomal DNA (rDNA). Specifically, ZCCHC17 acts as a negative regulator of rDNA transcription by interacting with the upstream binding factor (UBF) and reducing its binding to the rDNA promoter. This suggests that ZCCHC17 may play a role in regulating the expression of genes involved in ribosome biogenesis and function, which is important for cellular processes such as protein synthesis and cell growth. Additionally, ZCCHC17 has been shown to be involved in alternative splicing and trans-splicing, which are important mechanisms for regulating gene expression.",
    "llama-2-7b-chat-hf_fact_raw": "1. ZCCHC17 plays a role in regulating the transcription of ribosomal DNA (rDNA).\n2. ZCCHC17 acts as a negative regulator of rDNA transcription.\n3. ZCCHC17 interacts with the upstream binding factor (UBF).\n4. ZCCHC17 reduces the binding of UBF to the rDNA promoter.\n5. ZCCHC17 is involved in alternative splicing and trans-splicing.",
    "llama-2-7b-chat-hf_fact": [
      "ZCCHC17 plays a role in regulating the transcription of ribosomal DNA (rDNA).",
      "ZCCHC17 acts as a negative regulator of rDNA transcription.",
      "ZCCHC17 interacts with the upstream binding factor (UBF).",
      "ZCCHC17 reduces the binding of UBF to the rDNA promoter.",
      "ZCCHC17 is involved in alternative splicing and trans-splicing."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: ZCCHC17, also known as nucleolin, generally acts as a positive regulator of rDNA transcription.\n3. TRUE\n4. FALSE [correction]: ZCCHC17, by interacting with UBF, typically enhances the binding of UBF to the rDNA promoter, facilitating transcription.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 2861,
    "user_query": "Which proteins form the nuclear pore basket in human cells?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Documents 0 and 1, the proteins that form the nuclear pore basket in human cells are:\n1. TNPO1 (Transthyretin-related protein 1) - Document 0 mentions that proteins related to nuclear division and tRNA ligases are preferentially cargoes of TNPO1.\n2. HMG proteins (High-mobility group proteins) - Document 1 mentions that proteins related to DNA repair are transported through the nuclear pore complex (NPC). HMG proteins are involved in DNA repair and are known to be transported through the NPC.\nTherefore, the proteins that form the nuclear pore basket in human cells are TNPO1 and HMG proteins.",
    "llama-2-7b-chat-hf_fact_raw": "NO FACTS",
    "llama-2-7b-chat-hf_fact": [],
    "llama-2-7b-chat-hf_judge": []
  },
  {
    "id": 2919,
    "user_query": "What type of topoisomerase inhibitor is gepotidacin?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, it can be concluded that gepotidacin is a topoisomerase inhibitor. Specifically, it is a novel, bactericidal, first-in-class triazaacenaphthylene antibiotic that inhibits bacterial topoisomerase. This is evident from Document 0, which states that gepotidacin has a unique mechanism of action that is not anticipated to have the same risks to bone growth as those of fluoroquinolones.\nTopoisomerase inhibitors are a class of antibiotics that work by interfering with the activity of bacterial topoisomerases, which are enzymes that help bacteria to unwind and rewind their DNA during replication and repair. By inhibiting these enzymes, topoisomerase inhibitors can prevent bacterial DNA replication and repair, leading to cell death and bacterial inhibition.\nIn contrast to fluoroquinolones, which are a class of antibiotics that also inhibit bacterial topoisomerases, gepotidacin binds to a different site and has a novel mechanism of action. This suggests that gepotidacin may have a different mode of action than fluoroquinolones and may be less likely to induce bone growth inhibition, as mentioned in Document 0.\nTherefore, based on the information provided, it can be concluded that gepotidacin is a topoisomerase inhibitor, specifically a novel, bactericidal, first-in-class triazaacenaphthylene antibiotic that inhibits bacterial topoisomerase and has a unique mechanism of action compared to fluoroquinolones.",
    "llama-2-7b-chat-hf_fact_raw": "1. Gepotidacin is a topoisomerase inhibitor.\n2. Gepotidacin is classified as a novel, bactericidal, first-in-class triazaacenaphthylene antibiotic.\n3. Gepotidacin inhibits bacterial topoisomerase.\n4. Gepotidacin has a unique mechanism of action that differs from fluoroquinolones.\n5. Gepotidacin is not anticipated to have the same risks to bone growth as fluoroquinolones.",
    "llama-2-7b-chat-hf_fact": [
      "Gepotidacin is a topoisomerase inhibitor.",
      "Gepotidacin is classified as a novel, bactericidal, first-in-class triazaacenaphthylene antibiotic.",
      "Gepotidacin inhibits bacterial topoisomerase.",
      "Gepotidacin has a unique mechanism of action that differs from fluoroquinolones.",
      "Gepotidacin is not anticipated to have the same risks to bone growth as fluoroquinolones."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE\n\nGepotidacin is indeed a topoisomerase inhibitor and is classified as a novel, bactericidal, first-in-class triazaacenaphthylene antibiotic. It inhibits bacterial topoisomerase, specifically targeting bacterial DNA gyrase and topoisomerase IV, which are types of topoisomerases. Its mechanism of action is unique and differs from that of fluoroquinolones, which also target topoisomerases but bind differently. Due to its unique binding and mechanism, it is anticipated that gepotidacin will not have the same risks to bone growth as fluoroquinolones, which have been associated with such adverse effects.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2943,
    "user_query": "Describe Canvas SPW",
    "llama-2-7b-chat-hf_response": "Canvas SPW is a tool designed to support the identification of de novo variants, which are genetic mutations that are present in an individual for the first time, from diverse sequencing experiments. It is part of the Canvas suite of tools, which are developed by Illumina, a leading provider of sequencing technologies.\nCanvas SPW provides a number of features to help automate and streamline the identification of de novo variants, including:\n1. Support for a wide range of family structures: Canvas SPW can handle a variety of family structures, including small pedigrees, whole-genome matched tumor-normal, and single-sample normal resequencing.\n2. Scoring and filtering options: Canvas SPW provides a range of scoring and filtering options to help identify high-quality de novo variants. These options include the ability to filter by read depth, base quality, and other criteria.\n3. Availability and implementation: Canvas SPW is available for download from GitHub, and can be implemented in a variety of environments, including local servers, cloud-based infrastructure, and high-performance computing environments.\nFor more information on Canvas SPW, including documentation and contact details for the development team, please refer to the following resources:\nDocument 0: Canvas SPW User Guide (<https://github.com/Illumina/canvas/blob/master/doc/SPW_User_Guide.md>)\nDocument 1: Canvas: A Tool for Identification of Copy Number Changes from Diverse Sequencing Experiments (<https://www.nature.com/articles/sdata2017/pdf/sdata2017-0076-t1.pdf>)\nContact: sivakhno@illumina.com (for more information on Canvas SPW and related tools)",
    "llama-2-7b-chat-hf_fact_raw": "1. Canvas SPW is a tool designed to support the identification of de novo genetic mutations.\n2. It is part of the Canvas suite of tools developed by Illumina.\n3. Canvas SPW can handle various family structures, including small pedigrees and whole-genome matched tumor-normal.\n4. Canvas SPW offers scoring and filtering options to identify high-quality de novo variants.\n5. Canvas SPW is available for download from GitHub.",
    "llama-2-7b-chat-hf_fact": [
      "Canvas SPW is a tool designed to support the identification of de novo genetic mutations.",
      "It is part of the Canvas suite of tools developed by Illumina.",
      "Canvas SPW can handle various family structures, including small pedigrees and whole-genome matched tumor-normal.",
      "Canvas SPW offers scoring and filtering options to identify high-quality de novo variants.",
      "Canvas SPW is available for download from GitHub."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2960,
    "user_query": "List STING agonists.",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Documents 0 and 1, here are some STING agonists that have been identified:\n1. SHR1032: As mentioned in Document 1, SHR1032 is a novel STING agonist that stimulates anti-tumor immunity and directly induces apoptosis in acute myeloid leukemia (AML) cells.\n2. STING agonist 1: Document 0 mentions that cancer immunotherapy based on immune-checkpoint blockade has modified cancer treatment paradigms across many tumor types. STING agonist 1 is one of the immune-checkpoint blockade therapies that can stimulate anti-tumor immunity.\n3. STING agonist 2: Similar to STING agonist 1, STING agonist 2 is another immune-checkpoint blockade therapy that can stimulate anti-tumor immunity.\n4. Toll-like receptor (TLR) agonists: TLR agonists, such as resiquimod, can also stimulate STING pathway activation and induce anti-tumor immunity.\n5. Immune checkpoint inhibitors: Immune checkpoint inhibitors, such as anti-PD-1/anti-PD-L1 therapies, can also stimulate STING pathway activation and induce anti-tumor immunity.\nIt is important to note that these are just a few examples of STING agonists that have been identified, and there may be other STING agonists that have not been mentioned in the provided documents. Additionally, the effectiveness of these STING agonists in treating cancer is still being studied and may vary depending on the specific type of cancer and the individual patient.",
    "llama-2-7b-chat-hf_fact_raw": "1. SHR1032 is a novel STING agonist that stimulates anti-tumor immunity and induces apoptosis in acute myeloid leukemia cells.\n2. STING agonist 1 is used in cancer immunotherapy as an immune-checkpoint blockade therapy to stimulate anti-tumor immunity.\n3. STING agonist 2 is another immune-checkpoint blockade therapy that can stimulate anti-tumor immunity.\n4. Resiquimod is a Toll-like receptor agonist that can stimulate STING pathway activation and induce anti-tumor immunity.\n5. Anti-PD-1/anti-PD-L1 therapies are immune checkpoint inhibitors that can stimulate STING pathway activation and induce anti-tumor immunity.",
    "llama-2-7b-chat-hf_fact": [
      "SHR1032 is a novel STING agonist that stimulates anti-tumor immunity and induces apoptosis in acute myeloid leukemia cells.",
      "STING agonist 1 is used in cancer immunotherapy as an immune-checkpoint blockade therapy to stimulate anti-tumor immunity.",
      "STING agonist 2 is another immune-checkpoint blockade therapy that can stimulate anti-tumor immunity.",
      "Resiquimod is a Toll-like receptor agonist that can stimulate STING pathway activation and induce anti-tumor immunity.",
      "Anti-PD-1/anti-PD-L1 therapies are immune checkpoint inhibitors that can stimulate STING pathway activation and induce anti-tumor immunity."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN: Without specific scientific literature or data on SHR1032, it is not possible to confirm or refute the statement about its properties and effects on acute myeloid leukemia cells.\n2. FALSE [correction]: STING agonist 1 is used in cancer immunotherapy to stimulate anti-tumor immunity, but it is not an immune-checkpoint blockade therapy. It works by activating the STING pathway, which is distinct from checkpoint blockade mechanisms.\n3. FALSE [correction]: STING agonist 2, like STING agonist 1, would be expected to activate the STING pathway to stimulate anti-tumor immunity, but it is not an immune-checkpoint blockade therapy.\n4. TRUE: Resiquimod is known to be a Toll-like receptor agonist that can indirectly activate the STING pathway, which may lead to anti-tumor immunity.\n5. FALSE [correction]: Anti-PD-1/anti-PD-L1 therapies are indeed immune checkpoint inhibitors, but they do not directly stimulate the STING pathway. They work by blocking the PD-1/PD-L1 pathway, thereby preventing the inhibition of the immune response against tumor cells.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "false",
      "false",
      "true",
      "false"
    ]
  },
  {
    "id": 2964,
    "user_query": "Describe SLIC-CAGE",
    "llama-2-7b-chat-hf_response": "SLIC-CAGE (Sliced-View Combinatorial Activated Genome End sequencing) is a novel method for profiling the transcriptome that was developed in a study published in the journal Cold Spring Harbor Laboratory Press in 2018. The study demonstrated the ability of SLIC-CAGE to generate high-quality data for the genome-wide promoterome with a 1000-fold reduction in material compared to existing CAGE (Combinatorial Activated Genome End sequencing) methods.\nSLIC-CAGE is based on the idea of slicing the transcriptome into smaller, more manageable pieces called \"slices\" and then sequencing these slices using a combination of PCR and sequencing technologies. This approach allows for the generation of a complex, high-quality library from a relatively small amount of material, making it a powerful tool for studying the transcriptome.\nIn the study, the authors used SLIC-CAGE to generate a library from mouse embryonic day 11.5 primordial germ cells, which are cells that give rise to the reproductive cells in the body. They were able to generate a high-quality library with a 1000-fold reduction in material compared to existing CAGE methods, while also achieving a high level of accuracy and resolution in their transcriptome profiling.\nThe study also demonstrated the versatility of SLIC-CAGE by showing that it can be used to profile different aspects of the transcriptome, including strand-specific coverage of gene bodies and selective amplification of RNA 5' ends. These capabilities make SLIC-CAGE a valuable tool for a wide range of transcriptome-related applications, including gene expression analysis, RNA modification profiling, and non-coding RNA detection.",
    "llama-2-7b-chat-hf_fact_raw": "1. SLIC-CAGE was developed in a study published in the journal Cold Spring Harbor Laboratory Press in 2018.\n2. SLIC-CAGE allows for a 1000-fold reduction in material needed for genome-wide promoterome profiling compared to existing CAGE methods.\n3. The method involves slicing the transcriptome into smaller pieces and sequencing these slices using PCR and sequencing technologies.\n4. In the study, SLIC-CAGE was used to generate a library from mouse embryonic day 11.5 primordial germ cells.\n5. SLIC-CAGE can be used for various transcriptome-related applications, including gene expression analysis, RNA modification profiling, and non-coding RNA detection.",
    "llama-2-7b-chat-hf_fact": [
      "SLIC-CAGE was developed in a study published in the journal Cold Spring Harbor Laboratory Press in 2018.",
      "SLIC-CAGE allows for a 1000-fold reduction in material needed for genome-wide promoterome profiling compared to existing CAGE methods.",
      "The method involves slicing the transcriptome into smaller pieces and sequencing these slices using PCR and sequencing technologies.",
      "In the study, SLIC-CAGE was used to generate a library from mouse embryonic day 11.5 primordial germ cells.",
      "SLIC-CAGE can be used for various transcriptome-related applications, including gene expression analysis, RNA modification profiling, and non-coding RNA detection."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. TRUE\n\nThe statements about SLIC-CAGE are very specific, and without access to the actual study from Cold Spring Harbor Laboratory Press in 2018, it is not possible to verify the details provided in statements 1-4. However, statement 5 is generally true as methods like SLIC-CAGE are typically used for various transcriptome-related applications, including those listed.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 2978,
    "user_query": "What are the roles of LEM-3?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Documents 0 and 1, LEM-3 appears to play a crucial role in the following processes:\n1. Chromatin bridge resolution: LEM-3 processes chromatin bridges that arise from incomplete DNA replication, unresolved recombination intermediates, or the perturbance of chromosome structure.\n2. Meiotic recombination repair: The conserved LEM-3/Ankle1 nuclease is involved in the combinatorial regulation of meiotic recombination repair and chromosome segregation in Caenorhabditis elegans.\nIn summary, LEM-3 plays a role in both the resolution of chromatin bridges and the repair of meiotic recombination intermediates, ensuring proper chromosome segregation during cell division.",
    "llama-2-7b-chat-hf_fact_raw": "1. LEM-3 is involved in the resolution of chromatin bridges that can result from incomplete DNA replication or unresolved recombination intermediates.\n2. LEM-3 plays a role in the repair of meiotic recombination intermediates.\n3. Proper chromosome segregation during cell division is a process that LEM-3 ensures.\n4. LEM-3 is a conserved nuclease.\n5. LEM-3 functions in the combinatorial regulation of meiotic recombination repair and chromosome segregation in Caenorhabditis elegans.",
    "llama-2-7b-chat-hf_fact": [
      "LEM-3 is involved in the resolution of chromatin bridges that can result from incomplete DNA replication or unresolved recombination intermediates.",
      "LEM-3 plays a role in the repair of meiotic recombination intermediates.",
      "Proper chromosome segregation during cell division is a process that LEM-3 ensures.",
      "LEM-3 is a conserved nuclease.",
      "LEM-3 functions in the combinatorial regulation of meiotic recombination repair and chromosome segregation in Caenorhabditis elegans."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE\n\nLEM-3 is indeed involved in the resolution of chromatin bridges, which can be a consequence of incomplete DNA replication or unresolved recombination intermediates. It plays a role in the repair of meiotic recombination intermediates and is important for proper chromosome segregation during cell division. LEM-3 is a conserved nuclease, which means it is preserved across different species. Lastly, LEM-3 functions in the regulation of meiotic recombination repair and chromosome segregation specifically in the organism Caenorhabditis elegans, which is a model organism often used in genetic studies.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2992,
    "user_query": "List the releases of tmVar",
    "llama-2-7b-chat-hf_response": "Based on the information provided, here are the releases of tmVar:\n1. tmVar 2.0: According to Document 1, the Java code of tmVar 2.0 is publicly available, and it is also a part of PubTator Central, a web-based system that provides automatic annotation of biomedical concepts in PubMed and PMC articles.\n2. tmVar 3.0: Document 0 mentions that tmVar 3.0 provides advanced variant normalization options such as allele-specific identifiers from the ClinGen Allele Registry, and it exhibits state-of-the-art performance with over 90% in F-measure for variant recognition and normalization, when evaluated on three independent benchmarking datasets.\nTherefore, the two releases of tmVar are tmVar 2.0 and tmVar 3.0.",
    "llama-2-7b-chat-hf_fact_raw": "1. tmVar 2.0's Java code is publicly available.\n2. tmVar 2.0 is integrated into PubTator Central.\n3. tmVar 3.0 includes advanced variant normalization options.\n4. tmVar 3.0 uses allele-specific identifiers from the ClinGen Allele Registry.\n5. tmVar 3.0 achieved over 90% in F-measure for variant recognition and normalization on three independent benchmarking datasets.",
    "llama-2-7b-chat-hf_fact": [
      "tmVar 2.0's Java code is publicly available.",
      "tmVar 2.0 is integrated into PubTator Central.",
      "tmVar 3.0 includes advanced variant normalization options.",
      "tmVar 3.0 uses allele-specific identifiers from the ClinGen Allele Registry.",
      "tmVar 3.0 achieved over 90% in F-measure for variant recognition and normalization on three independent benchmarking datasets."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: tmVar 2.0 is an open-source tool, and its Java code is publicly available on GitHub.\n2. TRUE: tmVar 2.0 is integrated into PubTator Central, which is a web service for automated annotation of biomedical literature.\n3. UNKNOWN: Without specific information about the features of tmVar 3.0, it is not possible to confirm whether it includes advanced variant normalization options.\n4. UNKNOWN: Without specific information about the features of tmVar 3.0, it is not possible to confirm whether it uses allele-specific identifiers from the ClinGen Allele Registry.\n5. UNKNOWN: Without access to benchmarking results or a specific source confirming the performance of tmVar 3.0, it is not possible to verify the accuracy of the statement regarding its F-measure for variant recognition and normalization.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3018,
    "user_query": "Which is the database of somatic mutations in normal cells?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, the database of somatic mutations in normal cells is likely to be \"DSMNC\" (Document 0). According to the documents, DSMNC serves as a collection of somatic mutations in individual normal cells, allowing for the analysis of the burdens and signatures of somatic mutations in various types of heterogeneous normal cells. Therefore, it is the most likely candidate for the database of somatic mutations in normal cells.",
    "llama-2-7b-chat-hf_fact_raw": "1. DSMNC stands for the database of somatic mutations in normal cells.\n2. DSMNC is a collection of somatic mutations found in individual normal cells.\n3. The database allows for the analysis of burdens and signatures of somatic mutations.\n4. DSMNC includes data on various types of heterogeneous normal cells.",
    "llama-2-7b-chat-hf_fact": [
      "DSMNC stands for the database of somatic mutations in normal cells.",
      "DSMNC is a collection of somatic mutations found in individual normal cells.",
      "The database allows for the analysis of burdens and signatures of somatic mutations.",
      "DSMNC includes data on various types of heterogeneous normal cells."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3037,
    "user_query": "Are there graph kernel libraries available implemented in JAVA?",
    "llama-2-7b-chat-hf_response": "Yes, there are several graph kernel libraries available implemented in Java. Here are a few examples:\n1. GraphKernel: This is a Java library for computing graph kernels using various methods, including spectral, spectral-based, and machine learning-based approaches. It provides a simple API for computing graph kernels and can be used in combination with other Java libraries for graph processing, such as igraph and NetworkX.\n2. GraphKernels: This is a Java library for computing graph kernels using the eigendecomposition of the graph Laplacian matrix. It provides a simple API for computing graph kernels and can be used in combination with other Java libraries for graph processing, such as igraph and NetworkX.\n3. JGraphKernel: This is a Java library for computing graph kernels using the eigendecomposition of the graph Laplacian matrix. It provides a simple API for computing graph kernels and can be used in combination with other Java libraries for graph processing, such as igraph and NetworkX.\n4. GraphKernelMatrix: This is a Java library for computing graph kernels using the matrix factorization method. It provides a simple API for computing graph kernels and can be used in combination with other Java libraries for graph processing, such as igraph and NetworkX.\nAll of these libraries are available on GitHub and can be easily integrated into Java programs using the Maven or Gradle build tools.\nIn terms of citing the work on graph kernels, the paper \"Graph Kernels: A Survey\" by T. Schaub, et al. provides a comprehensive overview of the state-of-the-art in graph kernel computation and can be used as a reference for citing the work on graph kernels in Java.\nI hope this helps! Let me know if you have any further questions.",
    "llama-2-7b-chat-hf_fact_raw": "1. GraphKernel is a Java library for computing graph kernels using various methods.\n2. GraphKernels is a Java library that computes graph kernels using the eigendecomposition of the graph Laplacian matrix.\n3. JGraphKernel is a Java library for computing graph kernels, also using the eigendecomposition of the graph Laplacian matrix.\n4. GraphKernelMatrix is a Java library for computing graph kernels using the matrix factorization method.\n5. The paper \"Graph Kernels: A Survey\" by T. Schaub, et al. provides a comprehensive overview of graph kernel computation.",
    "llama-2-7b-chat-hf_fact": [
      "GraphKernel is a Java library for computing graph kernels using various methods.",
      "GraphKernels is a Java library that computes graph kernels using the eigendecomposition of the graph Laplacian matrix.",
      "JGraphKernel is a Java library for computing graph kernels, also using the eigendecomposition of the graph Laplacian matrix.",
      "GraphKernelMatrix is a Java library for computing graph kernels using the matrix factorization method.",
      "The paper \"Graph Kernels: A Survey\" by T. Schaub, et al. provides a comprehensive overview of graph kernel computation."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nWithout specific information about the libraries mentioned (GraphKernel, GraphKernels, JGraphKernel, GraphKernelMatrix) and the paper \"Graph Kernels: A Survey\" by T. Schaub, et al., it is not possible to determine the truthfulness of these statements. The names of the libraries suggest they are related to graph kernels, but without additional context or documentation, the details of their implementation and methods cannot be confirmed. Similarly, without access to the paper by T. Schaub, et al., the content and comprehensiveness of the overview cannot be verified.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3045,
    "user_query": "List the four advances integrated into the SHERLOCKv2 platform.",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Documents 0 and 1, the four advances integrated into the SHERLOCKv2 platform are:\n1. 4-channel single reaction multiplexing using orthogonal CRISPR enzymes: This allows for the detection of four different nucleic acid targets in a single reaction, using different CRISPR enzymes that do not interfere with each other.\n2. Quantitative measurement of input down to 2 aM: This feature enables the detection of very low concentrations of nucleic acids, making the SHERLOCKv2 platform highly sensitive.\n3. 3.5-fold increase in signal sensitivity by combining Cas13 with Csm6, an auxilary CRISPR enzyme: This combination results in a significantly stronger signal for the detection of nucleic acids, making the platform more sensitive overall.\nI hope this helps! Let me know if you have any further questions.",
    "llama-2-7b-chat-hf_fact_raw": "1. The SHERLOCKv2 platform integrates 4-channel single reaction multiplexing using orthogonal CRISPR enzymes.\n2. The SHERLOCKv2 platform can quantitatively measure nucleic acid concentrations as low as 2 attomolar (aM).\n3. The SHERLOCKv2 platform has a 3.5-fold increase in signal sensitivity by combining Cas13 with Csm6.\n4. The combination of Cas13 with Csm6 is used to enhance the detection of nucleic acids in the SHERLOCKv2 platform.",
    "llama-2-7b-chat-hf_fact": [
      "The SHERLOCKv2 platform integrates 4-channel single reaction multiplexing using orthogonal CRISPR enzymes.",
      "The SHERLOCKv2 platform can quantitatively measure nucleic acid concentrations as low as 2 attomolar (aM).",
      "The SHERLOCKv2 platform has a 3.5-fold increase in signal sensitivity by combining Cas13 with Csm6.",
      "The combination of Cas13 with Csm6 is used to enhance the detection of nucleic acids in the SHERLOCKv2 platform."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n\nThe SHERLOCK (Specific High-sensitivity Enzymatic Reporter unLOCKing) technology is a CRISPR-based diagnostic tool that can be used to detect specific sequences of RNA or DNA. The statements provided are consistent with the capabilities and enhancements made in the SHERLOCKv2 platform, which include multiplexing with orthogonal CRISPR enzymes, attomolar sensitivity, and increased signal sensitivity through the combination of Cas13 with Csm6. However, without access to the specific scientific literature or publication that these statements are derived from, I cannot independently verify the accuracy of the technical details provided. These responses are based on general knowledge of the SHERLOCK technology as of my knowledge cutoff date.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3078,
    "user_query": "Describe the bartender algorithm",
    "llama-2-7b-chat-hf_response": "The Bartender algorithm is a clustering algorithm specifically designed for counting high-complexity deeply sequenced barcode reads. According to Document 0, Bartender is the most accurate clustering algorithm in this regard, with a comparable speed to other existing algorithms. The algorithm's accuracy is due to a new statistical test schema that takes into account both the nucleotide sequence and the size of the clusters to prevent over-clustering and improve accuracy.\nBartender uses a fast and efficient clustering method to group barcode reads into distinct clusters based on their similarity. The algorithm is able to handle high-complexity data sets with a large number of barcode reads, making it a useful tool for researchers in the field of genomics and sequencing.\nThe Bartender algorithm was first introduced in Document 1, which provides a detailed description of the algorithm and its performance. The authors of the paper demonstrate the effectiveness of Bartender through experiments on real-world data sets, showing that it is able to accurately cluster barcode reads with a high degree of precision.\nOverall, the Bartender algorithm is a valuable tool for researchers working with deeply sequenced barcode reads, as it is able to accurately and efficiently cluster these data sets. Its ability to handle high-complexity data makes it a particularly useful tool for large-scale sequencing projects.",
    "llama-2-7b-chat-hf_fact_raw": "1. The Bartender algorithm is designed for counting high-complexity deeply sequenced barcode reads.\n2. Bartender is considered the most accurate clustering algorithm for its specific purpose, according to Document 0.\n3. The Bartender algorithm uses a new statistical test schema to improve accuracy and prevent over-clustering.\n4. The algorithm can handle large numbers of barcode reads, making it suitable for genomics and sequencing research.\n5. The Bartender algorithm was introduced in Document 1, which details its performance and effectiveness.",
    "llama-2-7b-chat-hf_fact": [
      "The Bartender algorithm is designed for counting high-complexity deeply sequenced barcode reads.",
      "Bartender is considered the most accurate clustering algorithm for its specific purpose, according to Document 0.",
      "The Bartender algorithm uses a new statistical test schema to improve accuracy and prevent over-clustering.",
      "The algorithm can handle large numbers of barcode reads, making it suitable for genomics and sequencing research.",
      "The Bartender algorithm was introduced in Document 1, which details its performance and effectiveness."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. UNKNOWN (The accuracy of the Bartender algorithm compared to others is not verifiable without access to \"Document 0\".)\n3. UNKNOWN (Without specific information on the Bartender algorithm's methodology, it's unclear whether it uses a new statistical test schema.)\n4. TRUE (The Bartender algorithm is indeed designed to handle large numbers of barcode reads, which is suitable for genomics and sequencing research.)\n5. UNKNOWN (Without access to \"Document 1\", it's not possible to verify when and where the Bartender algorithm was introduced or the details of its performance and effectiveness.)",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "unknown",
      "true",
      "unknown"
    ]
  },
  {
    "id": 3100,
    "user_query": "Which web-based pedigree editors are available?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, there are several web-based pedigree editors available. One of the most notable ones is Pedigreejs, which is an easily configurable, extensible, and lightweight pedigree editor that makes use of an open-source Javascript library to define a hierarchical layout and produce images in scalable vector graphics (SVG) format that can be viewed and edited in web browsers.\nAccording to Document 1, there are no freely available lightweight graphical pedigree editors that can be easily configured and incorporated into web applications. However, Pedigreejs seems to be an exception to this rule, as it is designed to be easily configurable and can be incorporated into web applications with ease.\nTherefore, based on the information provided, the answer to the user's question is: Pedigreejs is the only web-based pedigree editor that is available and can be easily configured and incorporated into web applications.",
    "llama-2-7b-chat-hf_fact_raw": "1. Pedigreejs is a web-based pedigree editor.\n2. Pedigreejs uses an open-source Javascript library.\n3. Pedigreejs produces images in scalable vector graphics (SVG) format.\n4. Pedigreejs can be viewed and edited in web browsers.\n5. Pedigreejs is designed to be easily configurable and can be incorporated into web applications.",
    "llama-2-7b-chat-hf_fact": [
      "Pedigreejs is a web-based pedigree editor.",
      "Pedigreejs uses an open-source Javascript library.",
      "Pedigreejs produces images in scalable vector graphics (SVG) format.",
      "Pedigreejs can be viewed and edited in web browsers.",
      "Pedigreejs is designed to be easily configurable and can be incorporated into web applications."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3107,
    "user_query": "Which curated databases exist for spider-venom toxins?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, there are two curated databases available for spider-venom toxins:\n1. ArachnoServer (www.arachnoserver.org): This is a manually curated database that provides detailed information about proteinaceous toxins from spiders. Key features of ArachnoServer include a new molecular target ontology designed especially for venom toxins, the most up-to-date taxonomic information available, and a powerful advanced search interface.\n2. [Your internal knowledge or additional research, if necessary]: Based on my internal knowledge and additional research, I can suggest that there may be other curated databases available for spider-venom toxins. Some examples include:\n* SpiderVenomDB (spidervenomdb.org): This is a comprehensive database of spider venom peptides and proteins, including their sequences, structures, and biological activities.\n* VenomDB (venomdb.org): This is a database of venom peptides and proteins from various sources, including spiders, snakes, and scorpions. It provides information on the sequences, structures, and functions of these toxins.\n* ToxinDB (toxindb.org): This is a database of toxins from various sources, including spiders, snakes, and scorpions. It provides information on the sequences, structures, and biological activities of these toxins.\nIt's important to note that these databases may not be exhaustive, and there may be other resources available that are not listed here.",
    "llama-2-7b-chat-hf_fact_raw": "1. ArachnoServer is a manually curated database that provides information about proteinaceous toxins from spiders.\n2. ArachnoServer includes a molecular target ontology designed for venom toxins.\n3. ArachnoServer contains the most up-to-date taxonomic information available.\n4. SpiderVenomDB is a comprehensive database of spider venom peptides and proteins.\n5. VenomDB is a database that includes venom peptides and proteins from various sources, such as spiders, snakes, and scorpions.",
    "llama-2-7b-chat-hf_fact": [
      "ArachnoServer is a manually curated database that provides information about proteinaceous toxins from spiders.",
      "ArachnoServer includes a molecular target ontology designed for venom toxins.",
      "ArachnoServer contains the most up-to-date taxonomic information available.",
      "SpiderVenomDB is a comprehensive database of spider venom peptides and proteins.",
      "VenomDB is a database that includes venom peptides and proteins from various sources, such as spiders, snakes, and scorpions."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. UNKNOWN\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "unknown",
      "true",
      "true"
    ]
  },
  {
    "id": 3111,
    "user_query": "Does Axitinib prolong survival of Pancreatic Cancer patients?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, there is limited evidence to suggest that Axitinib prolongs survival in patients with pancreatic cancer, specifically pancreatic ductal adenocarcinoma (PDAC).\nDocument 0 suggests that surgical resection of the primary tumor and systemic chemotherapy provide considerably longer overall survival for patients with localized PDAC. However, the majority of patients will eventually relapse, with a 5-year survival rate of only 2%-9%.\nDocument 1 highlights the poor prognosis of pancreatic cancer, with a 5-year survival rate of only 2%-9% for patients who relapse after initial treatment. There is limited evidence to suggest that Axitinib, a tyrosine kinase inhibitor, improves survival outcomes in patients with pancreatic cancer.\nWhile there are some risk factors for pancreatic cancer, including family history, pancreatitis, and diabetes, there is no conclusive evidence to suggest that these factors significantly impact survival outcomes.\nIn summary, while surgical resection and chemotherapy may improve survival outcomes for patients with localized PDAC, the prognosis for patients with advanced or relapsed pancreatic cancer remains poor. Further research is needed to identify effective treatment strategies for this aggressive disease.",
    "llama-2-7b-chat-hf_fact_raw": "1. Axitinib is a tyrosine kinase inhibitor.\n2. Surgical resection of the primary tumor and systemic chemotherapy can provide longer overall survival for patients with localized pancreatic ductal adenocarcinoma (PDAC).\n3. The majority of patients with localized PDAC will eventually relapse.\n4. The 5-year survival rate for patients with PDAC who relapse after initial treatment is only 2%-9%.\n5. There is limited evidence to suggest that Axitinib improves survival outcomes in patients with pancreatic cancer.",
    "llama-2-7b-chat-hf_fact": [
      "Axitinib is a tyrosine kinase inhibitor.",
      "Surgical resection of the primary tumor and systemic chemotherapy can provide longer overall survival for patients with localized pancreatic ductal adenocarcinoma (PDAC).",
      "The majority of patients with localized PDAC will eventually relapse.",
      "The 5-year survival rate for patients with PDAC who relapse after initial treatment is only 2%-9%.",
      "There is limited evidence to suggest that Axitinib improves survival outcomes in patients with pancreatic cancer."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 3113,
    "user_query": "Through which protein interaction does MLP regulate F-actin dynamics?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, MLP regulates F-actin dynamics through protein interaction with the actin-binding protein, actin-binding protein 1 (ABP-1). Document 0 mentions that actin-binding proteins play a crucial role in regulating force production in cells, and Document 1 highlights the importance of protein homeostasis in regulating mRNA transcription, degradation, and localization, which can affect the availability of mRNA and the potential rate of protein synthesis. Since MLP is a protein that interacts with actin filaments, it is likely that it regulates F-actin dynamics through its interaction with ABP-1 or other actin-binding proteins.",
    "llama-2-7b-chat-hf_fact_raw": "1. MLP regulates F-actin dynamics through interaction with the actin-binding protein, actin-binding protein 1 (ABP-1).\n2. Actin-binding proteins are crucial in regulating force production in cells.\n3. Protein homeostasis is important in regulating mRNA transcription, degradation, and localization.\n4. The availability of mRNA and the potential rate of protein synthesis can be affected by protein homeostasis.\n5. MLP is a protein that interacts with actin filaments.",
    "llama-2-7b-chat-hf_fact": [
      "MLP regulates F-actin dynamics through interaction with the actin-binding protein, actin-binding protein 1 (ABP-1).",
      "Actin-binding proteins are crucial in regulating force production in cells.",
      "Protein homeostasis is important in regulating mRNA transcription, degradation, and localization.",
      "The availability of mRNA and the potential rate of protein synthesis can be affected by protein homeostasis.",
      "MLP is a protein that interacts with actin filaments."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. TRUE\n3. FALSE [correction]: Protein homeostasis is important in regulating protein folding, repair, degradation, and synthesis, not directly regulating mRNA transcription, degradation, and localization.\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "true",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 3125,
    "user_query": "How many pseudokinases are there in the human kinome?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Documents 0 and 1, there are approximately 518 protein kinases in the human kinome. Of these, 478 contain a eukaryotic protein kinase (ePK) domain, while the remaining 40 lack sequence similarity to the ePK domain. Therefore, there are 478 pseudokinases in the human kinome.",
    "llama-2-7b-chat-hf_fact_raw": "1. There are approximately 518 protein kinases in the human kinome.\n2. Of the 518 protein kinases, 478 contain a eukaryotic protein kinase (ePK) domain.\n3. There are 40 protein kinases in the human kinome that lack sequence similarity to the ePK domain.\n4. There are 478 pseudokinases in the human kinome.",
    "llama-2-7b-chat-hf_fact": [
      "There are approximately 518 protein kinases in the human kinome.",
      "Of the 518 protein kinases, 478 contain a eukaryotic protein kinase (ePK) domain.",
      "There are 40 protein kinases in the human kinome that lack sequence similarity to the ePK domain.",
      "There are 478 pseudokinases in the human kinome."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: There are not 478 pseudokinases in the human kinome; pseudokinases are a subset of protein kinases that lack some of the conserved residues required for catalytic activity, but the number 478 refers to those with a eukaryotic protein kinase (ePK) domain, not pseudokinases. The exact number of pseudokinases in the human kinome is not specified in the statements provided.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 3139,
    "user_query": "List 3 apoE mimetics.",
    "llama-2-7b-chat-hf_response": "Based on the information provided, here are three apoE mimetics:\n1. ApoE mimetic based on apolipoprotein A-I (apoA-I): ApoA-I is one of the most well-studied apolipoproteins, and its mimetic has been developed as a potential therapeutic agent for various diseases, including atherosclerosis and Alzheimer's disease.\n2. ApoE mimetic based on apolipoprotein C-II (apoC-II): ApoC-II is another important apolipoprotein that has been studied extensively, and its mimetic has been shown to have potential in the treatment of dyslipidemia and other metabolic disorders.\n3. ApoE mimetic based on apolipoprotein E (apoE): ApoE is the most well-studied apolipoprotein, and its mimetic has been developed as a potential therapeutic agent for various diseases, including atherosclerosis, Alzheimer's disease, and cancer.\nIt is important to note that the development and use of apoE mimetics are still in the early stages, and more research is needed to fully understand their potential therapeutic applications and safety profiles.",
    "llama-2-7b-chat-hf_fact_raw": "1. An apoE mimetic has been developed based on apolipoprotein A-I (apoA-I) for potential therapeutic use in diseases like atherosclerosis and Alzheimer's disease.\n2. An apoE mimetic based on apolipoprotein C-II (apoC-II) has been shown to have potential in the treatment of dyslipidemia and other metabolic disorders.\n3. An apoE mimetic based on apolipoprotein E (apoE) has been developed for potential therapeutic use in diseases such as atherosclerosis, Alzheimer's disease, and cancer.",
    "llama-2-7b-chat-hf_fact": [
      "An apoE mimetic has been developed based on apolipoprotein A-I (apoA-I) for potential therapeutic use in diseases like atherosclerosis and Alzheimer's disease.",
      "An apoE mimetic based on apolipoprotein C-II (apoC-II) has been shown to have potential in the treatment of dyslipidemia and other metabolic disorders.",
      "An apoE mimetic based on apolipoprotein E (apoE) has been developed for potential therapeutic use in diseases such as atherosclerosis, Alzheimer's disease, and cancer."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: An apoE mimetic has been developed based on apolipoprotein E (apoE), not apolipoprotein A-I (apoA-I), for potential therapeutic use in diseases like atherosclerosis and Alzheimer's disease.\n2. UNKNOWN\n3. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "true"
    ]
  },
  {
    "id": 3140,
    "user_query": "What are there sex differences in SAMHD1 activity?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Documents 0 and 1, there are sex differences in the activity of the enzyme SAMHD1 in primary macrophages. Specifically, the study found that SAMHD1 exhibits increased activity in macrophages from female donors compared to male donors, which correlates with the lower infectivity of HIV-1 in female-derived macrophages. Additionally, the study found that depleting SAMHD1 in macrophages abrogated the sex-dependent differences in viral restriction, suggesting that SAMHD1 is an essential modulator of infectivity in a sex-dependent manner in macrophages. These findings suggest that there are sex differences in the activity of SAMHD1 in primary macrophages, with higher activity in female macrophages, which may play a role in the lower infectivity of HIV-1 in female-derived macrophages.",
    "llama-2-7b-chat-hf_fact_raw": "1. There are sex differences in the activity of the enzyme SAMHD1 in primary macrophages.\n2. SAMHD1 exhibits increased activity in macrophages from female donors compared to male donors.\n3. The increased activity of SAMHD1 in female macrophages correlates with the lower infectivity of HIV-1 in female-derived macrophages.\n4. Depleting SAMHD1 in macrophages removes the sex-dependent differences in viral restriction.\n5. SAMHD1 is an essential modulator of infectivity in a sex-dependent manner in macrophages.",
    "llama-2-7b-chat-hf_fact": [
      "There are sex differences in the activity of the enzyme SAMHD1 in primary macrophages.",
      "SAMHD1 exhibits increased activity in macrophages from female donors compared to male donors.",
      "The increased activity of SAMHD1 in female macrophages correlates with the lower infectivity of HIV-1 in female-derived macrophages.",
      "Depleting SAMHD1 in macrophages removes the sex-dependent differences in viral restriction.",
      "SAMHD1 is an essential modulator of infectivity in a sex-dependent manner in macrophages."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE\n\nPlease note that the responses are based on the assumption that the statements are derived from a passage containing these specific findings. In scientific contexts, such statements would typically be supported by experimental or observational data. If the passage in question is based on a study that found these results, then the responses are accurate. However, without the specific context or access to the latest research, it is not possible to independently verify these statements.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3205,
    "user_query": "Does RUNX2 inhibit astrocyte differentiation?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Documents 0 and 1, it appears that RUNX2 does not inhibit astrocyte differentiation, but rather promotes astrocyte maturation.\nDocument 0 suggests that NFIA and ATF3 are drivers of astrocyte differentiation from neural precursor cells, while RUNX2 promotes astrocyte maturation. This suggests that RUNX2 plays a role in the maturation of astrocytes, rather than inhibiting their differentiation.\nDocument 1 also supports this conclusion, as it states that RUNX2 is a master transcription factor of osteoblast differentiation, and that its expression in the bone and osteogenic front of a suture is important for bone development. This suggests that RUNX2 is involved in the regulation of cellular differentiation, but does not appear to inhibit astrocyte differentiation.\nTherefore, based on the information provided, it can be concluded that RUNX2 does not inhibit astrocyte differentiation, but rather promotes astrocyte maturation.",
    "llama-2-7b-chat-hf_fact_raw": "1. RUNX2 promotes astrocyte maturation.\n2. NFIA and ATF3 are drivers of astrocyte differentiation from neural precursor cells.\n3. RUNX2 is a master transcription factor of osteoblast differentiation.\n4. RUNX2's expression is important for bone development.\n5. RUNX2 is involved in the regulation of cellular differentiation.",
    "llama-2-7b-chat-hf_fact": [
      "RUNX2 promotes astrocyte maturation.",
      "NFIA and ATF3 are drivers of astrocyte differentiation from neural precursor cells.",
      "RUNX2 is a master transcription factor of osteoblast differentiation.",
      "RUNX2's expression is important for bone development.",
      "RUNX2 is involved in the regulation of cellular differentiation."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: RUNX2 is not known to promote astrocyte maturation; it is a master transcription factor for osteoblast differentiation.\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3209,
    "user_query": "Where, in the body, would the Cobb-Stainsby excision arthroplasty be performed?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, the Cobb-Stainsby excision arthroplasty would typically be performed in the foot, specifically in the metatarsal region. The procedure combines partial phalangectomy (Stainsby) with extensor tendon transfer to the metatarsal head (Cobb), which is located in the forefoot. The metatarsal head is the bony prominence at the base of the toes, and the procedure is designed to address dislocated metatarsophalangeal joints that can occur due to conditions such as clawed or hammer toes. Therefore, the Cobb-Stainsby excision arthroplasty is typically performed in the foot, specifically in the metatarsal region, to address these types of joint dislocations.",
    "llama-2-7b-chat-hf_fact_raw": "1. The Cobb-Stainsby excision arthroplasty is performed in the foot.\n2. The procedure specifically targets the metatarsal region of the foot.\n3. The Cobb-Stainsby excision arthroplasty combines partial phalangectomy with extensor tendon transfer to the metatarsal head.\n4. The metatarsal head is located in the forefoot.\n5. The procedure is designed to address dislocated metatarsophalangeal joints due to conditions such as clawed or hammer toes.",
    "llama-2-7b-chat-hf_fact": [
      "The Cobb-Stainsby excision arthroplasty is performed in the foot.",
      "The procedure specifically targets the metatarsal region of the foot.",
      "The Cobb-Stainsby excision arthroplasty combines partial phalangectomy with extensor tendon transfer to the metatarsal head.",
      "The metatarsal head is located in the forefoot.",
      "The procedure is designed to address dislocated metatarsophalangeal joints due to conditions such as clawed or hammer toes."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The Cobb-Stainsby excision arthroplasty is performed in the toe, not the foot in general.\n2. FALSE [correction]: The procedure specifically targets the proximal phalanx of the toe, not the metatarsal region of the foot.\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3243,
    "user_query": "Does GRHL2 over-expression lead to EMT?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, it is likely that GRHL2 over-expression leads to EMT (epithelial-to-mesenchymal transition).\nThe introduction of Document 1 states that GRHL2 suppresses EMT, which is required for the migration and invasion of carcinoma. This suggests that GRHL2 plays a role in preventing the loss of epithelial characteristics and the acquisition of mesenchymal properties, which are hallmarks of EMT.\nFurthermore, Document 0 suggests that GRHL2 is involved in the epigenetic control of epithelial genes during the intermediate phases of EMT/MET (metastasis). This implies that GRHL2 plays a role in regulating the expression of genes that are important for the maintenance of epithelial identity, and that its over-expression may lead to the loss of these genes and the acquisition of mesenchymal characteristics.\nTherefore, based on the information provided, it is likely that GRHL2 over-expression leads to EMT.",
    "llama-2-7b-chat-hf_fact_raw": "1. GRHL2 suppresses epithelial-to-mesenchymal transition (EMT), which is involved in the migration and invasion of carcinoma.\n2. GRHL2 is involved in the epigenetic control of epithelial genes during the intermediate phases of EMT/MET (metastasis).\n3. Over-expression of GRHL2 may lead to the loss of epithelial genes and the acquisition of mesenchymal characteristics.",
    "llama-2-7b-chat-hf_fact": [
      "GRHL2 suppresses epithelial-to-mesenchymal transition (EMT), which is involved in the migration and invasion of carcinoma.",
      "GRHL2 is involved in the epigenetic control of epithelial genes during the intermediate phases of EMT/MET (metastasis).",
      "Over-expression of GRHL2 may lead to the loss of epithelial genes and the acquisition of mesenchymal characteristics."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: Over-expression of GRHL2 is typically associated with the maintenance of epithelial characteristics and the suppression of mesenchymal gene expression, not the loss of epithelial genes and acquisition of mesenchymal characteristics.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 3254,
    "user_query": "Which T-UCRs have been implicated in lung cancer?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Documents 0 and 1, it appears that uc.339 has been implicated as an oncogene in lung cancer. The authors of Document 0 identify uc.339 as an oncogene in lung cancer, suggesting that it may play a role in the development and progression of the disease. Additionally, the fact that TUCRs are transcribed from 100% conserved DNA in human, mouse, and rat genomes suggests that they may be important in the regulation of gene expression and could potentially be involved in cancer development. However, further research is needed to fully understand the role of TUCRs in lung cancer and other diseases.",
    "llama-2-7b-chat-hf_fact_raw": "1. uc.339 has been implicated as an oncogene in lung cancer.\n2. T-UCRs are transcribed from 100% conserved DNA in human, mouse, and rat genomes.\n3. The role of T-UCRs in lung cancer requires further research for full understanding.",
    "llama-2-7b-chat-hf_fact": [
      "uc.339 has been implicated as an oncogene in lung cancer.",
      "T-UCRs are transcribed from 100% conserved DNA in human, mouse, and rat genomes.",
      "The role of T-UCRs in lung cancer requires further research for full understanding."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. FALSE [correction]: T-UCRs are transcribed from ultra-conserved regions of DNA that are 100% conserved among humans, mice, and rats, but not all T-UCRs are transcribed from regions that are 100% conserved across these species.\n3. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "false",
      "true"
    ]
  },
  {
    "id": 3268,
    "user_query": "What is known about the orphan receptor GPR151?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, here is what is known about the orphan receptor GPR151:\n1. GPR151 is an inhibitory G protein-coupled receptor that is enriched in the habenula, a small brain region involved in aversion and emotion regulation.\n2. GPR151 is an orphan receptor, meaning that it does not have a well-defined endogenous ligand or a clear physiological function.\n3. Recently, a rare, putative loss-of-function mutation in GPR151 was found to be associated with lower odds ratio for type 2 diabetes.\n4. GPR151 is also known as GPR151, HA107, and HA108.\n5. The functional role of GPR151 is not fully understood, but it is thought to play a role in the regulation of appetite and metabolism.\n6. GPR151 is expressed in various tissues, including the brain, pancreas, and adipose tissue.\n7. GPR151 has been implicated in the development and progression of certain diseases, including type 2 diabetes and obesity.\n8. GPR151 has been shown to interact with other receptors, including the mu opioid receptor (MOR), and may play a role in the regulation of opioid-mediated effects.\nOverall, while the functional role of GPR151 is not fully understood, it is clear that it plays a complex and multifaceted role in the regulation of various physiological processes, including appetite, metabolism, and emotion regulation. Further research is needed to fully elucidate the mechanisms of GPR151 and its potential as a therapeutic target for various diseases.",
    "llama-2-7b-chat-hf_fact_raw": "1. GPR151 is an inhibitory G protein-coupled receptor enriched in the habenula.\n2. GPR151 is considered an orphan receptor, which means its endogenous ligand or physiological function is not well-defined.\n3. A rare mutation in GPR151 has been associated with lower odds of developing type 2 diabetes.\n4. GPR151 is expressed in various tissues, including the brain, pancreas, and adipose tissue.\n5. GPR151 has been implicated in the development and progression of diseases such as type 2 diabetes and obesity.",
    "llama-2-7b-chat-hf_fact": [
      "GPR151 is an inhibitory G protein-coupled receptor enriched in the habenula.",
      "GPR151 is considered an orphan receptor, which means its endogenous ligand or physiological function is not well-defined.",
      "A rare mutation in GPR151 has been associated with lower odds of developing type 2 diabetes.",
      "GPR151 is expressed in various tissues, including the brain, pancreas, and adipose tissue.",
      "GPR151 has been implicated in the development and progression of diseases such as type 2 diabetes and obesity."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. UNKNOWN\n4. TRUE\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "unknown",
      "true",
      "unknown"
    ]
  },
  {
    "id": 3285,
    "user_query": "List the attenuated live viruses contained in the Fluzone intradermal quadrivalent vaccine.",
    "llama-2-7b-chat-hf_response": "Based on the information provided, the attenuated live viruses contained in the Fluzone intradermal quadrivalent vaccine are:\n* Influenza A subtype viruses\n* Type B viruses\nAccording to Document 0, the vaccine is indicated for active immunization for the prevention of influenza disease caused by these viruses. Document 1 provides additional information on the mechanism of intradermal vaccination and the clinical trial results supporting the immunogenicity and safety of Fluzone Intradermal Quadrivalent vaccine, including the unique microinjection system used to deliver the vaccine.",
    "llama-2-7b-chat-hf_fact_raw": "1. The Fluzone intradermal quadrivalent vaccine contains attenuated live influenza A subtype viruses.\n2. The Fluzone intradermal quadrivalent vaccine contains attenuated live type B viruses.\n3. The vaccine is indicated for active immunization for the prevention of influenza disease.\n4. Clinical trial results support the immunogenicity and safety of the Fluzone Intradermal Quadrivalent vaccine.\n5. The Fluzone Intradermal Quadrivalent vaccine uses a unique microinjection system for delivery.",
    "llama-2-7b-chat-hf_fact": [
      "The Fluzone intradermal quadrivalent vaccine contains attenuated live influenza A subtype viruses.",
      "The Fluzone intradermal quadrivalent vaccine contains attenuated live type B viruses.",
      "The vaccine is indicated for active immunization for the prevention of influenza disease.",
      "Clinical trial results support the immunogenicity and safety of the Fluzone Intradermal Quadrivalent vaccine.",
      "The Fluzone Intradermal Quadrivalent vaccine uses a unique microinjection system for delivery."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The Fluzone intradermal quadrivalent vaccine contains inactivated (killed) influenza viruses, not attenuated live viruses.\n2. FALSE [correction]: The Fluzone intradermal quadrivalent vaccine contains inactivated (killed) type B viruses, not attenuated live viruses.\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3345,
    "user_query": "Which part of the TNFR2 gene is genetically associated with Systemic Lupus Erythematosus?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Document 1, the TNFR2 gene is genetically associated with Systemic Lupus Erythematosus (SLE). Specifically, the TNFR2 rs1061624 polymorphism is associated with SLE in the Chinese population, with a higher risk of developing SLE in males.",
    "llama-2-7b-chat-hf_fact_raw": "1. The TNFR2 gene is genetically associated with Systemic Lupus Erythematosus (SLE).\n2. The TNFR2 rs1061624 polymorphism is associated with SLE in the Chinese population.\n3. There is a higher risk of developing SLE in males with the TNFR2 rs1061624 polymorphism.",
    "llama-2-7b-chat-hf_fact": [
      "The TNFR2 gene is genetically associated with Systemic Lupus Erythematosus (SLE).",
      "The TNFR2 rs1061624 polymorphism is associated with SLE in the Chinese population.",
      "There is a higher risk of developing SLE in males with the TNFR2 rs1061624 polymorphism."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: The TNFR2 gene has been reported to be genetically associated with Systemic Lupus Erythematosus (SLE) in various studies.\n2. TRUE: The TNFR2 rs1061624 polymorphism has been found to be associated with SLE in some studies, including those conducted on the Chinese population.\n3. UNKNOWN: The risk of developing SLE associated with the TNFR2 rs1061624 polymorphism may vary by sex, but without specific data or studies referenced, it is difficult to determine the accuracy of this statement. Generally, SLE is more common in females, but the statement's claim about males and the specific polymorphism requires more context to verify.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 3353,
    "user_query": "Is there a vaccine for peanut allergy?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, there is currently no vaccine available for peanut allergy. However, there are ongoing research and development of new treatments, including antibody treatments, that show promise in providing a safe and effective way to manage peanut allergy.\nThe pilot study mentioned in Document 0 suggests that one injection of an antibody treatment may allow individuals with severe peanut allergies to safely consume a small amount of peanut protein two weeks later. While this is encouraging, it is important to note that this is still an early-stage study and more research is needed to confirm the safety and efficacy of this treatment.\nAdditionally, Document 1 mentions allergen immunotherapy as a form of therapeutic vaccination for established IgE-mediated hypersensitivity to common allergen sources. While this may not specifically address peanut allergy, it suggests that there are other approaches being explored for the treatment of food allergies.\nIn summary, while there is currently no vaccine available for peanut allergy, ongoing research and development of new treatments offer hope for individuals with this condition. It is important to consult with a healthcare professional for the latest information and to discuss the best course of treatment for your specific situation.",
    "llama-2-7b-chat-hf_fact_raw": "1. There is currently no vaccine available for peanut allergy.\n2. Ongoing research and development are focused on new treatments for peanut allergy, including antibody treatments.\n3. A pilot study indicated that an injection of an antibody treatment might allow individuals with severe peanut allergies to consume a small amount of peanut protein two weeks later.\n4. Allergen immunotherapy is a form of therapeutic vaccination for established IgE-mediated hypersensitivity to common allergen sources.\n5. The safety and efficacy of the new antibody treatment for peanut allergy are still being researched and have not been confirmed.",
    "llama-2-7b-chat-hf_fact": [
      "There is currently no vaccine available for peanut allergy.",
      "Ongoing research and development are focused on new treatments for peanut allergy, including antibody treatments.",
      "A pilot study indicated that an injection of an antibody treatment might allow individuals with severe peanut allergies to consume a small amount of peanut protein two weeks later.",
      "Allergen immunotherapy is a form of therapeutic vaccination for established IgE-mediated hypersensitivity to common allergen sources.",
      "The safety and efficacy of the new antibody treatment for peanut allergy are still being researched and have not been confirmed."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: As of my knowledge cutoff in 2023, a vaccine called Palforzia has been approved by the FDA for the treatment of peanut allergy in children.\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3365,
    "user_query": "What is particular about the mouse Fxy gene's chromosomal position?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Documents 0 and 1, the Fxy gene in mice is particular about its chromosomal position in the following ways:\n1. The 5' end of the Fxy gene is X-unique in C57BL/6 mice, meaning that it is located only on the X chromosome.\n2. The 3' end of the Fxy gene is present on both the X and Y chromosomes in C57BL/6 mice, indicating that it is located on both chromosomes.\nIn contrast, the Fxy gene in humans and M. spretus is entirely X-unique, meaning that it is located only on the X chromosome.\nIt is worth noting that the Fxy gene was translocated into the highly recombining pseudoautosomal region in mice relatively recently in evolutionary terms, which resulted in an increase in GC content. This translocation event may have had consequences for the gene's expression and function.",
    "llama-2-7b-chat-hf_fact_raw": "1. The 5' end of the Fxy gene is located only on the X chromosome in C57BL/6 mice.\n2. The 3' end of the Fxy gene is present on both the X and Y chromosomes in C57BL/6 mice.\n3. In humans and M. spretus, the Fxy gene is located only on the X chromosome.\n4. The Fxy gene was translocated into the pseudoautosomal region in mice relatively recently in evolutionary terms.\n5. The translocation of the Fxy gene into the pseudoautosomal region resulted in an increase in GC content.",
    "llama-2-7b-chat-hf_fact": [
      "The 5' end of the Fxy gene is located only on the X chromosome in C57BL/6 mice.",
      "The 3' end of the Fxy gene is present on both the X and Y chromosomes in C57BL/6 mice.",
      "In humans and M. spretus, the Fxy gene is located only on the X chromosome.",
      "The Fxy gene was translocated into the pseudoautosomal region in mice relatively recently in evolutionary terms.",
      "The translocation of the Fxy gene into the pseudoautosomal region resulted in an increase in GC content."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: The Fxy gene (also known as Fxyd5 or Dysadherin) is typically located on the X chromosome, and in the context of C57BL/6 mice, if the statement specifies that the 5' end is only on the X chromosome, this can be considered true.\n2. FALSE [correction]: The 3' end of the Fxy gene is not present on both the X and Y chromosomes in C57BL/6 mice. In mice, the Fxy gene is located only on the X chromosome.\n3. TRUE: In humans, the FXYD5 gene is located on the X chromosome, and it is reasonable to assume that the same is true for M. spretus (a species of wild mouse) based on the context provided.\n4. UNKNOWN: Without specific evolutionary data or a reference to a scientific study, it is not possible to confirm the relative timing of the translocation of the Fxy gene into the pseudoautosomal region in mice.\n5. UNKNOWN: The statement about the increase in GC content as a result of the translocation of the Fxy gene into the pseudoautosomal region is specific and would require empirical data to confirm or refute. Without such data, the truth of this statement cannot be determined.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3397,
    "user_query": "What is the basis of the methidiumpropyl-EDTA sequencing (MPE-seq) method?",
    "llama-2-7b-chat-hf_response": "Thank you for asking! Based on the information provided in Documents 0 and 1, the basis of the MPE-seq method is the treatment of nuclei with a complex of methidiumpropyl-EDTA (MPE) and ferrous iron. This complex preferentially cleaves the linker DNA between nucleosomes, allowing for the genome-wide characterization of chromatin.\nMPE-seq is similar to another method called MNase-seq, which uses micrococcal nuclease (MNase) to cleave the linker DNA between nucleosomes. However, MPE-seq has several advantages over MNase-seq, including higher specificity and efficiency, as well as the ability to analyze larger genomes.\nThe MPE-seq method involves the following steps:\n1. Preparation of nuclei: Nuclei are isolated from cells and treated with MPE-Fe (II) to cleave the linker DNA between nucleosomes.\n2. Capture of DNA fragments: The cleaved DNA fragments are then captured using an oligonucleotide probe that binds to the 3' end of the fragments.\n3. Library preparation: The captured DNA fragments are then prepared for massively parallel sequencing by adding adapter sequences and amplifying the fragments using PCR.\n4. Sequencing: The prepared libraries are then sequenced using Next-Generation Sequencing (NGS) technologies.\nThe resulting data can be analyzed to provide information about the chromatin structure and dynamics of the cells, including the location and distribution of nucleosomes, the density of chromatin, and the interactions between different regions of the genome.\nI hope this helps! Let me know if you have any further questions.",
    "llama-2-7b-chat-hf_fact_raw": "1. The MPE-seq method uses a complex of methidiumpropyl-EDTA (MPE) and ferrous iron to cleave the linker DNA between nucleosomes.\n2. MPE-seq is designed for genome-wide characterization of chromatin.\n3. MPE-seq is considered to have higher specificity and efficiency compared to MNase-seq and can analyze larger genomes.\n4. The MPE-seq method includes steps such as preparation of nuclei, capture of DNA fragments, library preparation, and sequencing using Next-Generation Sequencing technologies.\n5. The data from MPE-seq can provide information about chromatin structure and dynamics, including the location and distribution of nucleosomes, chromatin density, and genomic interactions.",
    "llama-2-7b-chat-hf_fact": [
      "The MPE-seq method uses a complex of methidiumpropyl-EDTA (MPE) and ferrous iron to cleave the linker DNA between nucleosomes.",
      "MPE-seq is designed for genome-wide characterization of chromatin.",
      "MPE-seq is considered to have higher specificity and efficiency compared to MNase-seq and can analyze larger genomes.",
      "The MPE-seq method includes steps such as preparation of nuclei, capture of DNA fragments, library preparation, and sequencing using Next-Generation Sequencing technologies.",
      "The data from MPE-seq can provide information about chromatin structure and dynamics, including the location and distribution of nucleosomes, chromatin density, and genomic interactions."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. UNKNOWN\n4. TRUE\n5. TRUE\n\nThe third statement is difficult to verify without specific scientific evidence comparing the specificity and efficiency of MPE-seq to MNase-seq, as well as the ability to analyze larger genomes. This would require access to recent and specific scientific literature or studies that have made these comparisons.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "unknown",
      "true",
      "true"
    ]
  },
  {
    "id": 3400,
    "user_query": "Which programming language has been used for implementing GWAR?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, the programming language used for implementing GWAR is Python. Document 1 mentions that Python is an object-oriented, high-level programming language launched in 1992, and it's built in a way that makes it intuitive to write and understand, making it ideal for rapid development. This suggests that Python was likely the language used for implementing GWAR.",
    "llama-2-7b-chat-hf_fact_raw": "1. Python is an object-oriented, high-level programming language.\n2. Python was launched in 1992.\n3. Python is designed to be intuitive to write and understand.\n4. Python is considered ideal for rapid development.\n5. Python was likely the language used for implementing GWAR.",
    "llama-2-7b-chat-hf_fact": [
      "Python is an object-oriented, high-level programming language.",
      "Python was launched in 1992.",
      "Python is designed to be intuitive to write and understand.",
      "Python is considered ideal for rapid development.",
      "Python was likely the language used for implementing GWAR."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Python was first released in 1991.\n3. TRUE\n4. TRUE\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 3406,
    "user_query": "Does xaliproden improve prognosis of amyotrophic lateral sclerosis?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, there is limited evidence to suggest that xaliproden improves the prognosis of amyotrophic lateral sclerosis (ALS).\nDocument 0 mentions the development of a survival model from the European Network for the Cure of ALS, which could inform patients and their families about the disease course and improve end-of-life planning. However, there is no mention of xaliproden as a factor that improves prognosis.\nDocument 1 provides a definition of ALS and its symptoms, including the degeneration of upper motor neurons (UMNs) in the motor cortex and lower motor neurons (LMNs) in the spinal cord and brain stem. While this information may be relevant to understanding the progression of ALS, it does not provide any specific evidence that xaliproden improves prognosis.\nIn summary, while there is some information provided about the potential for improved prognosis in ALS, there is no direct evidence to suggest that xaliproden is a factor that improves prognosis. Further research may be necessary to determine the effectiveness of xaliproden in improving the prognosis of ALS.",
    "llama-2-7b-chat-hf_fact_raw": "1. Xaliproden is associated with the prognosis of amyotrophic lateral sclerosis (ALS).\n2. The European Network for the Cure of ALS developed a survival model to inform patients and families about the disease course.\n3. Amyotrophic lateral sclerosis involves the degeneration of upper motor neurons in the motor cortex.\n4. Amyotrophic lateral sclerosis also involves the degeneration of lower motor neurons in the spinal cord and brain stem.\n5. There is no direct evidence suggesting that xaliproden improves the prognosis of ALS.",
    "llama-2-7b-chat-hf_fact": [
      "Xaliproden is associated with the prognosis of amyotrophic lateral sclerosis (ALS).",
      "The European Network for the Cure of ALS developed a survival model to inform patients and families about the disease course.",
      "Amyotrophic lateral sclerosis involves the degeneration of upper motor neurons in the motor cortex.",
      "Amyotrophic lateral sclerosis also involves the degeneration of lower motor neurons in the spinal cord and brain stem.",
      "There is no direct evidence suggesting that xaliproden improves the prognosis of ALS."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: Xaliproden has been studied in relation to amyotrophic lateral sclerosis (ALS) and is associated with the disease in the context of research on potential treatments.\n2. UNKNOWN: Without specific information about the development of a survival model by the European Network for the Cure of ALS, the truth of this statement cannot be determined.\n3. TRUE: Amyotrophic lateral sclerosis does involve the degeneration of upper motor neurons in the motor cortex.\n4. TRUE: Amyotrophic lateral sclerosis also involves the degeneration of lower motor neurons in the spinal cord and brain stem.\n5. TRUE: As of my knowledge cutoff date, there is no direct evidence that xaliproden improves the prognosis of ALS. Clinical trials have been conducted, but results have not shown a definitive improvement in prognosis.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3410,
    "user_query": "In which chromosome are transgenes inserted in the case of the LiPS-A3S line?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Document 0, the LiPS-A3S line has a transgene inserted in the 3' UTR region of the gene on chromosome 15. Therefore, the answer to the user's question is: Chromosome 15.",
    "llama-2-7b-chat-hf_fact_raw": "1. The LiPS-A3S line has a transgene inserted in the 3' UTR region of a gene.\n2. The gene into which the transgene is inserted for the LiPS-A3S line is located on chromosome 15.",
    "llama-2-7b-chat-hf_fact": [
      "The LiPS-A3S line has a transgene inserted in the 3' UTR region of a gene.",
      "The gene into which the transgene is inserted for the LiPS-A3S line is located on chromosome 15."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n\nWithout specific context or additional information about the LiPS-A3S line, it is not possible to verify the accuracy of these statements.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3430,
    "user_query": "Which tool exist for predicting drug synergy with deep learning?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, there are several deep learning tools available for predicting drug synergy:\n1. DeepSynergy: As mentioned in Document 0, DeepSynergy is a deep learning tool for predicting drug synergy. It is available via the website <www.bioinf.jku.at/software/DeepSynergy> and can be contacted at klambauer@bioinf.jku.at.\n2. DrugSynergy: DrugSynergy is a deep learning model developed by the University of California, San Diego, for predicting drug synergy. It uses a combination of molecular descriptors and graph-based features to predict drug interactions.\n3. SynergyNet: SynergyNet is a deep learning model developed by the University of Texas Southwestern Medical Center for predicting drug synergy. It uses a multi-layer perceptron (MLP) to predict drug interactions and can be trained on large datasets of drug-drug interaction data.\n4. DrugCombinator: DrugCombinator is a deep learning tool developed by the University of California, Berkeley, for predicting drug combinations. It uses a combination of molecular descriptors and graph-based features to predict drug interactions and can be trained on large datasets of drug-drug interaction data.\nThese are just a few examples of the many deep learning tools available for predicting drug synergy. It is important to evaluate each tool's performance and capabilities to determine which one is best suited for a particular research question or application.",
    "llama-2-7b-chat-hf_fact_raw": "1. DeepSynergy is a deep learning tool for predicting drug synergy.\n2. DeepSynergy is available via the website <www.bioinf.jku.at/software/DeepSynergy>.\n3. DrugSynergy is a deep learning model developed by the University of California, San Diego.\n4. SynergyNet is a deep learning model developed by the University of Texas Southwestern Medical Center.\n5. DrugCombinator is a deep learning tool developed by the University of California, Berkeley.",
    "llama-2-7b-chat-hf_fact": [
      "DeepSynergy is a deep learning tool for predicting drug synergy.",
      "DeepSynergy is available via the website <www.bioinf.jku.at/software/DeepSynergy>.",
      "DrugSynergy is a deep learning model developed by the University of California, San Diego.",
      "SynergyNet is a deep learning model developed by the University of Texas Southwestern Medical Center.",
      "DrugCombinator is a deep learning tool developed by the University of California, Berkeley."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nThe truth value of statements 2 through 5 cannot be determined without additional context or access to current databases and research. The names of the tools and models mentioned could be accurate, but without specific knowledge of these tools or confirmation from reliable sources, their origins and developers cannot be verified.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3433,
    "user_query": "Which cloud-based platform has been developed for comparing GWAS?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Documents 0 and 1, the cloud-based platform that has been developed for comparing GWAS is easyGWAS.",
    "llama-2-7b-chat-hf_fact_raw": "1. easyGWAS is a cloud-based platform developed for comparing GWAS (Genome-Wide Association Studies).",
    "llama-2-7b-chat-hf_fact": [
      "easyGWAS is a cloud-based platform developed for comparing GWAS (Genome-Wide Association Studies)."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true"
    ]
  },
  {
    "id": 3434,
    "user_query": "Can CMB305 be used against sarcomas?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, it appears that CMB305 may be effective in treating sarcomas that express the NY-ESO-1 protein. Document 1 mentions a trial that tested the efficacy of CMB305 in combination with atezolizumab (a PD-L1 inhibitor) in patients with NY-ESO-1–expressing synovial or myxoid round cell liposarcoma. While the trial did not specifically focus on sarcomas, the results suggest that CMB305 may be a promising treatment option for this type of cancer.\nIt is important to note, however, that this is based on a single trial and more research is needed to confirm these findings and establish the safety and efficacy of CMB305 in treating sarcomas. Additionally, CMB305 is a complex vaccine regimen that consists of multiple components, and its mechanism of action may involve multiple pathways and immune responses. Therefore, it is possible that CMB305 may have different effects on different types of cancer, including sarcomas.\nIn summary, while the available information suggests that CMB305 may be effective in treating sarcomas that express the NY-ESO-1 protein, more research is needed to confirm these findings and establish the safety and efficacy of this treatment approach.",
    "llama-2-7b-chat-hf_fact_raw": "1. CMB305 may be effective in treating sarcomas that express the NY-ESO-1 protein.\n2. A trial tested the efficacy of CMB305 in combination with atezolizumab in patients with NY-ESO-1–expressing synovial or myxoid round cell liposarcoma.\n3. The trial mentioned did not specifically focus on sarcomas.\n4. More research is needed to confirm the findings and establish the safety and efficacy of CMB305 in treating sarcomas.\n5. CMB305 is a complex vaccine regimen that consists of multiple components.",
    "llama-2-7b-chat-hf_fact": [
      "CMB305 may be effective in treating sarcomas that express the NY-ESO-1 protein.",
      "A trial tested the efficacy of CMB305 in combination with atezolizumab in patients with NY-ESO-1–expressing synovial or myxoid round cell liposarcoma.",
      "The trial mentioned did not specifically focus on sarcomas.",
      "More research is needed to confirm the findings and establish the safety and efficacy of CMB305 in treating sarcomas.",
      "CMB305 is a complex vaccine regimen that consists of multiple components."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: The trial mentioned did specifically focus on sarcomas, as synovial and myxoid round cell liposarcoma are types of sarcomas.\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 3461,
    "user_query": "What are manifestations of the Saint's Triad?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, the manifestations of the Saint's Triad are:\n1. Hiatal hernia: This is a condition where the stomach bulges up into the chest through a weakened area in the diaphragm.\n2. Gallbladder disease: This can include gallstones or inflammation of the gallbladder.\n3. Diverticulosis: This is a condition where small pouches form in the wall of the colon.\nIt is important to note that these conditions can occur separately, but when they occur together in a patient, they are considered to be part of the Saint's Triad. This triad is often seen in patients with atypical abdominal symptoms, and it is important for healthcare providers to consider the possibility of multiple separate diseases when evaluating a patient's symptoms.",
    "llama-2-7b-chat-hf_fact_raw": "1. Hiatal hernia is a condition where the stomach bulges up into the chest through a weakened area in the diaphragm.\n2. Gallbladder disease can include gallstones or inflammation of the gallbladder.\n3. Diverticulosis is a condition where small pouches form in the wall of the colon.\n4. The Saint's Triad consists of the occurrence of hiatal hernia, gallbladder disease, and diverticulosis together in a patient.\n5. The Saint's Triad is associated with atypical abdominal symptoms.",
    "llama-2-7b-chat-hf_fact": [
      "Hiatal hernia is a condition where the stomach bulges up into the chest through a weakened area in the diaphragm.",
      "Gallbladder disease can include gallstones or inflammation of the gallbladder.",
      "Diverticulosis is a condition where small pouches form in the wall of the colon.",
      "The Saint's Triad consists of the occurrence of hiatal hernia, gallbladder disease, and diverticulosis together in a patient.",
      "The Saint's Triad is associated with atypical abdominal symptoms."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 3470,
    "user_query": "Is overexpression of LY6K associated with better prognosis for non-small cell lung cancer patients?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, it appears that overexpression of LY6K may be associated with a better prognosis for non-small cell lung cancer (NSCLC) patients.\nDocument 0 suggests that high levels of LY6K expression are associated with poor prognosis in cancer patients, as it can drive tumorigenesis and progression. However, Document 1 presents findings that contradict this notion for NSCLC patients. Specifically, the document shows that overexpression of PSMB8 and PSMB9, which are components of the immunoproteasome, is predictive of better survival and improved response to immune-checkpoint inhibitors in NSCLC patients.\nGiven that LY6K can stimulate the immune response of the body's immune cells, it is possible that overexpression of this gene may enhance the immune response against cancer cells, leading to a better prognosis for NSCLC patients. Therefore, based on the information provided, it can be inferred that overexpression of LY6K may be associated with a better prognosis for NSCLC patients.",
    "llama-2-7b-chat-hf_fact_raw": "1. Overexpression of LY6K may be associated with a better prognosis for non-small cell lung cancer (NSCLC) patients.\n2. High levels of LY6K expression are generally associated with poor prognosis in cancer patients.\n3. LY6K can drive tumorigenesis and progression in cancer patients.\n4. Overexpression of PSMB8 and PSMB9 is predictive of better survival and improved response to immune-checkpoint inhibitors in NSCLC patients.\n5. LY6K can stimulate the immune response of the body's immune cells.",
    "llama-2-7b-chat-hf_fact": [
      "Overexpression of LY6K may be associated with a better prognosis for non-small cell lung cancer (NSCLC) patients.",
      "High levels of LY6K expression are generally associated with poor prognosis in cancer patients.",
      "LY6K can drive tumorigenesis and progression in cancer patients.",
      "Overexpression of PSMB8 and PSMB9 is predictive of better survival and improved response to immune-checkpoint inhibitors in NSCLC patients.",
      "LY6K can stimulate the immune response of the body's immune cells."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Overexpression of LY6K is generally associated with a poor prognosis for non-small cell lung cancer (NSCLC) patients.\n2. TRUE\n3. TRUE\n4. UNKNOWN\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3473,
    "user_query": "List Cdk targets that are dephosphorylated during cytokinesis",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Documents 0 and 1, the following Cdk targets are dephosphorylated during cytokinesis:\n1. Cdc14: As mentioned in Document 0, upregulation of Cdc14, a phosphatase that counteracts Cdk activity, is essential for controlling the sequential steps of cytokinesis.\n2. Cyclin-dependent kinases (Cdks): Document 1 mentions that phosphoproteome analysis of mitotic exit identifies Cdk targets that are dephosphorylated at the time of cytokinesis. However, the specific Cdks involved in this process are not explicitly mentioned in the documents.\nIt is worth noting that the study in Document 0 focuses on budding yeast, while the study in Document 1 is more general and applies to various organisms, including budding yeast. Therefore, the results from Document 0 may be more relevant to the specific context of budding yeast cytokinesis.",
    "llama-2-7b-chat-hf_fact_raw": "1. Cdc14 is upregulated during cytokinesis and counteracts Cdk activity.\n2. Cdc14 is a phosphatase essential for controlling the sequential steps of cytokinesis.\n3. Phosphoproteome analysis identifies Cdk targets that are dephosphorylated during cytokinesis.\n4. The study mentioned in Document 0 focuses on budding yeast.\n5. The study in Document 1 applies to various organisms, including budding yeast.",
    "llama-2-7b-chat-hf_fact": [
      "Cdc14 is upregulated during cytokinesis and counteracts Cdk activity.",
      "Cdc14 is a phosphatase essential for controlling the sequential steps of cytokinesis.",
      "Phosphoproteome analysis identifies Cdk targets that are dephosphorylated during cytokinesis.",
      "The study mentioned in Document 0 focuses on budding yeast.",
      "The study in Document 1 applies to various organisms, including budding yeast."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. UNKNOWN\n5. UNKNOWN\n\nThe first three statements are consistent with known biological functions of Cdc14 and its role in cell cycle regulation, particularly during cytokinesis. However, without specific information from \"Document 0\" and \"Document 1,\" it is not possible to confirm the accuracy of statements 4 and 5.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3508,
    "user_query": "What is Xanamem?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, Xanamem is an inhibitor of 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1), an enzyme in the hypothalamic-pituitary-adrenal (HPA) axis of the body's stress response. 11β-HSD1 converts the stress hormone cortisol to its active form, which binds to glucocorticoid receptors. Xanamem works by inhibiting the activity of 11β-HSD1, which can help to reduce the production of cortisol in response to stress. This may have potential therapeutic benefits for conditions such as Alzheimer's disease, as excessive cortisol production has been linked to cognitive decline and memory impairment.\nIn addition to its role in the HPA axis, Xanamem is also being developed as a potential treatment for Alzheimer's disease. Actinogen Medical, the company developing Xanamem, acquired the rights to the drug in 2014, and it is currently in clinical trials for the treatment of Alzheimer's disease. Preclinical studies have suggested that Xanamem may have neuroprotective effects and improve cognitive function in Alzheimer's disease models.",
    "llama-2-7b-chat-hf_fact_raw": "1. Xanamem is an inhibitor of the enzyme 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1).\n2. 11β-HSD1 is involved in the body's stress response by converting cortisol to its active form.\n3. Xanamem aims to reduce the production of cortisol in response to stress.\n4. Actinogen Medical acquired the rights to Xanamem in 2014.\n5. Xanamem is currently in clinical trials for the treatment of Alzheimer's disease.",
    "llama-2-7b-chat-hf_fact": [
      "Xanamem is an inhibitor of the enzyme 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1).",
      "11β-HSD1 is involved in the body's stress response by converting cortisol to its active form.",
      "Xanamem aims to reduce the production of cortisol in response to stress.",
      "Actinogen Medical acquired the rights to Xanamem in 2014.",
      "Xanamem is currently in clinical trials for the treatment of Alzheimer's disease."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: 11β-HSD1 is involved in the body's stress response by converting inactive cortisone into its active form, cortisol.\n3. TRUE\n4. UNKNOWN\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "unknown",
      "true"
    ]
  },
  {
    "id": 3520,
    "user_query": "What is the role of the Hof1-Cyk3 interaction in yeast?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Documents 0 and 1, the role of the Hof1-Cyk3 interaction in yeast is related to cytokinesis. Specifically, the interaction between the Hof1 SH3 domain and a proline-rich motif in Cyk3 plays a role in cleavage-furrow ingression and primary-septum formation during yeast cytokinesis.\nAccording to Document 0, the interaction between Hof1 and Cyk3 is mediated by a direct binding of the Hof1 SH3 domain to a proline-rich motif in Cyk3, and occurs specifically at the time of cytokinesis. This interaction is independent of the (hyper)phosphorylation of both proteins that occurs at about the same time, and is dispensable for the normal localization of both proteins.\nDocument 1 provides further insight into the role of the Hof1-Cyk3 interaction in yeast cytokinesis. The authors found that the interaction between Hof1 and Cyk3 is required for cleavage-furrow ingression and primary-septum formation during cytokinesis. They also showed that the interaction between Hof1 and Cyk3 is necessary for the proper localization of the cleavage furrow and the formation of the primary septum, which are critical steps in the cell division process.\nIn summary, the role of the Hof1-Cyk3 interaction in yeast is to facilitate the proper progression of cytokinesis by promoting cleavage-furrow ingression and primary-septum formation.",
    "llama-2-7b-chat-hf_fact_raw": "1. The Hof1-Cyk3 interaction in yeast is related to cytokinesis.\n2. The interaction between the Hof1 SH3 domain and a proline-rich motif in Cyk3 plays a role in cleavage-furrow ingression and primary-septum formation during yeast cytokinesis.\n3. The interaction between Hof1 and Cyk3 is mediated by a direct binding of the Hof1 SH3 domain to a proline-rich motif in Cyk3.\n4. This interaction occurs specifically at the time of cytokinesis and is independent of the (hyper)phosphorylation of both proteins.\n5. The Hof1-Cyk3 interaction is necessary for the proper localization of the cleavage furrow and the formation of the primary septum during cytokinesis.",
    "llama-2-7b-chat-hf_fact": [
      "The Hof1-Cyk3 interaction in yeast is related to cytokinesis.",
      "The interaction between the Hof1 SH3 domain and a proline-rich motif in Cyk3 plays a role in cleavage-furrow ingression and primary-septum formation during yeast cytokinesis.",
      "The interaction between Hof1 and Cyk3 is mediated by a direct binding of the Hof1 SH3 domain to a proline-rich motif in Cyk3.",
      "This interaction occurs specifically at the time of cytokinesis and is independent of the (hyper)phosphorylation of both proteins.",
      "The Hof1-Cyk3 interaction is necessary for the proper localization of the cleavage furrow and the formation of the primary septum during cytokinesis."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: The interaction between Hof1 and Cyk3 is regulated by the (hyper)phosphorylation of both proteins, which affects the timing and strength of the interaction during cytokinesis.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 3598,
    "user_query": "Which T-UCRs have been implicated in gastric cancer?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Documents 0 and 1, T-UCRs have been implicated in gastric cancer through their involvement in three different regulatory mechanisms:\n1. CpG island methylation: T-UCRs have been shown to be involved in the methylation of CpG islands, which is a common epigenetic alteration in gastric cancer.\n2. Interaction with miRNAs: T-UCRs have been found to interact with miRNAs, which are known to play a role in the development and progression of gastric cancer.\n3. Direct binding to the target mRNAs: T-UCRs have been shown to directly bind to the target mRNAs involved in gastric cancer, leading to changes in gene expression.\nTherefore, based on the information provided, T-UCRs have been implicated in the development and progression of gastric cancer through these three regulatory mechanisms.",
    "llama-2-7b-chat-hf_fact_raw": "1. T-UCRs are involved in the methylation of CpG islands, an epigenetic alteration common in gastric cancer.\n2. T-UCRs interact with miRNAs, which play a role in the development and progression of gastric cancer.\n3. T-UCRs can directly bind to target mRNAs involved in gastric cancer, affecting gene expression.",
    "llama-2-7b-chat-hf_fact": [
      "T-UCRs are involved in the methylation of CpG islands, an epigenetic alteration common in gastric cancer.",
      "T-UCRs interact with miRNAs, which play a role in the development and progression of gastric cancer.",
      "T-UCRs can directly bind to target mRNAs involved in gastric cancer, affecting gene expression."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: T-UCRs (Transcribed Ultraconserved Regions) are not directly involved in the methylation of CpG islands. CpG island methylation is typically carried out by DNA methyltransferases. T-UCRs may play a role in epigenetic regulation, but they are not the agents that directly methylate DNA.\n2. TRUE: T-UCRs are known to interact with miRNAs (microRNAs), which are involved in gene regulation and can play a role in the development and progression of various cancers, including gastric cancer.\n3. TRUE: T-UCRs can indeed bind to target mRNAs, potentially affecting gene expression. This interaction can influence the development and progression of diseases, including cancer.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 3607,
    "user_query": "What is the Lupus Severity Index (LSI)?",
    "llama-2-7b-chat-hf_response": "The Lupus Severity Index (LSI) is a tool used to assess the severity of lupus, a chronic autoimmune disease that can affect various parts of the body, including the skin, joints, and organs. The LSI is based on the American College of Rheumatology (ACR) classification criteria for lupus and is used to predict the likelihood of immunosuppressive use and early mortality in patients with lupus.\nThe LSI is calculated by assigning weights to each of the ACR criteria based on their perceived importance in determining the severity of lupus. The weights are then multiplied by the number of criteria met, and the results are added up to give a total LSI score. The higher the score, the more severe the lupus is considered to be.\nIn the study you provided, the LSI was tested on an independent validation dataset and found to have high predictive accuracy for immunosuppressive use and early mortality. The study also found that the LSI was strongly correlated with a previously existing severity score for lupus.\nThe LSI can be useful in helping healthcare providers identify patients with lupus who are at high risk of developing severe complications, such as kidney damage or blood clots. This can help guide treatment decisions and improve patient outcomes.",
    "llama-2-7b-chat-hf_fact_raw": "1. The Lupus Severity Index (LSI) is used to assess the severity of lupus.\n2. The LSI is based on the American College of Rheumatology (ACR) classification criteria for lupus.\n3. The LSI is used to predict the likelihood of immunosuppressive use and early mortality in patients with lupus.\n4. The LSI score is calculated by assigning weights to each of the ACR criteria and adding the results.\n5. A higher LSI score indicates a more severe case of lupus.",
    "llama-2-7b-chat-hf_fact": [
      "The Lupus Severity Index (LSI) is used to assess the severity of lupus.",
      "The LSI is based on the American College of Rheumatology (ACR) classification criteria for lupus.",
      "The LSI is used to predict the likelihood of immunosuppressive use and early mortality in patients with lupus.",
      "The LSI score is calculated by assigning weights to each of the ACR criteria and adding the results.",
      "A higher LSI score indicates a more severe case of lupus."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN: The existence and use of a \"Lupus Severity Index\" (LSI) are not standard or widely recognized in medical literature. There are various tools and indices used to assess the severity of lupus, such as the SLE Disease Activity Index (SLEDAI), but without specific context, it's unclear whether the LSI is a recognized tool or a hypothetical or proprietary index not widely used.\n\n2. UNKNOWN: Since the LSI's existence and use are not confirmed, it's unclear whether it is based on the American College of Rheumatology (ACR) classification criteria for lupus. The ACR criteria are commonly used for classification and research purposes, but without specific information about the LSI, this statement cannot be verified.\n\n3. UNKNOWN: Without confirmation of the LSI's existence and its purpose, it's not possible to determine whether it is used to predict the likelihood of immunosuppressive use and early mortality in patients with lupus.\n\n4. UNKNOWN: The method of calculating the LSI score is not verifiable without specific information about the LSI itself. If the LSI is a hypothetical or proprietary tool, details of its scoring system would be needed to confirm this statement.\n\n5. UNKNOWN: Without knowing the specifics of the LSI, including whether it exists and how it is scored, it's not possible to confirm that a higher LSI score indicates a more severe case of lupus. Typically, in disease severity indices, a higher score would suggest more severe disease, but this cannot be assumed without proper context for the LSI.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3615,
    "user_query": "Which disorders are caused by de novo mutations in ZSWIM6?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, de novo mutations in ZSWIM6 have been associated with acromelic frontonasal dysostosis (AFND), an autosomal-dominant severe frontonasal and limb malformation syndrome. The specific de novo missense variant within the C-terminal Sin3-like domain of ZSWIM6 has been identified as the causative mutation for this disorder, and it is thought to result in a gain-of-function effect. Therefore, the answer to the user's question is:\nDe novo mutations in ZSWIM6 can cause acromelic frontonasal dysostosis (AFND).",
    "llama-2-7b-chat-hf_fact_raw": "1. De novo mutations in ZSWIM6 are associated with acromelic frontonasal dysostosis (AFND).\n2. Acromelic frontonasal dysostosis (AFND) is an autosomal-dominant severe frontonasal and limb malformation syndrome.\n3. A specific de novo missense variant within the C-terminal Sin3-like domain of ZSWIM6 is identified as the causative mutation for AFND.\n4. The mutation in ZSWIM6 thought to cause AFND results in a gain-of-function effect.",
    "llama-2-7b-chat-hf_fact": [
      "De novo mutations in ZSWIM6 are associated with acromelic frontonasal dysostosis (AFND).",
      "Acromelic frontonasal dysostosis (AFND) is an autosomal-dominant severe frontonasal and limb malformation syndrome.",
      "A specific de novo missense variant within the C-terminal Sin3-like domain of ZSWIM6 is identified as the causative mutation for AFND.",
      "The mutation in ZSWIM6 thought to cause AFND results in a gain-of-function effect."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Acromelic frontonasal dysostosis (AFND) is typically characterized as an autosomal-recessive disorder, not autosomal-dominant.\n3. TRUE\n4. FALSE [correction]: The mutation in ZSWIM6 thought to cause AFND results in a loss-of-function effect, not a gain-of-function effect.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "false"
    ]
  },
  {
    "id": 3626,
    "user_query": "Which disease can be classified using the Koos Classification?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, the disease that can be classified using the Koos Classification is vestibular schwannoma (VS).",
    "llama-2-7b-chat-hf_fact_raw": "1. The Koos Classification is used to classify vestibular schwannoma (VS).",
    "llama-2-7b-chat-hf_fact": [
      "The Koos Classification is used to classify vestibular schwannoma (VS)."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true"
    ]
  },
  {
    "id": 3628,
    "user_query": "What are the in vivo effects of AZD8601?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, AZD8601 appears to have in vivo effects related to improving vascularization and tissue oxygenation, as well as potential use in local administration for patients undergoing coronary artery bypass grafting (CABG).\nDocument 0 suggests that AZD8601 has the potential to improve vascularization and tissue oxygenation in the wound bed through sequential dosing. This is likely due to the ability of AZD8601 to increase the delivery of oxygen to the tissue, which can promote healing and reduce the risk of infection.\nDocument 1 provides information on the mRNA-based therapy of AZD8601, which encodes for VEGF-A for local administration in patients undergoing CABG. VEGF-A is a protein that plays a crucial role in angiogenesis, the formation of new blood vessels, and is involved in the regulation of vascular permeability and endothelial cell growth. By encoding for VEGF-A, AZD8601 may help to promote the formation of new blood vessels and improve blood flow to the tissue, which can be beneficial for patients undergoing CABG.\nOverall, the in vivo effects of AZD8601 appear to be related to its ability to improve vascularization and tissue oxygenation, as well as its potential use in local administration for patients undergoing CABG. However, further research is needed to fully understand the mechanisms of action of AZD8601 and its potential therapeutic applications.",
    "llama-2-7b-chat-hf_fact_raw": "1. AZD8601 has the potential to improve vascularization and tissue oxygenation in vivo.\n2. AZD8601 may increase the delivery of oxygen to tissue, which can promote healing and reduce the risk of infection.\n3. AZD8601 is an mRNA-based therapy that encodes for VEGF-A.\n4. VEGF-A, encoded by AZD8601, plays a crucial role in angiogenesis and the regulation of vascular permeability and endothelial cell growth.\n5. AZD8601 may be beneficial for patients undergoing coronary artery bypass grafting (CABG) by promoting the formation of new blood vessels and improving blood flow to the tissue.",
    "llama-2-7b-chat-hf_fact": [
      "AZD8601 has the potential to improve vascularization and tissue oxygenation in vivo.",
      "AZD8601 may increase the delivery of oxygen to tissue, which can promote healing and reduce the risk of infection.",
      "AZD8601 is an mRNA-based therapy that encodes for VEGF-A.",
      "VEGF-A, encoded by AZD8601, plays a crucial role in angiogenesis and the regulation of vascular permeability and endothelial cell growth.",
      "AZD8601 may be beneficial for patients undergoing coronary artery bypass grafting (CABG) by promoting the formation of new blood vessels and improving blood flow to the tissue."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: AZD8601 is designed to improve vascularization and tissue oxygenation in vivo by promoting angiogenesis, which is the formation of new blood vessels.\n2. TRUE: By improving vascularization, AZD8601 may indeed increase the delivery of oxygen to tissues, which can promote healing and reduce the risk of infection.\n3. TRUE: AZD8601 is an mRNA-based therapy that encodes for VEGF-A, which is a signal protein that stimulates the formation of blood vessels.\n4. TRUE: VEGF-A, which is encoded by AZD8601, is indeed a critical factor in angiogenesis and plays a significant role in the regulation of vascular permeability and endothelial cell growth.\n5. TRUE: AZD8601 has the potential to be beneficial for patients undergoing coronary artery bypass grafting (CABG) by promoting angiogenesis, which could improve blood flow to the heart tissue.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3640,
    "user_query": "How are SAHFS created?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Documents 0 and 1, SAHFS (Senescence Associated Heterochromatic Foci) are created as a result of cellular senescence, which is a stress response that can be triggered by various factors such as DNA damage, telomere erosion, and activation of oncogenic signaling.\nCellular senescence is a permanent cell cycle exit that occurs when cells reach a state of irreversible growth arrest due to various forms of cellular stress. This process is characterized by the accumulation of senescent cells in tissues, which can lead to a variety of negative consequences, including tissue aging and disease.\nThe formation of SAHFS is a key aspect of cellular senescence, as it is the result of the condensation of chromatin and the formation of heterochromatin in response to cellular stress. Heterochromatin is a type of chromatin that is characterized by the condensation of DNA and the formation of compact chromatin structures, which can be visualized as foci in the nucleus of senescent cells.\nIn summary, SAHFS are created as a result of cellular senescence, which is a stress response that can be triggered by various factors, leading to the accumulation of senescent cells in tissues and the formation of heterochromatin foci in the nucleus of these cells.",
    "llama-2-7b-chat-hf_fact_raw": "1. SAHFS (Senescence Associated Heterochromatic Foci) are created as a result of cellular senescence.\n2. Cellular senescence can be triggered by various factors such as DNA damage, telomere erosion, and activation of oncogenic signaling.\n3. Cellular senescence is characterized by a permanent cell cycle exit and irreversible growth arrest due to cellular stress.\n4. The accumulation of senescent cells in tissues can lead to negative consequences like tissue aging and disease.\n5. The formation of SAHFS involves the condensation of chromatin and the formation of heterochromatin in the nucleus of senescent cells.",
    "llama-2-7b-chat-hf_fact": [
      "SAHFS (Senescence Associated Heterochromatic Foci) are created as a result of cellular senescence.",
      "Cellular senescence can be triggered by various factors such as DNA damage, telomere erosion, and activation of oncogenic signaling.",
      "Cellular senescence is characterized by a permanent cell cycle exit and irreversible growth arrest due to cellular stress.",
      "The accumulation of senescent cells in tissues can lead to negative consequences like tissue aging and disease.",
      "The formation of SAHFS involves the condensation of chromatin and the formation of heterochromatin in the nucleus of senescent cells."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3672,
    "user_query": "What is the function of the PDZ domain in SATB1?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Documents 0 and 1, the function of the PDZ domain in SATB1 is to mediate interactions with several chromatin proteins. The PDZ domain is located at the N-terminal region of SATB1 and is involved in protein-protein interactions. Specifically, it binds to several chromatin proteins, which suggests that SATB1 plays a role in regulating chromatin structure and gene expression through its interactions with these proteins.\nIt is worth noting that the function of the PDZ domain in SATB1 is not directly mentioned in either document, but it can be inferred based on the information provided. The documents primarily focus on the functional domains of SATB1, including the N-terminal PDZ-like domain and the C-terminal DNA-binding region, and their roles in regulating gene expression and chromatin structure.",
    "llama-2-7b-chat-hf_fact_raw": "1. The PDZ domain in SATB1 mediates interactions with several chromatin proteins.\n2. The PDZ domain is located at the N-terminal region of SATB1.\n3. SATB1 is involved in protein-protein interactions through its PDZ domain.\n4. SATB1 plays a role in regulating chromatin structure and gene expression.\n5. The PDZ domain of SATB1 binds to several chromatin proteins.",
    "llama-2-7b-chat-hf_fact": [
      "The PDZ domain in SATB1 mediates interactions with several chromatin proteins.",
      "The PDZ domain is located at the N-terminal region of SATB1.",
      "SATB1 is involved in protein-protein interactions through its PDZ domain.",
      "SATB1 plays a role in regulating chromatin structure and gene expression.",
      "The PDZ domain of SATB1 binds to several chromatin proteins."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The PDZ-like domain in SATB1 mediates interactions with several chromatin proteins, but it is not a canonical PDZ domain.\n2. FALSE [correction]: The PDZ-like domain is located at the C-terminal region of SATB1, not the N-terminal.\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3678,
    "user_query": "What is the basis of the BLISS technique?",
    "llama-2-7b-chat-hf_response": "The basis of the BLISS technique is rooted in the principles of quantum healing, as described in Deepak Chopra's book \"Quantum Healing.\" The technique is designed to relieve and dissolve pain, improve healing, and create a strong foundation for immunity by balancing the mind-body system.\nAccording to Chopra, the BLISS technique is an advanced set of techniques that are taught in two parts during one session. In the first part, participants are given a technique to add to the end of every twice-daily meditation, which enhances bliss in the mind-body system. In the second part of the initiation, participants receive an additional practice with a specific Sanskrit mantra for adding into their meditation practice.\nThe BLISS technique is based on the idea that the mind and body are interconnected, and that by cultivating a state of bliss through meditation and other practices, individuals can experience improved health and well-being. By balancing the mind-body system, the BLISS technique aims to create a strong foundation for immunity and overall health.",
    "llama-2-7b-chat-hf_fact_raw": "1. The BLISS technique is based on the principles of quantum healing.\n2. Deepak Chopra describes the principles of the BLISS technique in his book \"Quantum Healing.\"\n3. The BLISS technique includes a set of techniques taught in two parts during one session.\n4. The first part of the BLISS technique involves adding a technique to the end of twice-daily meditation to enhance bliss.\n5. The second part of the BLISS technique initiation includes practicing a specific Sanskrit mantra during meditation.",
    "llama-2-7b-chat-hf_fact": [
      "The BLISS technique is based on the principles of quantum healing.",
      "Deepak Chopra describes the principles of the BLISS technique in his book \"Quantum Healing.\"",
      "The BLISS technique includes a set of techniques taught in two parts during one session.",
      "The first part of the BLISS technique involves adding a technique to the end of twice-daily meditation to enhance bliss.",
      "The second part of the BLISS technique initiation includes practicing a specific Sanskrit mantra during meditation."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN: The statement is vague and without additional context, it's unclear whether the BLISS technique is indeed based on the principles of quantum healing or if it is associated with another concept or practice.\n2. UNKNOWN: Without specific knowledge of the contents of Deepak Chopra's book \"Quantum Healing,\" it is not possible to confirm whether he describes the principles of the BLISS technique in this book.\n3. UNKNOWN: The structure of the BLISS technique is not specified, and without additional information, it cannot be determined if it is taught in two parts during one session.\n4. UNKNOWN: The details of the BLISS technique, including whether it involves adding a technique to the end of twice-daily meditation to enhance bliss, cannot be confirmed without more context or information about the technique.\n5. UNKNOWN: Similar to the previous statements, without specific information about the BLISS technique, it is not possible to verify if the second part of the initiation includes practicing a specific Sanskrit mantra during meditation.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3679,
    "user_query": "List 3 NK3R antagonists.",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Document 0, the following are three NK3R antagonists that have been studied for the treatment of menopausal vasomotor symptoms:\n1. MEN-1095: This is a potent and selective NK3R antagonist that has been shown to be effective in reducing hot flashes and night sweats in menopausal women.\n2. MEN-1105: This is another oral NK3R antagonist that has been studied for the treatment of menopausal vasomotor symptoms. It has been shown to be well-tolerated and effective in reducing hot flashes and night sweats.\n3. MEN-1110: This is a novel, orally available NK3R antagonist that has been shown to be effective in reducing hot flashes and night sweats in menopausal women. It has a unique chemical structure that allows for improved bioavailability and pharmacokinetics compared to other NK3R antagonists.\nIt is important to note that these are just three examples of NK3R antagonists that have been studied for the treatment of menopausal vasomotor symptoms, and there may be other agents in development that have similar efficacy and safety profiles.",
    "llama-2-7b-chat-hf_fact_raw": "1. MEN-1095 is a potent and selective NK3R antagonist studied for reducing hot flashes and night sweats in menopausal women.\n2. MEN-1105 is an oral NK3R antagonist that has been studied for the treatment of menopausal vasomotor symptoms.\n3. MEN-1110 is a novel, orally available NK3R antagonist that has been shown to be effective in reducing hot flashes and night sweats in menopausal women.\n4. MEN-1110 has a unique chemical structure that allows for improved bioavailability and pharmacokinetics compared to other NK3R antagonists.",
    "llama-2-7b-chat-hf_fact": [
      "MEN-1095 is a potent and selective NK3R antagonist studied for reducing hot flashes and night sweats in menopausal women.",
      "MEN-1105 is an oral NK3R antagonist that has been studied for the treatment of menopausal vasomotor symptoms.",
      "MEN-1110 is a novel, orally available NK3R antagonist that has been shown to be effective in reducing hot flashes and night sweats in menopausal women.",
      "MEN-1110 has a unique chemical structure that allows for improved bioavailability and pharmacokinetics compared to other NK3R antagonists."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: The correct name of the oral NK3R antagonist studied for the treatment of menopausal vasomotor symptoms is MEN-1095, not MEN-1105.\n3. UNKNOWN\n4. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3691,
    "user_query": "Which drug is the first oral ghrelin receptor inverse agonist to be profiled in healthy subjects?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Documents 0 and 1, the first oral ghrelin receptor inverse agonist to be profiled in healthy subjects is PF-05190457.",
    "llama-2-7b-chat-hf_fact_raw": "1. PF-05190457 is the first oral ghrelin receptor inverse agonist to be profiled in healthy subjects.",
    "llama-2-7b-chat-hf_fact": [
      "PF-05190457 is the first oral ghrelin receptor inverse agonist to be profiled in healthy subjects."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n\nWithout additional context or access to up-to-date scientific literature, I cannot verify the accuracy of the statement regarding PF-05190457 being the first oral ghrelin receptor inverse agonist profiled in healthy subjects.",
    "llama-2-7b-chat-hf_judge": [
      "unknown"
    ]
  },
  {
    "id": 3693,
    "user_query": "What is the protective efficacy of vaxchora against moderate to severe cholera?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, Vaxchora, the medicinal product in question, is a vaccine against cholera. The protective efficacy of Vaxchora against moderate to severe cholera can be determined from the information provided in Document 1.\nAccording to Document 1, Vaxchora is a recombinant vaccine composed of inactivated cholera bacteria, with a quantitative composition of 50% (w/w) of the cholera toxoid adsorbed onto aluminum hydroxide. The pharmaceutical form is a lyophilized powder for reconstitution with sterile water before use.\nThe clinical particulars of Vaxchora indicate that it is indicated for the prevention of cholera caused by Vibrio cholerae in adults 18 years of age and older who are traveling to or working in areas where cholera is common. The pharmacological properties of Vaxchora are based on the mechanism of action of the cholera toxoid, which is a toxin produced by the cholera bacteria that causes inflammation and diarrhea in the intestines.\nThe marketing authorization holder for Vaxchora is listed as GlaxoSmithKline Biologicals S.A., and the marketing authorization number is EU/01/271/001. The date of first authorization was March 20, 2001, and the authorization was renewed on March 20, 2006.\nBased on the information provided, Vaxchora has been shown to be effective in preventing moderate to severe cholera in adults who are traveling to or working in areas where cholera is common. The protective efficacy of Vaxchora against moderate to severe cholera is estimated to be around 70-80%, based on the results of clinical trials conducted in areas where cholera is common. However, it is important to note that the vaccine is not 100% effective, and individuals may still contract cholera despite being vaccinated. Therefore, it is important to follow proper hygiene practices and seek medical attention if symptoms of cholera develop after",
    "llama-2-7b-chat-hf_fact_raw": "1. Vaxchora is a vaccine indicated for the prevention of cholera caused by Vibrio cholerae in adults 18 years and older.\n2. The vaccine is composed of inactivated cholera bacteria, with a quantitative composition of 50% (w/w) of the cholera toxoid adsorbed onto aluminum hydroxide.\n3. Vaxchora is a lyophilized powder that is reconstituted with sterile water before use.\n4. The marketing authorization holder for Vaxchora is GlaxoSmithKline Biologicals S.A., with the authorization number EU/01/271/001.\n5. The protective efficacy of Vaxchora against moderate to severe cholera is estimated to be around 70-80% based on clinical trial results.",
    "llama-2-7b-chat-hf_fact": [
      "Vaxchora is a vaccine indicated for the prevention of cholera caused by Vibrio cholerae in adults 18 years and older.",
      "The vaccine is composed of inactivated cholera bacteria, with a quantitative composition of 50% (w/w) of the cholera toxoid adsorbed onto aluminum hydroxide.",
      "Vaxchora is a lyophilized powder that is reconstituted with sterile water before use.",
      "The marketing authorization holder for Vaxchora is GlaxoSmithKline Biologicals S.A., with the authorization number EU/01/271/001.",
      "The protective efficacy of Vaxchora against moderate to severe cholera is estimated to be around 70-80% based on clinical trial results."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Vaxchora is a live, attenuated vaccine and does not contain inactivated cholera bacteria or cholera toxoid adsorbed onto aluminum hydroxide.\n3. TRUE\n4. FALSE [correction]: The marketing authorization holder for Vaxchora is PaxVax Bermuda Ltd., not GlaxoSmithKline Biologicals S.A. The authorization number may also be incorrect, but without the specific authorization number database, this cannot be confirmed.\n5. TRUE (However, the exact efficacy can vary based on different clinical trials and conditions, so this statement should be verified against the latest clinical trial results for accuracy.)",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 3716,
    "user_query": "Which was the first cholera vaccine approved in the US?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Document 0, the first cholera vaccine approved in the US is Vaxchora, which was approved by the Food and Drug Administration (FDA) for the prophylaxis of cholera infection.",
    "llama-2-7b-chat-hf_fact_raw": "1. Vaxchora is the first cholera vaccine approved in the US.\n2. The Food and Drug Administration (FDA) approved Vaxchora for the prophylaxis of cholera infection.",
    "llama-2-7b-chat-hf_fact": [
      "Vaxchora is the first cholera vaccine approved in the US.",
      "The Food and Drug Administration (FDA) approved Vaxchora for the prophylaxis of cholera infection."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true"
    ]
  },
  {
    "id": 3737,
    "user_query": "Which is the most common monogenic cause of common variable immunodeficiency (CVID) in Europeans?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Document 1, the most common monogenic cause of common variable immunodeficiency (CVID) in Europeans is heterozygous loss-of-function variants in the NFKB1 gene.",
    "llama-2-7b-chat-hf_fact_raw": "1. The most common monogenic cause of common variable immunodeficiency (CVID) in Europeans is heterozygous loss-of-function variants in the NFKB1 gene.",
    "llama-2-7b-chat-hf_fact": [
      "The most common monogenic cause of common variable immunodeficiency (CVID) in Europeans is heterozygous loss-of-function variants in the NFKB1 gene."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true"
    ]
  },
  {
    "id": 3743,
    "user_query": "Which is the role of the IFIT1 gene in Systemic Lupus Erythematosus (SLE)?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Documents 0 and 1, the role of the IFIT1 gene in Systemic Lupus Erythematosus (SLE) is to play a crucial role in the regulation of inflammation. The IFIT1 gene is an interferon-stimulated gene (ISG) that is upregulated in response to interferon (IFN) production in SLE. The upregulation of IFIT1 has been shown to impact the immune responses and inflammatory factors in SLE, suggesting that it plays a key role in the pathogenesis of the disease.\nIFIT1 is a negative regulator of RNA polymerase II (RNAPII) and can inhibit the transcription of target genes by binding to the RNAPII complex. In the context of SLE, IFIT1 may play a role in regulating the overproduction of pro-inflammatory cytokines and autoantibodies that are characteristic of the disease.\nAdditionally, the IFIT1 gene has been shown to be differentially expressed in SLE patients compared to healthy controls, suggesting that it may be a useful biomarker for diagnosing and monitoring the disease.\nIn summary, the role of the IFIT1 gene in SLE is to play a crucial role in the regulation of inflammation by inhibiting the transcription of pro-inflammatory genes and modulating the immune response.",
    "llama-2-7b-chat-hf_fact_raw": "1. The IFIT1 gene plays a crucial role in the regulation of inflammation in Systemic Lupus Erythematosus (SLE).\n2. The IFIT1 gene is an interferon-stimulated gene that is upregulated in response to interferon production in SLE.\n3. Upregulation of IFIT1 impacts immune responses and inflammatory factors in SLE, suggesting a key role in the disease's pathogenesis.\n4. IFIT1 is a negative regulator of RNA polymerase II and can inhibit the transcription of target genes by binding to the RNAPII complex.\n5. The IFIT1 gene has been shown to be differentially expressed in SLE patients compared to healthy controls.",
    "llama-2-7b-chat-hf_fact": [
      "The IFIT1 gene plays a crucial role in the regulation of inflammation in Systemic Lupus Erythematosus (SLE).",
      "The IFIT1 gene is an interferon-stimulated gene that is upregulated in response to interferon production in SLE.",
      "Upregulation of IFIT1 impacts immune responses and inflammatory factors in SLE, suggesting a key role in the disease's pathogenesis.",
      "IFIT1 is a negative regulator of RNA polymerase II and can inhibit the transcription of target genes by binding to the RNAPII complex.",
      "The IFIT1 gene has been shown to be differentially expressed in SLE patients compared to healthy controls."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: The IFIT1 gene has been implicated in the regulation of inflammation in Systemic Lupus Erythematosus (SLE) and other autoimmune diseases.\n2. TRUE: The IFIT1 gene is indeed an interferon-stimulated gene that is upregulated in response to interferon production, which is a common feature in SLE.\n3. TRUE: The upregulation of IFIT1 is associated with immune responses and inflammatory factors in SLE, indicating its potential role in the disease's pathogenesis.\n4. FALSE [correction]: IFIT1 is not known to be a regulator of RNA polymerase II. Instead, it is involved in antiviral responses, typically by interfering with viral replication processes.\n5. TRUE: Studies have shown that the IFIT1 gene is differentially expressed in SLE patients compared to healthy controls, which supports its involvement in the disease.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 3752,
    "user_query": "What is the use of the Liverpool Elbow Score?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Document 1, the Liverpool Elbow Score (LES) is a valid and reliable elbow-specific scoring system used to evaluate joint functions in patients with elbow stiffness. The LES contains both subjective and objective parameters and is based on a 15-item tool with a scale ranging from 0 to 10 points, with higher scores indicating better function. The scoring system is designed to evaluate various aspects of elbow function, including pain, stiffness, range of motion, and strength. The LES has been validated in patients with elbow disorders and has been found to be a useful tool for clinicians to assess and monitor the effectiveness of treatment interventions.",
    "llama-2-7b-chat-hf_fact_raw": "1. The Liverpool Elbow Score (LES) is used to evaluate joint functions in patients with elbow stiffness.\n2. The LES includes both subjective and objective parameters.\n3. The LES is a 15-item tool with a scale ranging from 0 to 10 points.\n4. Higher scores on the LES indicate better elbow function.\n5. The LES has been validated in patients with elbow disorders.",
    "llama-2-7b-chat-hf_fact": [
      "The Liverpool Elbow Score (LES) is used to evaluate joint functions in patients with elbow stiffness.",
      "The LES includes both subjective and objective parameters.",
      "The LES is a 15-item tool with a scale ranging from 0 to 10 points.",
      "Higher scores on the LES indicate better elbow function.",
      "The LES has been validated in patients with elbow disorders."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: The Liverpool Elbow Score (LES) is a 10-item tool with a scale ranging from 0 to 100 points.\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 3763,
    "user_query": "Describe efforts on Sarcoma from the 100,000 Genomes Project",
    "llama-2-7b-chat-hf_response": "Thank you for providing the necessary information. Based on the documents you provided, here are some efforts on sarcoma from the 100,000 Genomes Project:\nAccording to Document 0, sarcoma ranked third overall among the number of patients' samples sent for sequencing as part of the 100,000 Genomes Project. This suggests that there was a significant amount of effort dedicated to studying sarcoma as part of the project.\nDocument 1 provides more details on the goals and aims of the 100,000 Genomes Project. One of the main aims of the project was to establish a genomic medicine service for the NHS, which would provide clinical diagnosis with new personalized treatment options. Sarcoma is a rare and complex cancer, and the project aimed to use whole genome sequencing (WGS) to improve diagnosis and treatment options for patients with this type of cancer.\nThe project also aimed to enable scientific discovery, which could lead to a better understanding of the genetic causes of sarcoma and other rare diseases. By analyzing the genomes of thousands of patients, including those with sarcoma, researchers hoped to identify new genetic mutations and variations that could be targeted with new treatments.\nFinally, the project aimed to improve patient outcomes by providing clinical diagnosis with new personalized treatment options. By using WGS to identify genetic mutations and variations that are specific to each patient's cancer, doctors could develop targeted therapies that are more effective and less toxic than traditional chemotherapy.\nOverall, the 100,000 Genomes Project dedicated significant effort to studying sarcoma, with the goal of improving diagnosis, treatment, and patient outcomes for this rare and complex cancer.",
    "llama-2-7b-chat-hf_fact_raw": "1. Sarcoma ranked third overall among the number of patients' samples sent for sequencing in the 100,000 Genomes Project.\n2. One of the main aims of the 100,000 Genomes Project was to establish a genomic medicine service for the NHS.\n3. The 100,000 Genomes Project aimed to use whole genome sequencing to improve diagnosis and treatment options for patients with sarcoma.\n4. The project sought to enable scientific discovery to better understand the genetic causes of sarcoma and other rare diseases.\n5. The 100,000 Genomes Project aimed to improve patient outcomes by providing clinical diagnosis with new personalized treatment options through the use of whole genome sequencing.",
    "llama-2-7b-chat-hf_fact": [
      "Sarcoma ranked third overall among the number of patients' samples sent for sequencing in the 100,000 Genomes Project.",
      "One of the main aims of the 100,000 Genomes Project was to establish a genomic medicine service for the NHS.",
      "The 100,000 Genomes Project aimed to use whole genome sequencing to improve diagnosis and treatment options for patients with sarcoma.",
      "The project sought to enable scientific discovery to better understand the genetic causes of sarcoma and other rare diseases.",
      "The 100,000 Genomes Project aimed to improve patient outcomes by providing clinical diagnosis with new personalized treatment options through the use of whole genome sequencing."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN: Without specific data on the ranking of patient sample types sent for sequencing in the 100,000 Genomes Project, it is not possible to confirm or deny the statement about sarcoma's rank.\n2. TRUE: One of the main aims of the 100,000 Genomes Project was indeed to establish a genomic medicine service within the NHS.\n3. TRUE: The 100,000 Genomes Project did aim to use whole genome sequencing to improve diagnosis and treatment options for patients with various conditions, including sarcoma.\n4. TRUE: The project sought to enable scientific discovery and better understand the genetic causes of rare diseases, including sarcoma.\n5. TRUE: The 100,000 Genomes Project aimed to improve patient outcomes by providing clinical diagnosis with personalized treatment options through the use of whole genome sequencing.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3777,
    "user_query": "Does protein ALEX1 contain armadillo repeats?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Document 0, it appears that protein ALEX1 does contain armadillo repeats. The document states that armadillo (arm) repeat-containing proteins, such as ARMCX1, are involved in development, maintenance of tissue integrity, and tumorigenesis, and that their common feature is a 42-amino acid motif, the arm repeat. Since ALEX1 is not specifically mentioned in the document as an exception, it is likely that it also contains armadillo repeats.",
    "llama-2-7b-chat-hf_fact_raw": "1. Protein ALEX1 contains armadillo repeats.\n2. Armadillo (arm) repeat-containing proteins are involved in development, maintenance of tissue integrity, and tumorigenesis.\n3. A common feature of armadillo repeat-containing proteins is a 42-amino acid motif known as the arm repeat.",
    "llama-2-7b-chat-hf_fact": [
      "Protein ALEX1 contains armadillo repeats.",
      "Armadillo (arm) repeat-containing proteins are involved in development, maintenance of tissue integrity, and tumorigenesis.",
      "A common feature of armadillo repeat-containing proteins is a 42-amino acid motif known as the arm repeat."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. TRUE\n3. FALSE [correction]: A common feature of armadillo repeat-containing proteins is a motif that is approximately 40 amino acids in length, not specifically 42.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "true",
      "false"
    ]
  },
  {
    "id": 3789,
    "user_query": "List enzymes that removes histone modifications.",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Documents 0 and 1, the following enzymes are known to remove histone modifications:\n1. Histone deacetylases (HDACs): These enzymes remove acetyl groups from histone proteins, thereby reversing the histone modifications made by histone acetyltransferases (HATs). HDACs are known to target promoter regions, where they play a role in regulating gene expression.\n2. Lysine-specific demethylase 1 (LSD1): This enzyme is involved in the removal of mono-methylation from histone H3 lysine 4 (H3K4me1), which is a repressive chromatin mark. LSD1 is known to play a role in the regulation of gene expression, particularly in the context of stem cells and development.\n3. JMJD2A: This enzyme is involved in the removal of di-methylation from histone H3 lysine 9 (H3K9me2), which is a repressive chromatin mark. JMJD2A is known to play a role in the regulation of gene expression, particularly in the context of stem cells and development.\n4. KDM5B: This enzyme is involved in the removal of acetylation from histone H3 lysine 5 (H3K5ac), which is a mark associated with active gene expression. KDM5B is known to play a role in the regulation of gene expression, particularly in the context of cancer.\nIt's worth noting that these enzymes are not the only ones involved in histone modification removal, and there may be other enzymes that have not been identified or characterized yet. Additionally, the specific role of each enzyme in histone modification removal can vary depending on the context in which it is studied.",
    "llama-2-7b-chat-hf_fact_raw": "1. Histone deacetylases (HDACs) remove acetyl groups from histone proteins.\n2. Lysine-specific demethylase 1 (LSD1) is involved in the removal of mono-methylation from histone H3 lysine 4 (H3K4me1).\n3. JMJD2A is involved in the removal of di-methylation from histone H3 lysine 9 (H3K9me2).\n4. KDM5B is involved in the removal of acetylation from histone H3 lysine 5 (H3K5ac).\n5. The role of these enzymes in histone modification removal can vary depending on the context in which they are studied.",
    "llama-2-7b-chat-hf_fact": [
      "Histone deacetylases (HDACs) remove acetyl groups from histone proteins.",
      "Lysine-specific demethylase 1 (LSD1) is involved in the removal of mono-methylation from histone H3 lysine 4 (H3K4me1).",
      "JMJD2A is involved in the removal of di-methylation from histone H3 lysine 9 (H3K9me2).",
      "KDM5B is involved in the removal of acetylation from histone H3 lysine 5 (H3K5ac).",
      "The role of these enzymes in histone modification removal can vary depending on the context in which they are studied."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Lysine-specific demethylase 1 (LSD1) is involved in the removal of mono- and di-methylation from histone H3 lysine 4 (H3K4me1 and H3K4me2).\n3. TRUE\n4. FALSE [correction]: KDM5B is involved in the removal of di- and tri-methylation from histone H3 lysine 4 (H3K4me2 and H3K4me3), not acetylation.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 3806,
    "user_query": "Does head ct increase brain tumor risk?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, there is some evidence to suggest that head CT scans may increase the risk of brain tumors, particularly in pediatric patients.\nDocument 0 notes that while head CT is instrumental in managing patients of all ages, the low dose radiation exposure from these scans may pose a low but non-zero risk of tumor induction in pediatric patients. This suggests that the risk of brain tumor induction from head CT scans is not zero, but rather a low but measurable risk.\nDocument 1 also supports this conclusion, as it suggests that CT scans, including head CT scans, may increase the risk of brain tumors. The study found that the use of computed tomography (CT) scans was associated with an increased risk of brain tumors in adults and children.\nIt is important to note that the risk of brain tumor induction from head CT scans is still relatively low, and the benefits of these scans in diagnosing and managing medical conditions often outweigh the risks. However, this information should be taken into account when deciding whether or not to undergo a head CT scan, particularly in pediatric patients.\nIn summary, while the evidence is not conclusive, there is some suggestion that head CT scans may increase the risk of brain tumors, particularly in pediatric patients. It is important to weigh the potential risks and benefits of these scans on a case-by-case basis and to consult with a medical professional for further guidance.",
    "llama-2-7b-chat-hf_fact_raw": "1. Head CT scans may increase the risk of brain tumors, particularly in pediatric patients.\n2. The radiation exposure from head CT scans poses a low but non-zero risk of tumor induction in pediatric patients.\n3. A study found that the use of computed tomography (CT) scans was associated with an increased risk of brain tumors in adults and children.\n4. The risk of brain tumor induction from head CT scans is considered relatively low.\n5. The benefits of head CT scans in diagnosing and managing medical conditions often outweigh the risks.",
    "llama-2-7b-chat-hf_fact": [
      "Head CT scans may increase the risk of brain tumors, particularly in pediatric patients.",
      "The radiation exposure from head CT scans poses a low but non-zero risk of tumor induction in pediatric patients.",
      "A study found that the use of computed tomography (CT) scans was associated with an increased risk of brain tumors in adults and children.",
      "The risk of brain tumor induction from head CT scans is considered relatively low.",
      "The benefits of head CT scans in diagnosing and managing medical conditions often outweigh the risks."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: Head CT scans involve radiation exposure, which may increase the risk of brain tumors, particularly in pediatric patients due to their developing tissues and longer expected lifetime.\n2. TRUE: The radiation exposure from head CT scans does pose a low but non-zero risk of tumor induction in pediatric patients.\n3. TRUE: Some studies have found an association between the use of computed tomography (CT) scans and an increased risk of brain tumors in both adults and children.\n4. TRUE: While there is a risk, it is generally considered relatively low compared to the diagnostic benefits of CT scans.\n5. TRUE: In clinical practice, the benefits of head CT scans for diagnosing and managing medical conditions are generally considered to outweigh the risks, especially when used judiciously.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3809,
    "user_query": "Which type of pluripotency is Otx2 associated with?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, Otx2 is associated with naive pluripotency. The documents mention that Otx2 is involved in the early differentiation of embryonic stem cells and that it drives enhancer activation through affecting chromatin marks and the activity of associated genes. This suggests that Otx2 is important for maintaining the pluripotent state of embryonic stem cells, which are characterized by a high level of naive pluripotency. Additionally, the documents mention that Oct4 is required for Otx2 expression, and reciprocally, Otx2 is required for efficient Oct4 recruitment to many enhancer regions, further supporting the association of Otx2 with naive pluripotency.",
    "llama-2-7b-chat-hf_fact_raw": "1. Otx2 is associated with naive pluripotency.\n2. Otx2 is involved in the early differentiation of embryonic stem cells.\n3. Otx2 affects chromatin marks and the activity of associated genes to drive enhancer activation.\n4. Embryonic stem cells are characterized by a high level of naive pluripotency.\n5. Oct4 is required for Otx2 expression, and Otx2 is required for efficient Oct4 recruitment to many enhancer regions.",
    "llama-2-7b-chat-hf_fact": [
      "Otx2 is associated with naive pluripotency.",
      "Otx2 is involved in the early differentiation of embryonic stem cells.",
      "Otx2 affects chromatin marks and the activity of associated genes to drive enhancer activation.",
      "Embryonic stem cells are characterized by a high level of naive pluripotency.",
      "Oct4 is required for Otx2 expression, and Otx2 is required for efficient Oct4 recruitment to many enhancer regions."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. UNKNOWN\n\nExplanation:\n1. Otx2 is indeed associated with naive pluripotency, which is a state of stem cells that allows them to differentiate into any cell type.\n2. Otx2 plays a role in the early differentiation of embryonic stem cells, helping to guide the cells to develop into specific cell types.\n3. Otx2 can affect chromatin marks and the activity of associated genes, which is part of the mechanism by which it drives enhancer activation during cell differentiation.\n4. Embryonic stem cells are characterized by their high level of naive pluripotency, which is what makes them so valuable for research and potential therapeutic applications.\n5. The relationship between Oct4 and Otx2 is complex and involves regulatory networks that control stem cell pluripotency and differentiation. While Oct4 is a well-known factor required for maintaining pluripotency, the specific requirement of Oct4 for Otx2 expression and vice versa, particularly in the context of enhancer regions, may be supported by some studies but is not universally established or may depend on the specific cellular context. Therefore, without specific context or reference, this statement is marked as UNKNOWN.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 3815,
    "user_query": "How many DNaseI hypersensitive sites (DHS) mark the murine beta globin locus region?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Document 0, the murine beta globin locus region contains 17 DNase I hypersensitive sites (DHSs). These sites are generic markers of regulatory DNA and can be used to identify genetic variations associated with diseases and phenotypic traits.\nDocument 1 provides additional information on the role of DHSs as markers of regulatory DNA. It highlights that DHSs have underpinned the discovery of all classes of cis-regulatory elements, including enhancers, promoters, insulators, and silencers. The document also notes that DHSs are associated with the regulation of gene expression and can be used to identify genetic variations that affect gene function.\nBased on this information, it is possible to estimate the number of DHSs marking the murine beta globin locus region. However, the exact number may vary depending on the specific method used to identify DHSs and the resolution of the maps provided in Document 0. Nevertheless, based on the information provided, it is reasonable to estimate that there are around 17 DHSs marking the murine beta globin locus region.",
    "llama-2-7b-chat-hf_fact_raw": "1. The murine beta globin locus region contains 17 DNase I hypersensitive sites (DHSs).\n2. DNase I hypersensitive sites are markers of regulatory DNA.\n3. DHSs can be used to identify genetic variations associated with diseases and phenotypic traits.\n4. DHSs have underpinned the discovery of all classes of cis-regulatory elements, including enhancers, promoters, insulators, and silencers.\n5. DHSs are associated with the regulation of gene expression.",
    "llama-2-7b-chat-hf_fact": [
      "The murine beta globin locus region contains 17 DNase I hypersensitive sites (DHSs).",
      "DNase I hypersensitive sites are markers of regulatory DNA.",
      "DHSs can be used to identify genetic variations associated with diseases and phenotypic traits.",
      "DHSs have underpinned the discovery of all classes of cis-regulatory elements, including enhancers, promoters, insulators, and silencers.",
      "DHSs are associated with the regulation of gene expression."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. TRUE\n3. TRUE\n4. FALSE [correction]: While DHSs have been instrumental in the discovery of many classes of cis-regulatory elements, it is not accurate to say they have underpinned the discovery of all classes, as new types of regulatory elements may still be discovered and not all may be associated with DHSs.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 3822,
    "user_query": "List as many European influenza vaccines as possible.",
    "llama-2-7b-chat-hf_response": "Based on the information provided, here are some European influenza vaccines:\n1. Adjupanrix (previously Pandemic influenza vaccine (H5N1) (split virion, inactivated, adjuvanted) - GlaxoSmithKline Biologicals)\n2. Pandemic influenza vaccine H5N1 - Baxter AG\n3. Pandemic influenza vaccine H5N1 - AstraZeneca (previously Pandemic influenza vaccine H5N1 - Medimmune)\n4. Seasonal influenza vaccines - various manufacturers\n5. Emergency procedure vaccines - various manufacturers\n6. A-Z disease list - including influenza\n7. Seasonal influenza prevention and control measures\n8. Types of seasonal influenza vaccine - including inactivated, recombinant, and subunit vaccines\nPlease note that this list may not be exhaustive, as there may be other European influenza vaccines available. Additionally, the information provided in the documents may be subject to change, and it is important to consult the most up-to-date sources for the most accurate information.",
    "llama-2-7b-chat-hf_fact_raw": "1. Adjupanrix is a European influenza vaccine previously known as Pandemic influenza vaccine (H5N1) (split virion, inactivated, adjuvanted) and is produced by GlaxoSmithKline Biologicals.\n2. Baxter AG manufactures a Pandemic influenza vaccine H5N1.\n3. AstraZeneca, previously known as Medimmune, produces a Pandemic influenza vaccine H5N1.\n4. There are various manufacturers that produce seasonal influenza vaccines in Europe.\n5. Emergency procedure vaccines for influenza are available from various manufacturers in Europe.",
    "llama-2-7b-chat-hf_fact": [
      "Adjupanrix is a European influenza vaccine previously known as Pandemic influenza vaccine (H5N1) (split virion, inactivated, adjuvanted) and is produced by GlaxoSmithKline Biologicals.",
      "Baxter AG manufactures a Pandemic influenza vaccine H5N1.",
      "AstraZeneca, previously known as Medimmune, produces a Pandemic influenza vaccine H5N1.",
      "There are various manufacturers that produce seasonal influenza vaccines in Europe.",
      "Emergency procedure vaccines for influenza are available from various manufacturers in Europe."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE - Baxter International (which Baxter AG is a part of) has been involved in the production of influenza vaccines, including pandemic vaccines.\n3. FALSE [correction]: AstraZeneca, which acquired MedImmune, produces influenza vaccines, but MedImmune was the name of the company before the acquisition by AstraZeneca, not the other way around.\n4. TRUE - There are multiple manufacturers that produce seasonal influenza vaccines in Europe.\n5. TRUE - In the event of a pandemic or other emergency, various manufacturers in Europe have the capability to produce emergency procedure vaccines for influenza.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 3832,
    "user_query": "Is the Paramyxovirus geneome segmented, negative-sense RNA?",
    "llama-2-7b-chat-hf_response": "Yes, the Paramyxovirus geneome is segmented, negative-sense RNA. According to Document 0, the paramyxovirus family has a genome consisting of a single strand of negative-sense RNA, which acts as a template for two distinct processes: transcription to generate subgenomic, capped and polyadenylated mRNAs, and genome replication. This indicates that the genome is segmented, meaning it is composed of multiple segments or regions, and is negative-sense RNA, meaning that the RNA sequence is complementary to the messenger RNA (mRNA) that is transcribed from it.\nAdditionally, Document 1 states that the nucleocapsid, which contains the genome, is a tubelike structure with helical symmetry and contains one molecule of single-stranded generally negative-sense RNA (molecular weight 5-8 × 106), the major nucleoprotein (NP), the phosphoprotein P, and the L protein. The L protein is the RNA polymerase, which is necessary for transcription of viral RNA, further confirming that the Paramyxovirus geneome is segmented, negative-sense RNA.",
    "llama-2-7b-chat-hf_fact_raw": "1. The Paramyxovirus genome consists of a single strand of negative-sense RNA.\n2. The Paramyxovirus genome acts as a template for transcription to generate subgenomic, capped, and polyadenylated mRNAs.\n3. The Paramyxovirus genome is used for genome replication.\n4. The nucleocapsid of the Paramyxovirus contains one molecule of single-stranded generally negative-sense RNA.\n5. The L protein within the Paramyxovirus nucleocapsid functions as the RNA polymerase necessary for transcription of viral RNA.",
    "llama-2-7b-chat-hf_fact": [
      "The Paramyxovirus genome consists of a single strand of negative-sense RNA.",
      "The Paramyxovirus genome acts as a template for transcription to generate subgenomic, capped, and polyadenylated mRNAs.",
      "The Paramyxovirus genome is used for genome replication.",
      "The nucleocapsid of the Paramyxovirus contains one molecule of single-stranded generally negative-sense RNA.",
      "The L protein within the Paramyxovirus nucleocapsid functions as the RNA polymerase necessary for transcription of viral RNA."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE\n\nEach of the statements provided is consistent with the general characteristics of Paramyxoviruses. The Paramyxovirus family includes viruses with a single-stranded RNA genome of negative sense, which is used as a template for transcription and replication. The nucleocapsid does contain a single molecule of RNA, and the L protein (large protein) functions as the RNA-dependent RNA polymerase necessary for transcription and replication of the viral RNA.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3869,
    "user_query": "Roflumilast Cream is effective for which disease?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, Roflumilast Cream is effective for the treatment of plaque psoriasis.",
    "llama-2-7b-chat-hf_fact_raw": "1. Roflumilast Cream is used for the treatment of plaque psoriasis.",
    "llama-2-7b-chat-hf_fact": [
      "Roflumilast Cream is used for the treatment of plaque psoriasis."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true"
    ]
  },
  {
    "id": 3885,
    "user_query": "Which tools have been developed for identifying and visualising ncRNA promoters?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Document 0, there are several tools that have been developed for identifying and visualizing ncRNA promoters:\n1. ncPro-ML: This is a new method proposed in Document 0 for identifying the promoters of non-coding RNA (ncRNA) in Homo sapiens and Mus musculus. The method uses different kinds of sequence encoding schemes to identify the promoters of ncRNA.\n2. R2DT: This is a framework for predicting and visualizing RNA secondary structure using templates, as mentioned in Document 1. While the tool is not specifically designed for identifying ncRNA promoters, it can be used to predict the secondary structure of ncRNA molecules, which may be useful in identifying potential promoter regions.\nIt is important to note that these tools are not able to identify the promoters of all ncRNAs, as stated in Document 0. Therefore, it is possible that other tools or methods may be needed to identify the promoters of specific ncRNAs.",
    "llama-2-7b-chat-hf_fact_raw": "1. ncPro-ML is a method for identifying the promoters of non-coding RNA in Homo sapiens and Mus musculus.\n2. ncPro-ML uses different kinds of sequence encoding schemes to identify the promoters of ncRNA.\n3. R2DT is a framework for predicting and visualizing RNA secondary structure using templates.\n4. R2DT is not specifically designed for identifying ncRNA promoters but can be used to predict the secondary structure of ncRNA molecules.\n5. The tools mentioned are not able to identify the promoters of all ncRNAs.",
    "llama-2-7b-chat-hf_fact": [
      "ncPro-ML is a method for identifying the promoters of non-coding RNA in Homo sapiens and Mus musculus.",
      "ncPro-ML uses different kinds of sequence encoding schemes to identify the promoters of ncRNA.",
      "R2DT is a framework for predicting and visualizing RNA secondary structure using templates.",
      "R2DT is not specifically designed for identifying ncRNA promoters but can be used to predict the secondary structure of ncRNA molecules.",
      "The tools mentioned are not able to identify the promoters of all ncRNAs."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE\n\nThe statements provided are consistent with the general understanding of the tools mentioned. ncPro-ML is indeed a method for identifying promoters of non-coding RNA in humans and mice, and it uses various sequence encoding schemes. R2DT is a framework for RNA secondary structure prediction and visualization, which is not specifically designed for promoter identification but can be used for studying the structure of ncRNA molecules. Lastly, it is true that no tool can identify the promoters of all ncRNAs due to the complexity and diversity of these molecules.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3918,
    "user_query": "List example genes that SWIM tool has identified and which are down-regulated in glioblastoma",
    "llama-2-7b-chat-hf_response": "Based on the information provided, SWIM tool has identified 171 down-regulated genes in glioblastoma stem-like cells compared to conventional glioma cell lines. These genes are involved in various biological pathways, including \"ECM-receptor interaction\" and \"focal adhesion\". Some examples of the genes identified by SWIM tool are:\n1. CAV1 (CAV1 gene): Also known as caveolin-1, this gene encodes a protein involved in cell signaling and the regulation of actin cytoskeleton organization.\n2. COL5A1 (COL5A1 gene): This gene encodes a protein involved in the structure and function of basement membranes, which provide a supportive matrix for cells to adhere to.\n3. COL6A3 (COL6A3 gene): Similar to COL5A1, this gene encodes a protein involved in the structure and function of basement membranes.\n4. FLNB (FLNB gene): This gene encodes a protein involved in the structure and function of focal adhesions, which are sites of cell-matrix interaction.\n5. HMMR (HMMR gene): This gene encodes a protein involved in the regulation of actin cytoskeleton organization and cell signaling.\n6. ITGA3 (ITGA3 gene): This gene encodes a protein involved in cell adhesion and the regulation of cell migration.\n7. ITGA5 (ITGA5 gene): Similar to ITGA3, this gene encodes a protein involved in cell adhesion and the regulation of cell migration.\n8. MET (MET gene): This gene encodes a protein involved in cell signaling and the regulation of cell growth and differentiation.\n9. SDC1 (SDC1 gene): This gene encodes a protein involved in the structure and function of basement membranes.\n10. THBS1 (THBS1 gene): Similar to SDC1, this gene encodes a protein involved in the structure and function of basement membranes.\n11. VEGFC (VEGFC gene): This gene encodes a protein involved in angiogenesis, the formation of new blood vessels.\nThese genes are down-regulated in glioblastoma stem-like",
    "llama-2-7b-chat-hf_fact_raw": "1. The SWIM tool has identified 171 down-regulated genes in glioblastoma stem-like cells.\n2. CAV1 gene encodes a protein involved in cell signaling and the regulation of actin cytoskeleton organization.\n3. COL5A1 gene encodes a protein involved in the structure and function of basement membranes.\n4. FLNB gene encodes a protein involved in the structure and function of focal adhesions.\n5. VEGFC gene encodes a protein involved in angiogenesis, the formation of new blood vessels.",
    "llama-2-7b-chat-hf_fact": [
      "The SWIM tool has identified 171 down-regulated genes in glioblastoma stem-like cells.",
      "CAV1 gene encodes a protein involved in cell signaling and the regulation of actin cytoskeleton organization.",
      "COL5A1 gene encodes a protein involved in the structure and function of basement membranes.",
      "FLNB gene encodes a protein involved in the structure and function of focal adhesions.",
      "VEGFC gene encodes a protein involved in angiogenesis, the formation of new blood vessels."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. TRUE\n3. FALSE [correction]: COL5A1 gene encodes a protein that is a component of type V collagen, which is involved in the structure and function of connective tissues, not specifically basement membranes.\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "true",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 3926,
    "user_query": "Which R packages have been developed for studying TADs?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, there are several R packages that have been developed for studying Topologically Associated Domains (TADs):\n1. TADsplimer: This is the first computational tool to systematically detect TAD splits and mergers across the genome between Hi-C samples, as mentioned in Document 0.\n2. SpectralTAD: This R package uses spectral clustering to define a hierarchy of TADs, as mentioned in Document 1.\n3. TADRank: This package uses a ranking algorithm to identify TADs based on their chromatin interactions, as mentioned in Document 2.\n4. ChromHMM: This package uses a hidden Markov model to predict TADs and their boundaries, as mentioned in Document 3.\n5. TAD-seq: This package provides a workflow for analyzing TAD-seq data, including the detection of TADs and their boundaries, as mentioned in Document 4.\nThese packages can be used to analyze TADs in various organisms, including humans, and can provide insights into the structure and dynamics of chromatin at the genomic scale.",
    "llama-2-7b-chat-hf_fact_raw": "1. TADsplimer is an R package developed to detect TAD splits and mergers across the genome between Hi-C samples.\n2. SpectralTAD is an R package that uses spectral clustering to define a hierarchy of TADs.\n3. TADRank is an R package that identifies TADs using a ranking algorithm based on chromatin interactions.\n4. ChromHMM is an R package that predicts TADs and their boundaries using a hidden Markov model.\n5. TAD-seq is an R package designed for analyzing TAD-seq data, including the detection of TADs and their boundaries.",
    "llama-2-7b-chat-hf_fact": [
      "TADsplimer is an R package developed to detect TAD splits and mergers across the genome between Hi-C samples.",
      "SpectralTAD is an R package that uses spectral clustering to define a hierarchy of TADs.",
      "TADRank is an R package that identifies TADs using a ranking algorithm based on chromatin interactions.",
      "ChromHMM is an R package that predicts TADs and their boundaries using a hidden Markov model.",
      "TAD-seq is an R package designed for analyzing TAD-seq data, including the detection of TADs and their boundaries."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: ChromHMM is an R package that uses a hidden Markov model to learn the chromatin states of genomic regions, not specifically to predict TADs and their boundaries.\n5. FALSE [correction]: TAD-seq is a sequencing technique designed for analyzing TADs and their boundaries, not an R package.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "false",
      "false"
    ]
  },
  {
    "id": 3927,
    "user_query": "Which bioconductor tool has been developed for accessing bacterial regulatory networks?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, the bioconductor tool that has been developed for accessing bacterial regulatory networks is RegulonDB. According to Document 0, RegulonDB has collected, harmonized, and centralized data from hundreds of experiments over nearly two decades, making it a point of reference for transcriptional regulation in Escherichia coli and other bacterial organisms. Document 1 also mentions RegulonDB as a resource for understanding the regulatory mechanisms of bacterial organisms, highlighting its utility in this context. Therefore, it can be inferred that RegulonDB is the bioconductor tool that has been developed for accessing bacterial regulatory networks.",
    "llama-2-7b-chat-hf_fact_raw": "1. RegulonDB is a bioconductor tool developed for accessing bacterial regulatory networks.\n2. RegulonDB has collected data from hundreds of experiments over nearly two decades.\n3. RegulonDB is a point of reference for transcriptional regulation in Escherichia coli.\n4. RegulonDB is also relevant for other bacterial organisms beyond Escherichia coli.\n5. RegulonDB is used to understand the regulatory mechanisms of bacterial organisms.",
    "llama-2-7b-chat-hf_fact": [
      "RegulonDB is a bioconductor tool developed for accessing bacterial regulatory networks.",
      "RegulonDB has collected data from hundreds of experiments over nearly two decades.",
      "RegulonDB is a point of reference for transcriptional regulation in Escherichia coli.",
      "RegulonDB is also relevant for other bacterial organisms beyond Escherichia coli.",
      "RegulonDB is used to understand the regulatory mechanisms of bacterial organisms."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: RegulonDB is a database developed for accessing bacterial regulatory networks, not specifically a bioconductor tool.\n2. TRUE\n3. TRUE\n4. FALSE [correction]: RegulonDB is primarily focused on Escherichia coli and may not be directly relevant for other bacterial organisms, although the principles and methodologies could potentially be applied more broadly.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 3933,
    "user_query": "What are the end products of the shikimate pathway?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, the end products of the shikimate pathway are chorismate and aromatic amino acids.",
    "llama-2-7b-chat-hf_fact_raw": "1. Chorismate is an end product of the shikimate pathway.\n2. Aromatic amino acids are end products of the shikimate pathway.",
    "llama-2-7b-chat-hf_fact": [
      "Chorismate is an end product of the shikimate pathway.",
      "Aromatic amino acids are end products of the shikimate pathway."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Chorismate is not an end product of the shikimate pathway; it is an intermediate compound that leads to the synthesis of other compounds.\n2. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true"
    ]
  },
  {
    "id": 3936,
    "user_query": "Is cabergoline used for treatment of the Nelson's syndrome ?",
    "llama-2-7b-chat-hf_response": "Yes, cabergoline can be used to treat Nelson's syndrome. According to the information provided, Nelson's syndrome is a potentially severe condition that may develop in patients with Cushing's disease treated with bilateral adrenalectomy. Cabergoline is a dopamine receptor agonist that has been used to treat hypercortisolism in patients with Nelson's syndrome.\nCabergoline works by reducing the production of cortisol in the adrenal glands, which can help to alleviate the symptoms of hypercortisolism associated with Nelson's syndrome, such as weight gain, high blood pressure, and diabetes. Additionally, cabergoline has been shown to reduce the size of the adrenal glands in patients with Nelson's syndrome, which can help to improve the patient's quality of life.\nIt is important to note that cabergoline is not a cure for Nelson's syndrome, and it may not be effective in all patients. Other treatments, such as surgery or radiation therapy, may also be necessary to manage the condition. It is important to work closely with a healthcare provider to determine the best course of treatment for each individual case.",
    "llama-2-7b-chat-hf_fact_raw": "1. Cabergoline can be used to treat Nelson's syndrome.\n2. Nelson's syndrome may develop in patients with Cushing's disease treated with bilateral adrenalectomy.\n3. Cabergoline is a dopamine receptor agonist.\n4. Cabergoline has been used to treat hypercortisolism in patients with Nelson's syndrome.\n5. Cabergoline can reduce the size of the adrenal glands in patients with Nelson's syndrome.",
    "llama-2-7b-chat-hf_fact": [
      "Cabergoline can be used to treat Nelson's syndrome.",
      "Nelson's syndrome may develop in patients with Cushing's disease treated with bilateral adrenalectomy.",
      "Cabergoline is a dopamine receptor agonist.",
      "Cabergoline has been used to treat hypercortisolism in patients with Nelson's syndrome.",
      "Cabergoline can reduce the size of the adrenal glands in patients with Nelson's syndrome."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Cabergoline is not typically used to treat Nelson's syndrome. Nelson's syndrome involves the growth of a pituitary tumor after bilateral adrenalectomy for Cushing's disease, and treatment options may include surgery, radiation therapy, or medication, but not specifically cabergoline.\n2. TRUE\n3. TRUE\n4. FALSE [correction]: Cabergoline has been used to treat hyperprolactinemia and Parkinson's disease, but it is not a standard treatment for hypercortisolism in patients with Nelson's syndrome.\n5. FALSE [correction]: Cabergoline does not reduce the size of the adrenal glands in patients with Nelson's syndrome because the condition is characterized by the growth of a pituitary tumor following the removal of the adrenal glands. Cabergoline may reduce the size of pituitary tumors secreting prolactin, but this is not directly related to Nelson's syndrome.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "false",
      "false"
    ]
  },
  {
    "id": 3939,
    "user_query": "What is the main manifestation of Liebenberg syndrome?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, the main manifestation of Liebenberg syndrome is abnormal development of the arms, resulting in characteristic arm malformations that can vary in severity. These malformations typically involve the bones and other tissues in the elbows, forearms, wrists, and hands, which can resemble related structures in the lower limbs.",
    "llama-2-7b-chat-hf_fact_raw": "1. Liebenberg syndrome is characterized by abnormal development of the arms.\n2. Liebenberg syndrome results in arm malformations that can vary in severity.\n3. The malformations in Liebenberg syndrome typically involve the bones and other tissues.\n4. The affected areas in Liebenberg syndrome include the elbows, forearms, wrists, and hands.\n5. The arm malformations in Liebenberg syndrome can resemble structures in the lower limbs.",
    "llama-2-7b-chat-hf_fact": [
      "Liebenberg syndrome is characterized by abnormal development of the arms.",
      "Liebenberg syndrome results in arm malformations that can vary in severity.",
      "The malformations in Liebenberg syndrome typically involve the bones and other tissues.",
      "The affected areas in Liebenberg syndrome include the elbows, forearms, wrists, and hands.",
      "The arm malformations in Liebenberg syndrome can resemble structures in the lower limbs."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Liebenberg syndrome is characterized by abnormal development of the elbows, forearms, wrists, and hands, which can resemble structures in the lower limbs.\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3977,
    "user_query": "List orally bioavailable MPS1 kinase inhibitors",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Documents 0 and 1, the following are orally bioavailable MPS1 kinase inhibitors:\n1. MPI-0479605 (IC50 = 0.004 μM for MPS1 enzyme and 0.1 μM for HCT-116 cells)\n2. Optimized compounds from the 1H-pyrrolo[3,2-c]pyridine scaffold (potent and selective inhibition of MPS1 in vitro and translation to cellular assays)\nPlease note that these are the only two inhibitors mentioned in the provided documents, and there may be other MPS1 kinase inhibitors that are not included in the information provided.",
    "llama-2-7b-chat-hf_fact_raw": "1. MPI-0479605 is an orally bioavailable MPS1 kinase inhibitor.\n2. MPI-0479605 has an IC50 value of 0.004 μM for the MPS1 enzyme.\n3. MPI-0479605 has an IC50 value of 0.1 μM for HCT-116 cells.\n4. Compounds from the 1H-pyrrolo[3,2-c]pyridine scaffold are orally bioavailable MPS1 kinase inhibitors.\n5. The 1H-pyrrolo[3,2-c]pyridine scaffold compounds show potent and selective inhibition of MPS1 in vitro and are effective in cellular assays.",
    "llama-2-7b-chat-hf_fact": [
      "MPI-0479605 is an orally bioavailable MPS1 kinase inhibitor.",
      "MPI-0479605 has an IC50 value of 0.004 μM for the MPS1 enzyme.",
      "MPI-0479605 has an IC50 value of 0.1 μM for HCT-116 cells.",
      "Compounds from the 1H-pyrrolo[3,2-c]pyridine scaffold are orally bioavailable MPS1 kinase inhibitors.",
      "The 1H-pyrrolo[3,2-c]pyridine scaffold compounds show potent and selective inhibition of MPS1 in vitro and are effective in cellular assays."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. UNKNOWN\n3. UNKNOWN\n4. TRUE\n5. TRUE\n\nThe statements regarding the specific IC50 values for MPI-0479605 (statements 2 and 3) cannot be verified without access to specific scientific data or literature references. Therefore, the truthfulness of these statements remains unknown. The other statements are consistent with general knowledge about kinase inhibitors and the characteristics of compounds derived from the 1H-pyrrolo[3,2-c]pyridine scaffold.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "unknown",
      "true",
      "true"
    ]
  },
  {
    "id": 4031,
    "user_query": "Was golimumab tested for diabetes?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, it appears that golimumab has not been specifically tested for the treatment of diabetes, including type 1 diabetes.\nDocument 0 mentions that golimumab is a human monoclonal antibody specific for tumor necrosis factor alpha (TNF-alpha), which is a protein that plays a role in the immune system. However, the document does not provide any information on the use of golimumab for diabetes.\nDocument 1 mentions that immunotherapy, including more specific/targeted treatments, have been tested in stage 3 type 1 diabetes. However, golimumab is not mentioned as one of these treatments.\nTherefore, based on the information provided, it cannot be concluded that golimumab has been tested for diabetes, including type 1 diabetes.",
    "llama-2-7b-chat-hf_fact_raw": "1. Golimumab is a human monoclonal antibody specific for tumor necrosis factor alpha (TNF-alpha).\n2. TNF-alpha is a protein that plays a role in the immune system.\n3. Immunotherapy treatments have been tested in stage 3 type 1 diabetes.\n4. Golimumab has not been specifically tested for the treatment of diabetes, including type 1 diabetes, according to the provided information.",
    "llama-2-7b-chat-hf_fact": [
      "Golimumab is a human monoclonal antibody specific for tumor necrosis factor alpha (TNF-alpha).",
      "TNF-alpha is a protein that plays a role in the immune system.",
      "Immunotherapy treatments have been tested in stage 3 type 1 diabetes.",
      "Golimumab has not been specifically tested for the treatment of diabetes, including type 1 diabetes, according to the provided information."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 4055,
    "user_query": "Is progeria caused by an autosomal recessive gene?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, it is likely that progeria is caused by an autosomal recessive gene. This is because the disorder is described as an \"extremely rare genetic disorder\" that is inherited in an autosomal recessive pattern. This means that a child must inherit two copies of the mutated gene, one from each parent, in order to develop the disorder.\nAutosomal recessive genetic disorders are caused by mutations in genes that are located on non-sex chromosomes (autosomes). These genes are responsible for a wide range of functions, including growth and development. When a child inherits two copies of a mutated gene, one from each parent, the gene is unable to function properly, leading to the development of the disorder.\nIt is worth noting that the exact genetic cause of progeria is still not fully understood, and there may be additional genetic or environmental factors that contribute to the disorder. However, based on the information provided, it is likely that progeria is caused by an autosomal recessive gene.",
    "llama-2-7b-chat-hf_fact_raw": "NO FACTS",
    "llama-2-7b-chat-hf_fact": [],
    "llama-2-7b-chat-hf_judge": []
  },
  {
    "id": 4082,
    "user_query": "What are common variants at 12q14 and 12q24 associated with?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Documents 0 and 1, common variants at 12q14 and 12q24 are associated with hippocampal volume. Specifically, the ENIGMA Consortium & the Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) Consortium found that variants at 12q14 and 12q24 are associated with reduced hippocampal volume in dementia-free individuals. Additionally, a GWAS of dementia-free persons identified 46 SNPs at four loci with P values of <4.0 × 10(-7) near 12q14 and 12q24, which were also associated with reduced hippocampal volume.",
    "llama-2-7b-chat-hf_fact_raw": "1. Common variants at 12q14 and 12q24 are associated with hippocampal volume.\n2. The ENIGMA Consortium & the Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) Consortium found associations between variants at 12q14 and 12q24 and reduced hippocampal volume in dementia-free individuals.\n3. A GWAS of dementia-free persons identified 46 SNPs at four loci near 12q14 and 12q24 with P values of <4.0 × 10(-7).\n4. The identified SNPs near 12q14 and 12q24 were associated with reduced hippocampal volume.",
    "llama-2-7b-chat-hf_fact": [
      "Common variants at 12q14 and 12q24 are associated with hippocampal volume.",
      "The ENIGMA Consortium & the Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) Consortium found associations between variants at 12q14 and 12q24 and reduced hippocampal volume in dementia-free individuals.",
      "A GWAS of dementia-free persons identified 46 SNPs at four loci near 12q14 and 12q24 with P values of <4.0 × 10(-7).",
      "The identified SNPs near 12q14 and 12q24 were associated with reduced hippocampal volume."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: A GWAS of dementia-free persons identified SNPs at four loci near 12q14 and 12q24 with P values of <5.0 × 10^(-8), which is the standard threshold for genome-wide significance.\n4. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 4096,
    "user_query": "Which are the ligands of the Roundabout (Robo) receptors?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Documents 0 and 1, the ligands of the Roundabout (Robo) receptors are the Slit protein family, specifically SLIT1, SLIT2, and SLIT3. These ligands interact with the Robo receptors on the cell surface, leading to the regulation of axonal guidance and cell migration.",
    "llama-2-7b-chat-hf_fact_raw": "1. The ligands of the Roundabout (Robo) receptors are the Slit protein family.\n2. Specific ligands for the Robo receptors include SLIT1, SLIT2, and SLIT3.\n3. The interaction between Slit proteins and Robo receptors regulates axonal guidance.\n4. The interaction between Slit proteins and Robo receptors regulates cell migration.",
    "llama-2-7b-chat-hf_fact": [
      "The ligands of the Roundabout (Robo) receptors are the Slit protein family.",
      "Specific ligands for the Robo receptors include SLIT1, SLIT2, and SLIT3.",
      "The interaction between Slit proteins and Robo receptors regulates axonal guidance.",
      "The interaction between Slit proteins and Robo receptors regulates cell migration."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 4112,
    "user_query": "Is there a role for TFII-I in megakaryopoiesis?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Documents 0 and 1, there is evidence to suggest that TFII-I plays a role in megakaryopoiesis.\nTFII-I is a transcription factor that has been shown to act as a repressor of β-globin gene transcription, which is involved in the production of hemoglobin in red blood cells. The data in Documents 0 and 1 suggest that TFII-I is implicated in the differentiation of erythro-megakaryocytic cells, which are the cells that give rise to red blood cells and platelets. This suggests that TFII-I may play a role in regulating the expression of genes involved in these cell types during megakaryopoiesis.\nWhile the data do not provide direct evidence of TFII-I's role in megakaryopoiesis, they do suggest that it is involved in the regulation of genes involved in this process. Further research is needed to fully understand the role of TFII-I in megakaryopoiesis and to determine the specific mechanisms by which it regulates gene expression during this process.\nIn summary, based on the information provided, there is evidence to suggest that TFII-I plays a role in megakaryopoiesis, although further research is needed to fully understand the nature of this role.",
    "llama-2-7b-chat-hf_fact_raw": "1. TFII-I is a transcription factor that acts as a repressor of β-globin gene transcription.\n2. β-globin gene transcription is involved in the production of hemoglobin in red blood cells.\n3. TFII-I is implicated in the differentiation of erythro-megakaryocytic cells.\n4. Erythro-megakaryocytic cells give rise to red blood cells and platelets.\n5. There is evidence suggesting that TFII-I is involved in the regulation of genes during megakaryopoiesis.",
    "llama-2-7b-chat-hf_fact": [
      "TFII-I is a transcription factor that acts as a repressor of β-globin gene transcription.",
      "β-globin gene transcription is involved in the production of hemoglobin in red blood cells.",
      "TFII-I is implicated in the differentiation of erythro-megakaryocytic cells.",
      "Erythro-megakaryocytic cells give rise to red blood cells and platelets.",
      "There is evidence suggesting that TFII-I is involved in the regulation of genes during megakaryopoiesis."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: TFII-I is a transcription factor that generally acts as an activator, not a repressor, of β-globin gene transcription.\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 4145,
    "user_query": "Is atenolol metabolized by CYP2D6?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Documents 0 and 1, atenolol is not metabolized by CYP2D6 to a clinically significant extent. While CYP2D6 does metabolize atenolol to some extent, the metabolism is not considered clinically significant compared to the metabolism by CYP3A4. Therefore, the answer to the user's question is:\nAtenolol is not metabolized by CYP2D6 to a clinically significant extent.",
    "llama-2-7b-chat-hf_fact_raw": "1. Atenolol is metabolized by CYP2D6 to some extent.\n2. The metabolism of atenolol by CYP2D6 is not considered clinically significant.\n3. CYP3A4 plays a more significant role in the metabolism of atenolol compared to CYP2D6.",
    "llama-2-7b-chat-hf_fact": [
      "Atenolol is metabolized by CYP2D6 to some extent.",
      "The metabolism of atenolol by CYP2D6 is not considered clinically significant.",
      "CYP3A4 plays a more significant role in the metabolism of atenolol compared to CYP2D6."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Atenolol is not significantly metabolized by the liver and thus CYP2D6 is not involved to a significant extent.\n2. TRUE\n3. FALSE [correction]: CYP3A4 does not play a significant role in the metabolism of atenolol; atenolol is primarily excreted unchanged in the urine.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "false"
    ]
  },
  {
    "id": 4158,
    "user_query": "List versions of ExpansionHunter",
    "llama-2-7b-chat-hf_response": "Based on the information provided, the latest version of ExpansionHunter is v5.0.0.",
    "llama-2-7b-chat-hf_fact_raw": "NO FACTS",
    "llama-2-7b-chat-hf_fact": [],
    "llama-2-7b-chat-hf_judge": []
  },
  {
    "id": 4164,
    "user_query": "What is the role of Adamts18 in hormone receptor signaling?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Documents 0 and 1, Adamts18 appears to play a role in hormone receptor signaling by interacting with the basement membrane and other proteins involved in this process.\nDocument 0 suggests that Adamts18 is required for stem cell activation, which implies that it may play a role in regulating the expression of hormone receptors on stem cells. The document also mentions that Adamts18 interacts genetically with Col18a1, a basal membrane-specific proteoglycan, which suggests that Adamts18 may be involved in the regulation of basement membrane dynamics and hormone receptor signaling.\nDocument 1 provides further insight into the role of Adamts18 in development and disease. The document highlights that ADAMTS18 is a secreted protease that is involved in the regulation of extracellular matrix (ECM) remodeling, which is critical for tissue development and homeostasis. The document also suggests that dysregulation of ADAMTS18 has been implicated in various diseases, including cancer and cardiovascular disease, which may be related to its role in hormone receptor signaling.\nOverall, based on the information provided in Documents 0 and 1, Adamts18 appears to play a role in hormone receptor signaling by interacting with the basement membrane and other proteins involved in this process, and dysregulation of Adamts18 may have implications for tissue development and disease.",
    "llama-2-7b-chat-hf_fact_raw": "1. Adamts18 is suggested to be required for stem cell activation.\n2. Adamts18 is reported to interact genetically with Col18a1, a basal membrane-specific proteoglycan.\n3. ADAMTS18 is a secreted protease involved in the regulation of extracellular matrix remodeling.\n4. Dysregulation of ADAMTS18 has been implicated in various diseases, including cancer and cardiovascular disease.\n5. Adamts18 may play a role in regulating the expression of hormone receptors on stem cells.",
    "llama-2-7b-chat-hf_fact": [
      "Adamts18 is suggested to be required for stem cell activation.",
      "Adamts18 is reported to interact genetically with Col18a1, a basal membrane-specific proteoglycan.",
      "ADAMTS18 is a secreted protease involved in the regulation of extracellular matrix remodeling.",
      "Dysregulation of ADAMTS18 has been implicated in various diseases, including cancer and cardiovascular disease.",
      "Adamts18 may play a role in regulating the expression of hormone receptors on stem cells."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. TRUE\n4. TRUE\n5. UNKNOWN\n\nThe statements about ADAMTS18's functions and implications in diseases are consistent with the general roles of ADAMTS (A Disintegrin and Metalloproteinase with Thrombospondin Motifs) family members in extracellular matrix remodeling and disease. However, without specific references to scientific literature or studies, it is not possible to confirm the accuracy of the first, second, and fifth statements regarding the specific roles of Adamts18 in stem cell activation, its interaction with Col18a1, or its role in regulating the expression of hormone receptors on stem cells.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 4208,
    "user_query": "What is the mode of action of Thiazovivin?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, Thiazovivin's mode of action is likely to be as a ROCK inhibitor. ROCK (Rho-associated protein kinase) inhibitors are a class of compounds that inhibit the activity of ROCK proteins, which are involved in regulating cellular processes such as cell migration, differentiation, and survival. Thiazovivin is specifically mentioned as an alternative to other ROCK inhibitors such as Y27632 and HA-1077, with adjustments in concentrations. This suggests that Thiazovivin is effective at lower concentrations and is therefore a more cost-effective option.\nAdditionally, the information provided in Document 1 suggests that small molecules, including Thiazovivin, can stimulate endogenous stem cells to enhance tissue regeneration. This further supports the idea that Thiazovivin's mode of action is related to its ability to modulate cellular processes involved in tissue regeneration.\nOverall, based on the information provided, it can be inferred that Thiazovivin's mode of action is likely to involve the inhibition of ROCK proteins, which can lead to improved cellular processes such as cell survival, migration, and differentiation, and may also play a role in tissue regeneration.",
    "llama-2-7b-chat-hf_fact_raw": "1. Thiazovivin is a ROCK inhibitor.\n2. ROCK inhibitors inhibit the activity of Rho-associated protein kinase proteins.\n3. Rho-associated protein kinase proteins are involved in regulating cellular processes such as cell migration, differentiation, and survival.\n4. Thiazovivin is mentioned as an alternative to other ROCK inhibitors like Y27632 and HA-1077.\n5. Thiazovivin is effective at lower concentrations compared to other ROCK inhibitors.",
    "llama-2-7b-chat-hf_fact": [
      "Thiazovivin is a ROCK inhibitor.",
      "ROCK inhibitors inhibit the activity of Rho-associated protein kinase proteins.",
      "Rho-associated protein kinase proteins are involved in regulating cellular processes such as cell migration, differentiation, and survival.",
      "Thiazovivin is mentioned as an alternative to other ROCK inhibitors like Y27632 and HA-1077.",
      "Thiazovivin is effective at lower concentrations compared to other ROCK inhibitors."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. UNKNOWN\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "unknown",
      "unknown"
    ]
  }
]